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Abstract
Despite  the  advances  in  diagnostic  and  therapeutic  techniques,  the  outcome  and 
survival  of  patients  suffering  from  head  and  neck  cancer  has  remained  poor, 
primarily  due  to  late  detection,  and  the  tendency  of the  disease  to  develop  loco- 
regional  metastasis.  A  key  to  its  control  is  early  detection  and  treatment  and 
prevention  of recurrence  and  metastasis.  Tumour  metastases  can  be  considered  as 
complex  multi-step  molecular  events  which  involve  the  interplay  between  several 
processes including changes in cell survival, adhesion, proteolysis, and angiogenesis. 
Based  on these considerations,  a positive correlation between tumour invasiveness 
and  expression/suppression  of these  processes  would  be  expected.  Photodynamic 
Therapy  (PDT)  is  a  novel  treatment  modality  for  a  variety  of malignant  tumours, 
including  head  and  neck  cancer.  The  technique  is  based  on  the  combination  of a 
photosensitive drug and visible light to disrupt cell function and induce cytotoxicity, 
but there is little agreement on its efficacy.  Furthermore, PDT is indicated for early 
tumour  without  metastases,  yet  it  is  crucial  to  determine  its  influence  on  the 
metastasis process.
The aims of the study were:
(i)  to  explore,  using  an  in  vitro  model,  the  influence  of  PDT,  alone  or  in 
combination  with  either  chemotherapy  or  small  molecules,  on  cell  toxicity, 
expression  of  a5(31  and  avp6  integrins  and  epidermal  growth  factor  receptor 
(EGFR),  production  of matrix  metalloproteinases,  MMP-2,  MMP-9  and  MMP-13, 
urokinase  plasminogen  activator  (uPA)  and  vascular  endothelial  growth  factor 
(VEGF);
(ii) to  clinically  evaluate  the  potential  of PDT  as  a tool  for head  and  neck  cancer 
treatment;
(iii) to clinically evaluate the ability of an optical system, based on fluorescence and 
elastic scattering spectroscopy, to distinguish between normal, potentially malignant 
and malignant tissues and to develop an applicable algorithm that can be used as a 
standard for the subsequent analysis of “unknown” lesions;
(iv) to monitor the sensitiser photobleaching during PDT in patients with superficial 
basal cell carcinoma (BCC), and compare this to clinical outcome.
It was found that, using a series of human oral squamous cell carcinoma cell lines, a 
marked  decrease  of tumour  invasion  and  migration  is  evident  after PDT;  this  was 
associated  with  the  downregulation  of  MMP-9,  -2  and  -13,  uPA  and  VEGF. 
Moreover, this migratory inhibition was further enhanced when PDT was combined 
with either cisplatin chemotherapy or tyrosine kinase inhibitors.
Clinically,  a  complete  response  with  excellent  cosmetic  results  was  achieved  on 
patients  treated  with  PDT.  Both  fluorescence  and  elastic  scattering  spectroscopy 
have shown a great potential to both non-invasively identify dysplastic changes at an 
early stage and to be used as a screening tool for the detection of subsequent primary 
lesions.
This thesis  has demonstrated that,  PDT  and  its  related  optical  system  together  are 
able to detect, treat and reduce invasion and metastasis of head and neck carcinoma.
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Chapter 1
Introduction
1.0  Overview
Head  and  neck  cancers  are  a  worldwide  problem  with  different  histopathologies, 
clinical  behaviour  and  response  to  treatment  (Forastiere  et  al.,  2001).  In  the 
European Union, there are approximately 85, 000 new cases of head and neck cancer 
reported every year,  and,  in the  UK alone,  around  10.2  per  100,000 males  and  5.4 
per  100,000  females  respectively,  are  diagnosed  every  year  (Ferley  et  al.,  2000). 
Globally, there were estimated to be over 500,000 cases of head and neck cancer in 
2000.  In  the  US,  40,000  new  cases  were  diagnosed,  with  approximately  12,500 
deaths (Greenlee et al., 2001). Over 90% of the head and neck cancers reported were 
of a particular type,  i.e.  squamous  cell  carcinomas  (Vokes  et  al.,  1993).  The  high 
infiltrative  potential  of  head  and  neck  tumours,  regardless  of  any  prognostic 
parameters, may result in an early recurrence or regional metastases, with subsequent 
functional  disturbance and aesthetic morbidity (Gath and Brakenhoff,  1999).  A key 
to  all  forms  of  cancer  control  is  early  detection,  treatment  and  prevention  of 
recurrence  and  metastasis.  Optical  techniques  offer  many  advantages  in  cancer 
detection and treatment at an early stage.
This thesis is based on both clinical and laboratory-based studies. They are linked by 
a  common  goal:  to  control  the  cancer  by  using  light  based  techniques,  namely 
Photodynamic  Therapy  (PDT)  for  treatment,  and  fluorescence  and  elastic 
spectroscopy  for  early  diagnosis;  two  modalities  of what  is  often  termed  ‘optical 
biopsy\
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This  chapter will  present  a brief overview of the current  state  of PDT  and related 
spectroscopy and give a general introduction to each of the areas of investigation to 
be addressed in the thesis.
1.1  Photodynamic therapy
In efforts to treat cancer, one can make use of a whole armamentarium of therapeutic 
means.  It  is  in  this  context  that  the  newly  developed  treatment  known  as 
photodynamic  therapy (PDT)  appears to  offer some  hope.  PDT has  been  approved 
for clinical treatment for various oncologic and non-oncologic indications, including 
the management of patients with head and neck cancer. PDT can be a selective and 
curative  therapy,  with  many  potential  advantages  over  the  available  alternative 
therapies. PDT can be repeated many times with minimal resistance and can be used 
in  combination  with  other  treatment  modalities  without  contraindications.  The 
exposure of adjacent normal tissues to  laser light is harmless,  with few deleterious 
consequences.  A  single  treatment  can  eradicate  the  disease  and  also  have  an 
excellent  cosmetic  result  (see  Figure  1.1),  which  makes  it  a viable  option  for  the 
treatment  of skin  cancers  and  other  soft tissue  tumours.  The  technique  of PDT  is 
based  on  the  use  of  a  light-sensitive  dye  (photosensitiser)  that  accumulates  in 
neoplasms  and  does  not  affect  other tissues  and organs.  A measured  dose  of light 
(mostly  from  lasers),  with  a  wavelength  selected  for  each  photosensitiser  in  the 
presence  of an  adequate  concentration  of molecular  oxygen,  activates  in  situ  the 
photosensitiser agent  and  generates  a photochemical  reaction.  An active  molecular 
species, most probably a singlet oxygen species ('0 2), is formed during this reaction, 
which disrupts the cell function and induces cytotoxicity (Dougherty, 2002).
Among  numerous  types  of  light  sources,  lasers  are  the  most  convenient  and 
controllable.  The  laser  light  is  coherent  and  monochromatic,  and  can  also  be 
directed  along  fibre  optic  cables,  which  allow  light  to  be  introduced  into  hollow 
organs and deep-seated tumours. Other non-coherent sources include Light Emitting 
Diodes (LEDs) and xenon lamps and have mostly been developed for dermatological
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applications. Diode lasers are cost effective, with a light weight that is far less than 
metal vapour or tuned-dye lasers, and have become alternative light sources.  Diode 
lasers emit light between 660 and 700 nm, and now others of wavelength, 780 -850 
nm are available (Brancaleon and Moseley, 2002).
The selective uptake by the hyperproliferating tissues of most photosensitive drugs, 
together  with  their  intrinsic  fluorescence,  has  expanded  their  use  as  minimally 
invasive tools in the fluorescent detection of cancers, pre-cancers and non-cancerous 
dysplasias.  This  procedure  is  called  Fluorescence  Diagnosis  (FD),  Fluorescence 
Spectroscopy  (FS)  or  Photodynamic  Diagnosis  (PDD).  The  term  TD D ’  was 
introduced to indicate its relation to PDT.
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Figure 1.1  Clinical pictures showing the cosmetic result of a lesion of the left 
temple following PDT (6 months after treatment).
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1.1.1  from photodynamic action to photodynamic therapy
The use of photodynamic action or photosensitisation by light has been explored for 
many  years.  The  civilisations  of  China,  India,  Egypt  and  Greece  placed  great 
emphasis  on  exposure  to  the  sun  to  cure  several  diseases  and  restore  health.  The 
earliest photodynamic investigation dated to the late nineteenth century, when Oscar 
Raab  and  von  Tappeiner (1900)  were  investigating the  toxicity of acridine  orange 
dye in cultures and observed a great increase in acridine killing rate when combined 
with  light.  Five years later,  von Tappeiner recognised the  importance of oxygen in 
this  process,  by  applying eosin  and  light  for the treatment of basal  cell  carcinoma 
(Ackroyd  et  al.,  2001).  Then  the  expression  “photodynamic”  was  coined  for  this 
“light  effective”  phenomenon,  and  this  marked  the  beginning  of  PDT  (Bonnett, 
1999).
Despite  the  early  investigations  using  PDT,  the  field  was  largely  neglected  until 
1960, when investigators at the Mayo Clinic (Boston; USA) found that the injection 
of  hematoporphyrin  caused  the  preferential  fluorescence  of  tumours.  This 
observation  stimulated  the  development  of  photosensitisers  with  improved 
specificity toward tumour cells.  Among these was the porphyrin mixture known as 
hematoporphyrin  derivatives  (HpD).  HpD  then  underwent  some  refinement  and 
purification  to  produce  the  commercially  known  sensitiser  Photofrin.  The  first 
clinical report on the use of HpD in the treatment of cancer appeared in  1976, when 
Kelly  and  Snell  published  results  of their  trials  of early  bladder  cancer  treatment 
(Kelly and Snell,  1976).  Over a 20 year period, several studies into the treatment of 
cancer were  conducted  at  different  centres.  The  first  report  on the  dermatological 
application  of  PDT  with  5-aminolevulinic  acid  (5-ALA)  was  published  in  1990 
(Kennedy et al.,  1990). Since  1994, various photosensitisers have been developed for 
clinical use as reviewed in (Detty et al., 2004) or references contained therein.
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1.1.2 Photosensitisers 
1.1.2.1 Photofrin
Hematoporphyrin  derivatives  (HpD)  are  the  most  frequently  clinically  used 
photosensitisers  with  successful  outcomes  (Biel,  1998;  Allison  et  al.,  2001). 
Photofrin  (profimer  sodium)  was  the  first  photosensitiser  used  for  a  variety  of 
clinical trials (Dougherty,  1996), but the lack of therapeutic selectivity, limited depth 
effect:  (0.5cm), weak absorbance in the red region of the spectrum, where light can 
penetrate most efficiently  into tissues,  and prolonged  skin  sensitivity,  which  keeps 
the  patient  out  of daylight  for more  than  6  weeks  after PDT  (Gomer et  al.,  1984; 
Braichotte et al.,  1995), have forced researchers to develop new and improved drugs.
1.1.2.2 Foscan
The  second  generation  meta-tetrahydroxyphenylchlorin  (m-THPC;  temoporfin, 
Foscan,  Biolitec  Pharma,  Scotland,  U.K.)  is  a  reduced  porphyrin  of the  synthetic 
chlorins, and is perhaps the most potent second-generation photosensitiser available 
for use in clinical oncology. Foscan has received approval in Europe for use against 
head and neck cancer and other cancerous conditions. Foscan has a strong absorption 
peak in the red part of the spectrum (absorption coefficient 22 400 M/cm at 652 nm) 
(www.biolitecpharma.com).  In  animal  studies,  no  significant  correlation  between 
tumour  Foscan  levels  and  PDT  response  has  been  found,  which  suggests  that 
Foscan-PDT effects are most likely to be associated with vascular damage (Cramers 
et  al.,  2003).  Many  trials  work  with  some  degree  of  success  to  improve  drug 
selectivity by conjugating Foscan to other structures,  such as poly (ethylene glycol) 
conjugates  eg.  PEG-mTHPC  (Krueger  et  al.,  2003).  Foscan  is  currently  being 
evaluated in phase III clinical trials for a wide variety of cutaneous lesions, including 
head and neck tumours (Dilkes et al., 2003; Copper et al., 2003).
The  major  side  effect  of Foscan  is  skin photosensitivity,  and this  can  last  up  to  4 
weeks post treatment. The drug now is used in multicentre trials for the treatment of
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early or recurrent cancer and the palliative control of resistant oral tumours.  All of 
the  released  results  have  shown  promising  tumour  response  rates  (Hopper  et  al., 
2004a;  Kubler  et  al.,  2001).  A  clinical  study  on  128  patients  with  advanced 
squamous cell carcinoma who were treated with Foscan-PDT demonstrated that 43% 
of all  patients  achieved  100%  tumour  mass  reduction,  while  53%  experienced  a 
significant quality of life benefit (D’Cruz et al., 2004).
1.1.2.3  Aminolevulinic acid
Aminolevulinic  Acid  (ALA)  is  another  photosensitiser  that  shows  promise  in  the 
treatment and detection of early and advanced malignant lesions, including head and 
neck cancer tumours.  ALA is an endogenous precursor of the biosynthetic pathway 
of haem. Following exogenous administration, ALA is transformed enzymatically by 
ferrochelatase  into  fluorescing  protoporphyrin  IX  (PpIX).  A  simplified  scheme  of 
this biosynthetic pathway is  shown in Figure  1.2.  The administration of exogenous 
ALA can overload the haem biosynthesis pathway and the normal feedback control 
mechanism is then bypassed, leading to the transient accumulation of PpIX to levels 
more than those normally present in the body.
Since  the  first  successful  clinical  application  of ALA,  various  publications  have 
subsequently  demonstrated  that  the  accumulation  of PpIX  is  increased  in tumours 
relative to the surrounding normal tissues and it has been suggested that this is due to 
the  increased  permeability  of tumorous  vasculature  and the  reduced  ferrochelatase 
concentrations  in  tumour  tissue  (el-Sharabasy,  1992;  Rittenhouse-Diakun  et  al., 
1995; Ackermann et al.,  1998; Detty et al., 2004). ALA-PDT has received approval 
in  Europe  for the  treatment  of superficial  cutaneous  lesions  (www.photocure.com) 
such as actinic keratosis (AK) and basal cell carcinoma (BCC), with a high complete 
response rate (Dolmans et al., 2003).
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Figure 1.2  Representative diagram of haem biosynthetic pathway, adapted from 
(Peng et al., 1997)
1.1.3  Singlet oxygen and the photophysics of PDT
The  destruction mechanism  of malignant tissue  following  PDT mostly takes place 
through  two  reactions,  type  I  and  II.  This  photooxidation  process  requires 
photosensitiser drugs, a light source, and oxygen. Each photosensitiser absorbs light 
with specific wavelengths to produce an excited electronic state (Figure 1.3).
After the successful absorption of the light photons by the photosensitiser, chemical 
reactions  are  initiated  and proceed when the photosensitiser electrons  are  elevated 
from a ground low energy state to an excited high energy singlet state. This state is 
short lived and can subsequently dissipate directly to a ground state with the release
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of fluorescence, but without photodynamic action. This phenomenon forms the basis 
of light-induced fluorescence, a method used to detect cancer at an early stage with 
the help of an imaging device. Other relatively long-lived states are formed when the 
photosensitiser is further excited to a first triplet state (Tl), where electrons can be 
lost  and  radical  cations  (RC)  are  formed.  These  radicals  can  either react with the 
adjacent  cellular  membranes  or  endogenous  alcohols  (type  I  photoreaction)  or 
transfer  their  energy  to  molecular,  triplet-state  oxygen,  producing  singlet-state 
oxygen ('0 2) (type II photoreaction) and returning the sensitiser back to the ground 
state, where it can absorb another photon (Dougherty et al., 1998). This J0 2 is highly 
cytotoxic to all  cells  hosting the  photosensitiser,  including normal  cells.  The  short 
lifetime (<0.04 ps) and short radius of action (<0.02 pm) of *02 can result in limiting 
the  action  to  the  irradiated  tissue  loaded  with  sufficient  concentration  of 
photosensitiser  and  oxygen.  In  addition,  the  relative  preferential  uptake  of  the 
photosensitiser  in  cancerous  tissue  also  provides  the  basis  for  selective  cancer 
treatment (Moan and Berg, 1991; Niedre et al., 2003).
Figure 1.3  Principles of photodynamic therapy. SO: ground state, SI excited 
singlet state, F: fluorescence emission, T l: excited triplet state of the photosensitiser, 
'0 2 singlet state, 30 2 triplet state
Oxygen
SO f
Photosensitiser
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1.1.4  Fluorescence photobleaching
Photobleaching  occurs  when  the  transient  species  reacts  with  the  photosensitiser, 
resulting  in  the  production  of  photoproducts  that  deplete  the  concentration  of 
photosensitiser during treatment and consequently reduce the PDT efficiency.  This 
photoproduct has different characteristics from the photosensitiser (Georgakoudi and 
Foster,  1998). Generally, photobleaching is measured as the decrease in fluorescence 
over time,  since the concentration of photosensitiser and fluorescence intensity are 
proportional  (Mang  et  al.,  1987).  Once  the  photosensitiser has  been  used  up,  any 
further irradiation has  no  extra effect.  This  seems to prevent overdosage (Taber et 
al.,  1998).  The  monitoring  of  the  sensitiser  photobleaching  via  fluorescence 
measurement can, therefore, provide a means of real time dosimetry in order to solve 
some  of  the  problems  encountered  by  clinicians  due  to  insufficient  PDT  dose 
(Wilson et al., 1997).
Researchers  have  attempted  to  measure  photobleaching  fluorescence  in  vivo  with 
controversial  results  (Moan,  1986;  Rhodes  and  Diffey,  1997).  The  amount  of ]C > 2 
required in tissue for efficient PDT depends partly on the photosensitiser, the tissue 
type,  and  the  rate  of light  delivered  (fluence  rate).  Currently,  The  PDT  dose  is 
determined according to photosensitiser concentration and the light applied. The unit 
giving the total energy delivered is the joule (J), which is calculated as the product of 
the fluence rate in watts (W), multiplied by time in seconds. The number of photons 
(N) in a joule depends upon the wavelength of the light. If two different wavelengths 
of light are used, the number of photons per joule varies as the inverse ratio of the 
wavelength. One has to take into account the effect of the delivered rate of the light 
(fluence rate = W/area) and thus the treatment time depends on the light source used. 
If the  light  is  delivered  at  a high  rate,  significant heating  of the  molecule  and  its 
surrounding area may take place.
Many researchers have evaluated what is termed the “on-and-off protocol, which is 
based  on  the  concept  that  the  re-oxygenation  of the  areas  where  the  oxygen  was
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depleted by photochemistry is probably the most important effect (Messmann et al., 
1997; Babilas et al., 2003) . In vivo, re-oxygenation is partly due to the diffusion of 
oxygen from the capillaries and partly to the relaxation of the vasculature that has 
been subject to vasoconstriction (Pogue et al., 2002). In a normal rat colon sensitised 
with ALA-induced  PpIX,  the  introduction  of a break  of approximately  150  s  was 
found  to  increase  markedly  the  volume  of necrosis,  with  a reduction  of the  total 
delivered  light  dose  (Cumow  et  al.,  2000).  The  use  of  hyperbaric  oxygen  to 
compensate  for the  depletion  of oxygen  has  also  been reported,  with encouraging 
results (Maier et al., 2000; Tomaselli et al., 2001; Huang et al., 2003). According to 
the discussion from the previous papers, it seems that dependence on sensitiser and 
light  dose  are  insufficient  to  predict  treatment  outcome.  Chapter  8  of this  thesis 
presents the clinical results of photobleaching of the ALA-induced PpIX.
1.1.5  Biological considerations
Necrosis  was  considered  the  only  cell  death  mechanism  caused  by  PDT  until  an 
apoptotic response to PDT was reported in  1991  (Agarwal et al.,  1991). Since then, 
apoptosis has been observed in a variety of tumour cell lines (Figure  1.4). In vitro, 
the  primary  cellular  target  of photodynamic  therapy  is  clearly  determined  by  the 
subcellular  location  of a  given  photosensitiser.  Photosensitisers  localizing  in  the 
plasma membrane usually exert their destruction either by inactivation of membrane 
bound  apparatus,  endoplasmic  reticulum  and  cytoplasm  are  usually  involved  in 
signal transduction enzymes or by direct photoperoxidation of the membrane itself, 
which  causes  (i)  loss  of membrane  integrity  and  favours  necrotic  cell  death;  (ii) 
while  photosensitisers  accumulated  in  mitochondria  lead  to  disruption  of their 
function  which  causes  the  release  of cytochrome  C,  several  events  are  initiated 
which result in an apoptotic mode of cell death (Almeida et al., 2004; Oleinick et al., 
2002; Marchal et al., 2005).
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Figure  1.4  A  schematic  diagram  of  the  extrinsic  and  the  mitochondria- 
mediated  cell death  pathways following exposure to PDT leading to cell death.
Adapted from (Almeida et al., 2004)
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1.2  Optical spectroscopy
Reflection, refraction, absorption and scattering are the main mechanisms that occur 
when light migrates  in tissue.  The light can interact with tissue by photochemical, 
thermal,  photoablation,  and  photodisruption,  depending  on  the  tissue  and  light 
parameters  used.  In  biological  tissues,  the  light may  either be  absorbed  by tissue 
molecules  such  as  water proteins  and  hemoglobin  or  scattered  by  tissue  particles 
such as cells nuclei. Absorption occurs when an electromagnetic wave interacts with 
an  elastically  bound  charged  particle,  which then vibrates  at the  frequency  of the 
electromagnetic wave.  Scattering, on the other hand, takes place at frequencies not 
corresponding to the natural  frequencies of these particles.  For wavelengths >850- 
900  nm,  the  photons  may  not  have  sufficient  energy  to  participate  in  a 
photochemical reaction.  Therefore, the wavelength range between 600 and 800 nm 
has  been  determined  as  the  practical  therapeutic  window  (Richards-Kortum  and 
Sevick-Muraca, 1996).
The  term  spectroscopy  refers  to  the  study  of the  interaction  of electromagnetic 
radiation  with  matter.  There  are  three  aspects  to  a  spectroscopic  measurement: 
irradiation  of  a  sample  with  electromagnetic  radiation;  measurement  of  the 
absorption, spontaneous emission (fluorescence, phosphorescence) and/or scattering 
(Rayleigh  elastic  scattering,  Raman  inelastic  scattering)  from  the  sample;  and 
analysis and interpretation of these measurements. Clinically, the term describes the 
process  of  evaluation  of  the  tissue  optical  properties  with  subsequent  spectral 
analysis of the acquired data by using an in vivo system. A diagnosis or monitoring 
of tissue status is then attempted, based on in situ optical measurement which can be 
performed non-invasively, without the need for surgical biopsy (Hammes, 2005).  It 
has  become  universally  known that early detection of premalignant and malignant 
lesions  can  substantially  reduce  the  risk  or  improve  the  prognosis  in  oral  cancer. 
Clinical  differentiation  of  lesions  is  usually  based  on  morphological  changes  in 
tissues;  this  technique  is  quite  difficult  to  implement  and  experience  usually  is 
considered to  be  a major factor in its  success.  However it can be found to be  less
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sensitive  in differentiating between lesions with similar clinical and morphological 
characteristics, i.e. dysplasia and carcinoma in situ.
There is always a risk of a premalignant lesion transforming into a malignant one if 
certain factors or conditions lead to its excitation; these usually require continuous 
monitoring, which can sometimes be difficult since it might require multiple biopsies 
to  be  taken  from  the  patient,  which  can  be  uncomfortable,  time  consuming  and 
costly. Moreover, it is difficult to screen a large number of the population who are at 
high risk of developing the disease. Several diagnostic and alternative methods have 
been employed to increase the detection of mucosal lesions, such as histopathology, 
radiology,  biological  markers  or  application  of  certain  dyes,  including  iodine 
solution,  Lugol’s  iodine,  and  Toluidine  blue;  combining  two  or  more  techniques 
together  has  been  shown  to  increase  the  sensitivity  and  specificity  (Kurita  and 
Kurashina,  1996;  Onizawa  et  al.,  1999;  Onizawa  et  al.,  1996).  Caution  must  be 
exercised, as the vital staining is only appropriate for dysplastic changes that appear 
on the surface and has no value if there is underlying infiltrating carcinoma that does 
not  produce  surface  dysplasia.  Moreover,  some  of these  medical  techniques  are 
costly  and  only  available  to  a  limited  number  of  populations.  Screening  and 
detection of cancer at an early stage may be improved by optical techniques which 
are now under scientific investigation.
The  main  techniques  currently  utilised  in  the  detection  of  oral  dysplasia  and 
malignancies  are  Fluorescence,  Raman  and  Elastic  Scattering  spectroscopy.  This 
thesis,  however,  concentrates  on  fluorescence  and  elastic  scattering  spectroscopy. 
All  three  types  utilise  light  within,  or  just  outside,  the  visible  range  of 
electromagnetic radiation (Figure 1.5).
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Figure 1.5  Diagrammatic representation of the visible spectrum demonstrating 
colour versus wavelength
1.2.1  Raman spectroscopy
Raman  spectroscopy  is  an  optical  method  based  on  inelastic  light  scattering.  A 
Raman  spectrum  is  a plot  of scattered  intensity as  a function of energy difference 
between  incident  and  scattered  photons,  i.e.  Raman  effects  are  produced  when 
incident  light  excites  sample  molecules  and  scatter them  at  different wavelengths. 
This inelastically scattered light is called the Raman scatter.  From the energy level 
point of view, the process of Raman scattering can be viewed as the transition of a 
molecule  from  its  ground  state  to  an  excited  vibration  state,  accompanied  by  the 
simultaneous  absorption  of an  incident photon and emission of a Raman  scattered 
photon.  Recent  developments  in  fibre-optic  probe  technology  have  enabled  its 
application  as  an in  vivo technique to  study the  structure and dynamic  function of 
important molecules (Hanlon et al., 2000).
Many studies have shown that high quality Raman spectra can be interpreted from a 
biochemical  viewpoint  for  the  possibility  of diagnosing  the  pre-cancerous  tissues 
(Stone et al., 2000; de et al., 2005).
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1.2.2  Fluorescence spectroscopy
Fluorescence spectroscopy or diagnosis is relatively simple, especially in the case of 
the photosensitiser-enhanced fluorescence imaging of facial skin and the oral cavity, 
or it may be more complex in the case of fluorescence endoscopy. The phenomenon 
is based on laser or a high-powered filtered lamp source in the near-UV or UV extent 
of the  light  spectrum,  which  excites  tissue  molecules  (fluorophores)  and transfers 
them into an excited state that rapidly reverts to a more stable and less energetic state 
after the emission of fluorescent light (Figure 1.6).
The fluorescence can either occur as autofluorescence (induced by UV light), or as a 
laser-induced phenomenon and may also be enhanced by either topical or systemic 
application of 5-aminolevulinic  acid  (5-ALA)  and  can be  used  for  single-point  or 
imaging  measurements.  5-ALA  is  a  precursor  of the  fluorescent  photosensitiser, 
protoporphyrin IX (PpIX), and can be administered systemically or applied topically 
to  the  oral  mucosa  and  facial  skin.  The  main  characteristic  of tissue  fluorescence 
used  for medical  diagnostics  are that one may see  (i)  an obvious difference in the 
emission  spectrum  at  a  set  excitation  wavelength  between  diseased  and  healthy 
tissue;  (ii)  differences  in  the  excitation  spectrum,  the  fluorescence  lifetime  and 
polarization (Andersson-Engels et al.,  1997). Fluorescence diagnostics offers several 
clinical benefits and has therefore been extensively studied in preclinical and clinical 
studies  since  1990  as  reviewed  in  (Sokolov et al.,  2002).  The use of native tissue 
fluorescence  for  the  early  detection  of  malignant  tissues  was  investigated.  The 
results  were  encouraging  but  varied  greatly  between  some  patients  and  appeared 
inappropriate for others (Betz et al., 1999). In addition, there are a high percentage of 
false-positive  and  false-negative  results,  which  may  be  attributed  to  insufficient 
number of patients,  whereas  fluorescence  spectroscopy of exogenous  fluorophores 
has shown high sensitivity and specificity.
Dysplastic and malignant tissues, as well as having different spectral characteristics, 
tend  to  have  increased  red  fluorescence  and  decreased  green  fluorescence,  with
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significant  increase  of the  red/green  fluorescence  ratio  (Rhodes  and  Diffey,  1997; 
Leunig et al., 2001; Zheng et al., 2002a). Chapter 6 of this thesis presents the clinical 
results  of fluorescence  imaging  of the  ALA-induced  PpIX  for  early  detection  of 
tissue dysplasia.
Incident light  Emitted Fluorescent Light
Tissue
Figure 1.6  Optical biopsy using fluorescence spectroscopy. Emitted fluorescence 
light of different wavelengths to incident light
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1.2.3  Elastic scattering spectroscopy
Elastic  Scattering  Spectroscopy  (ESS)  is  an  emerging  technique  that  generates  a 
wave-length  dependant  spectrum  that reflects  structural  and morphological  change 
within tissues.  Elastic scattering implies that the light returns with the same kinetic 
energy  as  the  incident  photons.  The  incident  light  can  undergo  single,  or  more 
commonly,  multiple  scattering  events  before  being  collected  again  at  the  same 
surface by an optical probe, and the resulting data is analysed (Figure 1.7).
The acquired data reflects both the scattering and absorptive properties of that tissue. 
(Bigio  and  Mourant,  1997).  This  scattering  process  has  been  shown  to  occur  at 
gradients in the optical index of refraction resulting from differences in densities that 
occur at a cellular and  sub-cellular level.  The  structures that induce the  scattering 
(collectively known as scattering centres) are the nucleus, chromatin concentration, 
and  sub-cellular organelles.  Thus,  ESS  has  been  shown to  be  sensitive to  nuclear 
size, chromatin content and nuclear/cytoplasmic ratio, which are all criteria that the 
histopathologist looks for when establishing malignancy within a tissue (Perelman et 
al., 1997; Wallace et al., 2000; Mourant et al., 2000; Drezek et al., 2003).
ESS has the advantage of being fast, reliable and cost effective and potentially offers 
a non-invasive diagnosis in-situ,  and in real time. The technique has not been used 
only  in  the  diagnosis  of dysplasia  and  malignancy,  but  can  be  used  to  monitor 
chemotherapy  levels  and  possibly  free-flap  oxygenation  levels.  It  can  also  enable 
guided rather than random biopsies, and assess surgical margins and regional lymph 
nodes intra-operatively (Gollnick et al., 2001; Mourant et al., 2000; Nordstrom et al., 
2001;  Jerjes  et  al.,  2005).  ESS  has,  in  a  number  of studies,  been  combined  with 
extracted  intrinsic  fluorescence  and  diffused  reflectance,  forming  a  “tri-modal 
spectroscopy”  device  which  has  been  shown  to  have  a  higher  sensitivity  and 
specificity when examining premalignant and malignant lesions (Georgakoudi et al.,
2001).  Chapter  7  of this  thesis  presents  the  clinical  results  of ESS  for  an  early 
detection of tissue dysplasia.
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Figure 1.7  Schematic illustration of elastic scattering in human tissue.
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1.3 Cancer invasion and metastasis
To achieve a better understanding of the cancer process, we need to understand the 
molecular alterations that take place during carcinogenesis. This knowledge will help 
in prediction, diagnosis and prospective therapy. Normal tissues are characterized by 
a  homeostatic  balance  between  cellular  proliferation  and  cell  death,  and  any 
disturbance can  lead to the development of the disease.  Malignant cells most often 
have  disturbances  in  both  of  these  processes.  The  development  of  a  tumour 
metastasis  can  be  considered \ s   a  complex  multi-step  molecular  process  which 
involves  the  interplay  between  several  processes  including  altered  cell  adhesion, 
survival,  proteolysis,  migration  and  angiogenesis.  In  epithelial  tissue, the  invading 
cells should be able (i) to induce the development of blood vessels by expressing a 
gene for blood vessel growth factors;  (ii) to pass through a basement membrane by 
altered  interactions  of  the  invading  cells  with  extracellular  matrix  (ECM) 
components  such  as  laminin,  collagen  type  I  and -IV  and  fibronectin  .  Adhesion 
molecules, such as integrins and cadherins, are also involved in both cell-to-cell and 
cell-to-ECM interactions (Hanahan and Weinberg, 2000), as illustrated in Figure 1.8.
Normal epithelial organization  Invading tumour cells
E-cadherin Epithelium
Integrin
Laminin
Fibronectin
Basement
membrane Collagen
Fibroblast
Stroma Blood vessel
Figure 1.8  A simplified schematic illustration of events during tumour cell 
invasion.
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1.3.1 Angiogenesis
The formation of new capillary blood vessels (angiogenesis) represents an essential 
requirement for the continued growth and invasion of solid tumour cells, including 
those found in head and neck squamous cell carcinoma. This process is regulated by 
a  balance  between  proangiogenic  factors,  such  as  the  vascular  endothelial  growth 
factor (VEGF) and its family, and the antiangiogenic factors (Laughner et al., 2001).
Angiogenesis is a sequential process emanating from the microvascular endothelial 
cells, when proangiogenic factors bind to cell receptors and stimulate growth. As a 
consequence, more proteases are secreted from the endothelial cells. These proteases 
can digest the extracellular matrix proteins, which also results in the further release 
of proangiogenic  factors.  Following  digestion,  the  cells  start  to  move  toward  the 
sources of the stimulus (tumour cells) and undergo morphological changes to form 
new blood vessels which contribute to solid tumour feeding (Bhushan et al., 2002).
1.3.2 Cell adhesion
The environment can regulate cellular function in several ways: Receptor molecules 
for  ECM  proteins  can  mediate  both  mechanical  stress  and  ligand  specific 
interactions,  leading  to  the  activation  of  specific  intracellular  signal  pathways 
(outside-in  signalling).  Conversely,  intracellular events  can  lead  to  changes  in the 
expression  and  affinity  state  of  cell  surface  adhesion  receptors  (inside-out- 
signalling).
Cell  adhesion  molecules  (CAMs)  are  membrane-based  proteins  with  cytoplasmic, 
transmembrane and extracellular domains. The cytoplasmic tail often interacts with 
the  cytoskeletal  proteins  that  serve  as  the  actual  anchor  within  the  cell.  The 
extracellular  domains  extend  from  the  cell  and  binds  to  adjacent  cells  or  to  an 
extracellular  matrix  through  homophilic,  heterophilic  or  an  intermediary  linker.
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CAMs  are  divided  into  four major  families:  cadherins,  the  immunoglobulin  super 
family, integrins and selectins (Juliano, 2002). This thesis, however, concentrates on 
a subset of integrins.
1.3.2.1 Cadherin
E-Cadherin  is  the  main  adhesion  molecule  of epithelia  and  is  sometimes  called 
‘molecular  glue’.  It  is  a  transmembrane  glycoprotein  which  mediates  calcium 
dependent  intracellular  adhesion  proteins  in  the  epithelial  tissues  through  its 
extracellular  domain.  The  cytoplasmic  domain  of E-cadherin  can  play  a  role  in 
transmission of anti-growth  signals  (Christofori and  Semb,  1999).  Over-expression 
of these molecules may result in an inverse relationship with the metastatic capacity 
of the tumour cells (Luo et al., 1999).
1.3.2.2 Integrins
Integrins are a large  family of transmembrane cell  surface receptor proteins which 
play a crucial role in cellular stability by providing adhesive function in cell-to-cell 
and  cell-to-ECM  interactions,  and  mediate  numerous  intra-cellular  pathways  that 
regulate  many  cell  functions,  such  as  proliferation,  differentiation,  migration, 
invasion,  apoptosis,  and  gene  expression  (Mizejewski,  1999).  Functional  integrins 
consist  of heterodimeric  complexes  of noncovalently  linked  a-  and  P-chains  and 
serve as a link between the ECM and the cytoskeleton of the cell (Hynes, 2002). At 
present, 18 different a  subunits and 8 p subunits are known to combine to form more 
than 24 integrins, each has a distinct ligand binding specificity (Mizejewski,  1999), 
as  illustrated  in Table  1.1.  Following binding to  ligand,  integrins undergo  a set of 
dynamic changes. Integrin expression is dependent on anatomy and tissue condition, 
e.g.  in  normal  epithelia,  a3pi,  a2pl  and  a6p4  integrin  receptors  are  generally 
expressed,  while  in  oral  squamous  cell  carcinoma,  a5pi  and  avp6  expression  are 
more  obvious;  this  may  correlate  with  the  downregulation  of  avp5  subunits 
(Giannelli et al., 2001; Maragou et al., 1999).
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Table 1.1  List of currently known ligands of different a- and p-subunits
for integrin family (Mizejewski,  1999).
a  subunit P  subunit Known Ligands substrate
al PI Collagens, Laminins
a2 PI Collagens, Laminins
a3 PI Laminins, Fibronectin, Thrombospondin
a4 PI Fibronectin, VC  AM
a4 P7 Fibronectin, VC  AM,
a5 PI Fibronectin
a6 PI Laminins
a6 P4 Laminins
a7 PI Laminins
a8 PI Fibronectin, Tenascin
a9 PI Tenascin
alO PI Collagens
a ll PI Collagens
aD P2 VCAM, ICAMs
aE p7 E-cadherin
aL PI ICAMs
aM PI Fibrinogen, ICAMS
aX P2 Fibrinogen
av PI Fibronectin, Vitronectin
av P3
Fibronectin, Vitronectin, Fibrinogen, von
Willebrand’s factor, Thrombospondin
av P5 Vitronectin
av p6 Fibronectin, Tenascin
av P8 Collagens, Laminins, Fibronectin
allb P3
Collagens, Fibronectin, Vitronectin, Fibrinogen,
Von Willebrand’s factor, Thrombospondin
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1.3.3 Extracellular matrix
The  extracellular  matrix  (ECM),  the  network  of proteins  surrounding  cells,  is  a 
highly  organized  fibrillar  meshwork,  consisting  mainly  of collagens,  fibronectin, 
vitronectin and laminins, which serve as substratum for cell adhesion and migration.
1.3.3.1 Collagens
Collagens  represent  the  major  protein  comprising  the  ECM  with  more  than  20 
different collagen types identified so far (Gelse et al., 2003). Collagen types I, II and 
III are the most abundant fibrils of similar structure. Types IV and VII collagen form 
a two-dimensional  reticulum,  which  represents  the  major  component  of the  basal 
lamina.  Collagens  are  secreted  inactive  into  the  extracellular  space  and  require 
activation  by  the  extracellular  enzymes.  This  is  implicated  in  both  the  normal 
physiological  processes,  such  as  embryogenesis  and  wound  healing,  and 
carcinogenesis (O’Toole, 2001).
1.3.3.2 Fibronectin
Fibronectin is a large, multidomain glycoprotein of high molecular weight found on 
cell surfaces, extracellular matrix and in plasma. It interacts with several molecules 
found  within  the  extracellular  matrix,  basement  membranes  and  cell-surface 
receptors.  Integrin  molecules  mediate  its  binding  to  the  cell  surface  and  serve  to 
trigger cellular signalling. Fibronectin plays special roles in cell adhesion, migration, 
differentiation and cytoskeletal organization (Pankov and Yamada, 2002).
1.3.4 Matrix metalloproteinases
Cell function and fate are dictated by both the intrinsic cellular signalling pathways 
and the external microenvironment. The microenvironment signals may regulate cell 
adhesion,  differentiation,  division,  and  apoptosis.  Limited  proteolysis  via
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components  known  as  matrix  metalloproteinases  (MMPs),  allow  cells  to  move 
through modified matrix. This movement involves continuous ECM attachments and 
detachments by invading cells.
1.3.4.1 Structure of MMPs
MMPs  are  a  family  of  more  than  24  zinc  and  calcium-dependent  members  of 
metalloenzymes  (Table  1.2).  MMPs  are  numbered  according  to  their  order  of 
discovery,  and  divided  according  to  their  substrate  specificity  into  interstitial 
collagenases  (MMPs  -1,  -8  and  -13),  stromelysins  (MMPs  -3,  -10  and  -11), 
gelatinases (MMPs -2, and -9), and other membrane types (MT)-MMPs (Kleiner and 
Stetler-Stevenson,  1999).  MMPs are also divided into subclasses according to their 
shared functional domains into eight distinct classes: five are secreted and three are 
membrane-bound (Kerkela and Saarialho-Kere, 2003).
1.3.4.2 Regulation of MMPs activity
The synthesis of MMPs is regulated by several factors, including growth factors and 
cytokines  secreted  by  lymphocytes,  stromal  cells,  tumour cells  and ECM proteins. 
All MMPs are produced in a pro-form, which needs extracellular activation through 
the  removal  of their  propeptide  domains.  The  soluble  types  of MMPs,  such  as 
gelatinases  and  collagenases,  are  activated  mainly  by  other  MMPs  or  plasmin 
(Figure  1.9),  while  the  activation  of membrane  type  MMPs  is  a  more  complex 
process (Curran and Murray,  1999).  The four members of the tissue inhibitor MPs 
(TIMP-1,  -2,  -3  and  -4)  can  bind  to  MMPs  and  reversibly  inhibit  their  activity 
(Fassina et al., 2000).
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MT-MMP uPA
Plasminogen Plasmin
MMP-2 MMP-13
MMP-1  + MMP-3
*   MMP-9
Figure 1.9  Activation cascade of MMPs. Adapted from (Curran and Murray, 
1999).
1.3.4.3  Function of MMPs
MMPs  have  a  role  in  the  normal  development  of the  tissues  and  organs  during 
embryogenesis. This function however, is altered in malignant tissues. MMPs have a 
dual  role  in  tumour  growth  and  metastasis.  They  promote  tumour  growth  by 
degrading  most of the  ECM  components,  and enhancing  angiogenesis  (Rundhaug, 
2005).  They  also  provide  cells  with  directional  information  by  modifying  the 
environment in front of the cell (Bogenrieder and Herlyn, 2003; Kramer et al., 2005).
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Table  1.2  A list of some tumour associated MMPs and their substrates 
(Kerkela and Saarialho-Kere, 2003)
Enzyme MMP number Matrix substrates
Collagenases-1 MMP-1 Collagens I, II, III, VII, VIII, X and XI, 
gelatin, entactin, tenascin, aggrecan, 
fibronectin, vitronectin, casein.
Collagenases-2 MMP-8 Collagens I, II and III, aggrecan.
Collagenase-3 MMP-13
Collagens I, II, III, IV, IX, X, XIV, gelatin, 
fibronectin, aggrecan, casein.
Gelatinase A MMP-2 Collagens I, II, III, IV, V, VII and X, 
gelatin, fibronectin, laminin, aggrecan, 
elastin, vitronectin, tenascin.
Gelatinase B MMP-9
Collagens IV, V, XI, XIV, elastin, aggrecan, 
decorin, laminin, fibronectin.
Collagens III, IV, V, IX, X, and XI, gelatin,
Stromelysin-1 MMP-3 aggrecan, elastin, fibronectin, vitronectin, 
laminin, entactin, tenascin, decorin.
Collagens III, IV and V, gelatin, fibronectin,
Stromelysin-2 MMP-10 elastin, aggrecan, casein, pro-MMP-1, pro- 
MMP-2, pro-MMP-9, pro-TNF-a.
Stromelysin 3 MMP-11 Ealstin, collagen IV, gelatin, fibronectin,
Metal loelastase MMP-12 vitronectin, laminin, entactin,
MT1-MMP MMP-14 ProMMP-2, proMMP-13, collagens I, II and
MT2-MMP MMP-15
III, gelatin, fibronectin, vitronectin, laminin- 
1  and -5.
MT3-MMP MMP-16
ProMMP-2, laminin, fibronectin, tenascin, 
entactin, aggrecan, perlecan.
MT4-MMP MMP-17 Fibrinogen, fibrin, pro-TNF-a.
MT6-MMP MMP-25
Collagen IV, gelatin, fibrinogen, 
fibronectin.
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1.3.5 The Plasminogen activation system
The Plasminogen Activator System (PA), which consists of two types, is involved in 
the conversion of plasminogen to active plasmin. It can be classified according to its 
immunologic  or  biological  characteristics,  namely:  tissue-type  plasminogen  (t-PA) 
and  urokinase-type  plasminogen  activator  (u-PA).  There  are  also  plasminogen 
activator inhibitors  (PAIs)  which are  divided  into three  groups,  namely:  PAI-1,  -2 
and  -3).  In  addition,  there  are  the  protease  nexins,  which  also  inhibit  PA.  Under 
normal physiological  conditions, the  activation of plasminogen into  active enzyme 
occurs  to  numerous  processes,  e.g.  during  fibrinolysis,  cell  migration,  wound 
healing, trophoblast invasion, angiogenesis, tissue destruction, and the activation of 
growth factors and other proteolytic enzymes (Figure  1.9). Many of the roles of the 
Pas in normal physiology are equally important in cancer progression (Dano et al., 
2005).
1.3.6 Growth factor receptors
The  growth  factor  receptors  play  an  influential  role  in  signalling  that  direct  the 
behaviour  of normal  and  tumour  cells.  Therapies  targeting these  receptors  are the 
main focus of recent research, attempting to control replication, or tumourigenesis or 
cytotoxic effects on tumours.
1.3.6.1  Epidermal growth factor receptor
The  epidermal  growth  factor  receptor  (EGFR)  is  a  transmembrane  glycoprotein 
present  in  many  human  tissues.  EGFR  is  one  of four  membrane  growth  factor 
receptor proteins that share similarities in structure and function making together the 
c-erbB family of receptor tyrosine kinases. EGFR is a 170-kDa glycoprotein , which 
also  known  as  c-erbB-1,  is  composed  of  three  major  domains:  a  cystein  rich 
extracellular  ligand-binding  domain  connected  to  an  intracellular  protein  tyrosine 
kinase domain with tyrosine kinase function (Yarden, 2001).
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Multiple ligands bind to and activate the EGFR, including epidermal growth factor 
(EGF),  transforming  growth  factor-a  (TGF-a),  and  amphiregulin  (Salomon  et  al., 
1995).  EGFR  become  activated  by  binding  to  its  ligands,  leads  to 
autophosphorylation of receptor tyrosine kinase and subsequent activation of signal 
transduction  pathways,  which  played  an  important  role  in  cell  growth, 
differentiation,  angiogenesis,  adhesion,  metastasis  and  the  inhibition  of apoptosis 
(Herbst,  2004).  In  addition  to  ligand  binding,  EGFR  can  also  be  activated  by 
additional  EGFR  activation  mechanisms,  such  as  metalloproteinase-mediated 
cleavage of precursor membrane-bound EGF ligands (Prenzel et al.,  1999), and uP 
receptors  (Liu  et  al.,  2002).  Over  the  past  decade,  work  has  been  directed  at 
developing anticancer agents that able to stop or reduce the EGFR activity. The most 
common studied to date approaches consist of monoclonal antibodies, such as C-225
(fi) (cetuximab, Erbitux  ), directed to block ligand binding to the extracellular domain, 
and small molecules inhibitors,  such as ZD 1839 (Iressa, Gefitinib), which interfere 
with intracellular tyrosine kinase activity.
1.3.6.2  Hepatocyte growth factor receptor
The  receptor  for  the  hepatocyte  growth  factor  (HGF),  also  known  as  the  scatter 
factor  (SF),  is  a  transmembrane  tyrosine  kinase  receptor,  c-met  protein,  which  is 
predominantly  expressed  on  endothelial  cells,  whereas  the  mesenchymal  cells 
generally  express  their  ligand,  which  tends  to  act  in  a  paracrine  manner.  The 
activation of c-met by interaction with its ligand, HGF, has been shown to induce a 
variety of cellular responses, including epithelial cell proliferation, survival, tumour 
angiogenesis, invasion and metastasis (Maulik et al., 2002).
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1.4  Background to oral cancer
Oral  cancer remains a disfiguring disease associated with high mortality rate.  It is 
the sixth most common cancer diagnosed in world (Ferley et al., 2000).  Squamous 
cell  carcinoma  is  the  most  common  type  of  oral  cancer,  and  associated  with 
environmental exposure to carcinogens, particularly smoking tobacco  and betel nut 
chewing, which represent the major risk factors for oral cancer (Zavras et al., 2001). 
There  is  also  association  with  alcohol  consumption  and  possibly  viral  infection, 
particularly Human papilloma viruses (Smith et al., 2004).
Squamous  cell  carcinoma  is  a  heterogeneous  disease  with  distinct  presentation. 
Clinically,  the  appearance  of the  lesion  will  be  easier  if the  clinician  follows  a 
systemic and logical sequence, including full history and physical examination of all 
regions.  The  lesion arises  from the  surface mucosa lining the  oral  cavity,  and can 
readily  be  detected  by  visual  inspection  and  palpation.  At  an  early  stage,  it  may 
appear  as  an ulcer,  with  or  without  central  necrosis  and  exophytic  margins,  or  as 
mucosal erosion.
Currently,  Computerised  Tomography  (CT),  Magnetic  Resonance  Imaging  (MRI), 
and  Ultrasound  Scans  (US)  are  still  the  most  vital  tools  being  used  for  the 
assessment  of advanced  tumours  and to  determine  the  stage  of the  disease.  Much 
promise  has  been  also  shown  by  the  use  of the  newer  imaging  tools,  such  as 
lymphoscintigraphy for identification of sentinel nodes (Payoux et al., 2005; Kovacs 
et al.,  2005).  Other emerging non-invasive optical methods,  including fluorescence 
spectroscopy,  elastic  light  scattering  and  Raman  spectroscopy  are  still  under 
investigation, as discussed in Chapters 6 and 7 of this thesis.
At present, the genetic factors that contribute to the development of squamous cell 
carcinoma  are  still  not  clearly  defined,  and  data  showed  differences  in  genetic 
aberrations  in  different  nations,  which  may  be  due  to  different  etiological  factors 
(Jeon  et  al.,  2004;  Ginos  et  al.,  2004).  One  example  is  the p53  gene,  a  tumour
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suppressor gene,  whose  detection may be used as a prognostic  indicator,  since the 
risk of oral cancer is increased as the gene expression decreased (Greenblatt et al., 
2003).
In the management of cancer of the oral cavity, surgical resection and radiation with 
or  without  adjuvant  chemotherapy,  are  the  basic  treatment  for  early  disease 
(Forastiere et al., 2001). Isolated tumours in young patients may be best treated with 
an  excision  operation,  to  avoid  the  risk  of long-term  radiotherapy  complications, 
while  an  elderly  or  frail  patient  may  well  be  referred  for  radiotherapy,  even  for 
lesions that could easily be treated by surgery. For many patients, surgery is simply 
not an option because of general poor health or perhaps because of previous surgery 
to the head and neck region. Radiation therapy is effective in the treatment of loco- 
regional disease.
The debilitating effect of neck dissection on its function is reduced by the use of 
selective and super-selective neck dissection which involves only removal of 
affected lymph nodes, and the improvement in reconstruction methods of tissue 
defects caused by surgery (Robbins et al., 2005).
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1.5  Metastatic promoting factors in oral carcinoma
The prognosis  of patients with OSCC  is still poor due to the high rate of invasion 
and metastasis.  This process requires  efficient ECM digestion and nutrient supply, 
which  is  accomplished  through  the  activity  of  several  proteolytic  and  growth 
promoting factors, including MMPs, plasmin system, adhesion receptors and growth 
factors.  Based  on  these  considerations,  a positive  correlation between  malignancy 
and  expression/suppression  of these  factors  would  be  expected  (Myoung  et  al.,
2002). This thesis, however, concentrates on ECM proteinases; MMP-2, -9 and -13 
and uPA, proangiogenic factor; VEGF and avp6 and a5pl integrin receptors.
1.5.1  Expression of MMP-2, MMP-9 and MMP-13
MMPs  play  a  dual  role  in  tumour  growth  and  metastasis.  They  promote  tumour 
growth  by  digesting  the  matrix  barrier  and  enhancing  angiogenesis.  Numerous  in 
vitro studies have suggested a positive correlation between invasion and metastasis 
and the expression of MMP-2  and MMP-9  (Sundelin et al., 2005; Robinson et al., 
2003; Nyberg et al.,  2002;  Kawahara et al.,  1993;  Bennett et al., 2000). In vivo,  a 
study  of  the  presence  of  MMPs  in  human  surgical  biopsy  specimens  of  oral 
squamous cell carcinoma demonstrated a marked expression of MMP-2 and MMP-9; 
this was significantly associated with invasion and lymph node metastasis (Kurahara 
et al.,  1999). In 91  head and neck squamous cell carcinoma samples, the presence of 
MMP-2  and  MMP-9  was  investigated  using  immunohistochemistry,  and  a  close 
relationship  between  the  expression  of MMP-2  and  MMP  -9  and  clinical  stages, 
nodal metastases and tumour-stages was found (Do et al., 2004). In a recent study by 
de  Vicente  and  his  group  using  immunohistochemistry  examination,  MMP-2  and 
MMP-9 were  detected only  in  19  (28%) and  12  (17.6%) cases, respectively, of 68 
primary OSCC samples (de Vicente et al., 2005). Also, MMP-13 in vivo is found in 
invasive  head  and  neck  carcinomas.  In a study of 78  patients with head and neck 
squamous  cell  carcinoma,  using  immunohistochemical  techniques,  44  (56.4%) 
tumours were found to  significantly express MMP-13, whereas none of the normal
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tissues examined was found to express this protein.  Moreover, these high levels of 
MMP-13,  in  highly  invasive  tumours  were  noted regardless  of patient age,  sex or 
tumour site (Culhaci et al., 2004). More recently, Using p6-transfected OSCC cells, 
the  MMP-13  expression  at  both  mRNA  and  protein  level  was  recently  observed 
(Ylipalosaari et al., 2005).
1.5.2 Expression of uPA
According to  its function, the uPA is believed to influence the progress of tumour 
dissemination  and  metastasis.  The  contribution  of uPA to  the  invasive process  of 
OSCC was clearly demonstrated, in which invasion was substantially reduced when 
the  catalytic  site  of  urokinase  was  blocked  (dayman  et  al.,  1993).  It  was 
demonstrated that OSCC was able to  activate plasminogen and produce significant 
u-PA  levels  in vitro,  higher than those  of controls (Ghosh et al.,  2002).  In human 
tumour specimens, expression of uPA found to correlates with the mode of invasion 
and  secondary  regional  lymph  node  metastasis  of  OSCC  (Yasuda  et  al.,  1997; 
Nozaki et al., 2005). Furthermore, it was also found that patients suffering from oral 
cavity  tumour  recurrence  had  statistically  significant  higher  levels  of uPA  in  the 
tumour tissue  as  well  as  in tumour positive  lymph nodes  (Zemzoum  et  al.,  2003; 
Hundsdorfer et al., 2005).
1.5.3 Expression of VEGF
VEGF is one of the main regulators of angiogenesis, which is now accepted to play a 
vital  role  in  the  continued  growth  and  metastasis  of solid  tumours  (Sauter  et  al., 
1999). Based on these considerations, a positive correlation between malignancy and 
expression /suppression  of these  factors would be  expected.  However,  few studies 
have  reported  the  correlation  between  VEGF  expression  and prognosis  of OSCC. 
Immunohistochemistry  studies  using  antibodies  to  the  VEGF  from  tumour 
specimens obtained from 45 patients with oral squamous cell carcinoma revealed a 
minority  of tumours  expressed  VEGF.  Thus,  19  carcinomas  (42.2%)  were  VEGF
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positive  and  26  (57.8%)  were  negative  (Maeda  et  al.,  1998).  The  relationship 
between VEGF expression value, prognosis and regional lymph node metastasis was 
evaluated clinically in 63  patients with oral squamous cell carcinoma.  It was found 
that  values  of VEGF  expression  were  significantly  higher  for  patients  with  poor 
prognosis than for those with good prognosis, but regarding lymph node metastasis, 
no  significant  correlation  was  found,  since  the  average  percentage  of  VEGF 
immunopositive  area was  19.4%  in patients  with regional  lymph node metastasis, 
and 24.0% in patients without a metastatic lymph node (Uehara et al., 2004).
1.5.4  Expression of avp6 and a5pi integrins
The pattern of integrin expression in oral  squamous cell carcinoma varied between 
each malignant lesion,  but avP6  is  one  of the most commonly unregulated  in oral 
carcinomas  and  is  found  to  correlate  with  tumour  progression  and  invasiveness 
(Regezi  et  al.,  2002;  Thomas  et  al.,  1997;  Li  et  al.,  2003).  The  adhesion  of oral 
squamous  cell  carcinoma  cells  to  fibronectin  in  the  presence  of  neutralizing 
antibodies to both avp6 and a5pi  was tested in vitro. It was found that blocking of 
a5pl  alone reduced the adhesion to  70%, whereas if both avp6 and a5pl  integrins 
were  blocked,  adhesion  was  completely  lost.  In  addition,  an  81%  reduction  in 
migration was achieved when avp6 was  blocked (Xue et al., 2001).  A significant 
increase  in  OSCC  invasiveness  was  observed  when  non-invasive  Cl  line  was 
retrovirally  infected  with  p6  cDNA  to  produce  highly  invasive  VB6  cell  line 
(Thomas  et  al.,  2001a).  Using  similar  approach,  Ramos  et  al.  showed  that  avp6 
expression correlated with OSCC  invasion and tumour growth in vitro and in vivo 
when poorly invasive  SCC9 cell line was transfected with p6 cDNA (Ramos et al., 
2002).
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1.6  Metastatic  promoting  factors  following  PDT  in  oral 
carcinoma
PDT is currently under clinical  investigation for the treatment of early cancer.  The 
biological  effects  of  PDT  are  primarily  mediated  by  the  generation  of reactive 
oxygen species that result in cytotoxic effects on treated cells.  The oxidative stress 
produced  by  PDT  has  been  shown to  induce  the  expression  or activity  of several 
proteins  and  initiation  of  numerous  signal  transduction  pathways  that  control 
motility, growth and metastasis (Mitra et al., 2003).
1.6.1  PDT and cell adhesion
Prevention  of  cell  adhesiveness  represents  an  important  parameter  in  cancer 
metastasis.  Most  sensitisers used  in PDT accumulate in cellular membranes where 
the  obvious  cell  destruction  is  initiated.  This  results  in  alterations  in  tumour  cell 
adhesiveness with a possible distant spread. Only few studies have demonstrated the 
effect  of PDT  on adhesion.  It was  suggested  earlier that  PDT  is  a safe treatment 
when  considering  metastases  (Foultier  et  al.,  1994).  Vonarx  (1995)  found  an 
increased  adhesiveness  rate  of  some  colonic  cancer  cells  on  plastic  substratum, 
while, on ECM, the adhesion was decreased and this was correlated with a decreased 
metastatic potential in vivo (Vonarx et al.,  1995). Rousset et al (1999) demonstrated 
a  transient  decrease  in  the  expression  of ICAM-I,  MHC-I  and  CD44V6  surface 
adhesion molecules after Photofrin-PDT (Rousset et al.,  1999).  In brain tumours, a 
significant inhibitory effect on the ability of the cells to migrate through an artificial 
basement  membrane  was  observed  following  a  sublethal  dose  of Photofrin-PDT 
(Jiang et al., 2002).
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1.6.2 PDT and MMPs
Photosensitisation of mouse mammary tumour cells  with Photofrin-PDT increased 
MMP-9  protein  levels  (Ferrario  et  al.,  2004).  In  vitro  studies  using  the  5-ALA 
sensitiser  also showed an increase in MMP-1  and MMP-3 mRNA transcription and 
in  protein  levels  in  scleroderma  fibroblasts  cells  subjected  to  PDT  (Karrer  et  al.,
2003).  Interestingly,  no  change  in  MMP-1  and  MMP-3  levels  was  observed  in 
keratinocyte cells (Karrer et al., 2004).
1.6.3 PDT and VEGF
To  date,  there  is,  however,  little  information  about the  in vivo  effects  of PDT  on 
VEGF.  Most  previous  studies  on  VEGF  have  been  done  in  vitro  (Lisnjak  et  al., 
2005;  Togashi  et  al.,  2006a).  It  was  found  that  treatment  of  BALB/c  mice 
transplanted with  fibrosarcoma  BFS1  tumour with  PDT had reduced the  levels  of 
VEGF in mice sera and by 46% (the concentrations of control group after 24 h did 
not  exceed  70.8  pg/ml  whereas  in  tumourbearing,  untreated  mice,  VEGF 
concentration  was  over  150pg/ml  (Osiecka  et  al.,  2003).  Using 
immunohistochemical  staining,  The  PDT  treated  mice  cells  expressed  a  transient 
elevation of VEGF for up to 6 h, which subsequently returned to normal levels at 24 
h after PDT (Uehara et al.,  2001).  In  vivo  studies have revealed that VEGF  levels 
were higher in tumour surrounding tissues of rat brain (Jiang et al., 2004). In a recent 
study using human oral squamous cell carcinoma xenograft, a significant difference 
of VEGF expression between the control and experimental groups at 6 h after PDT 
(p  =  0.0436)  whereas  no  significant  differences  between  the  control  and 
experimental groups at 0, 3, 24, 48, and 72 h after PDT was demonstrated  (Togashi 
et al., 2006b).
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1.7  PDT in combination therapies
The  excellent  cosmetic  results,  the  low toxicity of the modem photosensitiser, the 
absence  of significant morbidity,  and the low cost of PDT compared to traditional 
modalities  make  PDT  a  competitive  treatment  choice  (Hopper  et  al.,  2004b). 
However, and importantly, there are several side effects to PDT, such as prolonged 
photosensitization  and  limited  target  depth,  which,  at  times,  cause  the  long-term 
follow-up  results  to  be  worse  than  their  conventional  treatments.  At  the  cellular 
level,  the  anti-tumour  efficiency  of any  drug  can  be  measured  by  the  apoptosis 
cascades initiated.  Regardless of the numerous apoptotic factors, other factors have 
been  identified  to  prevent  cell  death  (anti-apoptotic),  such  as  growth  factors  and 
cytokine ligands; all can lead us to consider ways to improve PDT cancer treatment. 
Therefore,  a combination of more than one treatment may increase the therapeutic 
outcome and reduce the side effects of each treatment used in isolation.
1.7.1  PDT and chemotherapy
The combination of PDT with chemotherapy may result in enhanced clinical results. 
At sub-toxic doses of PDT, the further addition of cytotoxic drugs may produce an 
additive effect (no more than the addition of the efficiency of each modality alone). 
This does not mean that there are no clinical benefits, since the adverse effect profile 
of the two modalities may combine to give a greater therapeutic ratio. Alternatively, 
the two modalities may produce a synergistic effect that exceeds the value of each 
modality.  Many researchers have study the effect of PDT combined with cytotoxic 
chemotherapeutic  agents,  and  some  suggest that the two modalities are  synergistic 
with  supra-additive  effects  (Dima  et  al.,  1990;  Ma  et  al.,  1993;  Ma  et  al.,  1992; 
Gantchev et al.,  1996).  Others also suggest that the cytotoxic effects are stronger if 
the  chemotherapy  is  applied  before  the  PDT  (Datta  et  al.,  1997).  Thus,  clinical 
studies based on the combination of two treatment modalities are needed in order to 
optimise and establish this approach.  Chapter 5 of this thesis presents the results of 
combination of PDT with chemotherapy.
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1.7.2  PDT and small molecules
One approach to enhancing the effects of PDT and reduce limitations is to add PDT 
either  simultaneously  or  concurrently  to  other  antitumour  agents.  The  EGFR  is 
considered  to  enhance  cell  proliferation,  motility,  adhesion,  invasion  and 
angiogenesis,  (Almeida  et  al.,  2004).  Several  approaches  have  been  designed  to 
diminish EGFR function.  One  of these  is the  development of a family of tyrosine 
kinase  inhibitors  (TKIs)  that  block  the  adenosine  triphosphate  (ATP)  site  in  the 
EGFR  tyrosine  kinase  domain  and  abrogate  the  receptor  autophosphorylation  and 
inhibit cell proliferation. The first small molecule found to have the ability to inhibit 
the tyrosine kinase pathways is Gefitinib (Iressa; ZD 1839), which been licensed in 
many  countries  for  non-small-cell  lung  cancer.  Pre-clinical  evaluation  of different 
tumour  types  has  shown  that  an  enhanced  cytotoxicity  has  been  observed  when 
ZD 1839  is used in combination with a number of conventional therapeutic agents, 
including cisplatin  and radiation  (Al-Hazzaa et al., 2005; Magne et al., 2002), but 
no report, at the time of writing, could be found regarding the combination of Iressa 
with PDT.
It has previously been reported earlier that treatment of epidermoid carcinoma A431 
cells  with  hypericin-PDT  irreversibly  inhibited  the  tyrosine  kinase  activity  of the 
epidermal growth factor (EGF) and insulin growth factor (IGF) receptors (Agostinis 
et al.,  1995). This was also increased in the mouse lymphoma L5178Y-R cells when 
sensitised  with  silicon  pthalocyanine  (Xue  et  al.,  1997)  and  murine  mastocytoma 
P815 cells sensitised with benzoporphyrin derivative monoacid ring A and subjected 
to PDT (Granville et al.,  1998). This increase in phosphorylation was later suggested 
as  being,  at  least  in  part,  secondary  to  Ca  ion  release  (Pereira  et  al.,  2003). 
Recently,  there  has  been  reported  evidence  that  intraperitoneal  administration  of 
C225, a monoclonal antibody that inhibits the EGFR and benzoporphyrin derivative 
monoacid-A (BPD) - based PDT acts synergistically to prevent or inhibit tumour cell 
growth  and  extend  survival  in  a  murine  model  of  ovarian  cancer  peritoneal 
metastasis.  The survival rate was approximately threefold greater than controls (no­
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treatment)  and  33%  and  10%  greater  than  treatment  with  only  C225  or  PDT, 
respectively (del Carmen et al., 2005).
1.8  Summary
Despite  the  advances  in  diagnostics  and  therapeutic  techniques,  the  outcome  and 
survival  of patients  suffering  from  head  and  neck  carcinomas  has  remained poor, 
primarily  due  to  late  detection,  and  the  tendency  of the  disease  to  develop  loco- 
regional  metastases.  A  key  to  its  control  is  early  detection  and  treatment  and 
prevention of recurrence and metastasis. Invasion and metastasis represent complex 
multistage  processes  which  require  migration,  invasion,  angiogenesis  and 
proteolysis.  The invasion of tumour cells is associated with the secretion of various 
types  of degrading  enzymes.  Several  studies  have  identified  the  roles  of MMPs, 
VEGF and uPA in this process (Yoshizaki et al., 2001; Franchi et al., 2002; Wemer 
et  al.,  2002;  Pacheco  et  al.,  2002).  Many  methods  were  applied  to  the  control  of 
invasion  using  growth  factor  antagonists  and  signal  transduction  inhibitors,  all  of 
which have resulted in varied results and limited success.
PDT  is  a recent treatment  modality  for a variety  of malignant tumours,  including 
head and neck cancer. The technique is based on the combination of a photosensitive 
drug and visible light which result in cytotoxic effects on treated cells. The selective 
uptake by the hyperproliferating tissues of most photosensitive drugs, together with 
their intrinsic fluorescence and negligible dark toxicity, has expanded also their use 
as  minimally  invasive  tools  in  the  early  detection  of cancers  and  non-cancerous 
dysplasias.
In  recent  years,  the  use  of PDT  for  treatment,  and  fluorescence  and  elastic  light 
spectroscopy  for  early  diagnosis,  have  been  studied  extensively,  resulting  in 
numerous publications,  but there is little agreement on their efficacy.  Furthermore, 
PDT is indicated for early tumour without metastasis, yet it is crucial to determine 
the influence of PDT on the metastatic process.  Thus, this thesis hypothesises that
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exposure of head and neck cancer tumour cells to PDT will affect particular cellular 
functions or processes that might reduce metastasis.
1.9  Aims
The aims of the study were:
(i)  to  explore,  using  in  vitro  models,  the  influence  of PDT,  alone  or  in 
combination  with  either  chemotherapy  or  small  molecules,  on  cell 
toxicity, expression of a5pl  and  avP6 integrins and growth receptors and 
expression of MMP-2, -9 and -13, uPA and VEGF in OSCC;
(ii)  to  clinically  evaluate  the  ability  of  an  optical  system,  based  on 
fluorescence  and  elastic  scattering  spectroscopy,  to  distinguish between 
normal,  potentially  malignant  and  malignant tissues  and  to  develop  an 
applicable  algorithm  that  can  be  used  as  a  standard  for the  subsequent 
analysis of “unknown” lesions;
(iii)  to  clinically evaluate  the  potential  of PDT as  a tool  for head  and neck 
cancer treatment, using ALA sensitiser and red laser light;
(iv)  to  clinically  monitor the  sensitiser photobleaching pre-,  peri-  and post- 
PDT in facial lesions, and compare this to clinical outcome.
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Chemical reagents and kits
Bromophenol blue 
BSA
Chromogenic substrates 
Cisplatin
Collagen type-1  (rat tail)
Coomassie brilliant blue R250
DMEM
DMF
DMSO
EGF
FCS
Fibronectin (human)
Formalin.
Foscan (m-THPC; temoporfin)
Glycerol
Glycine
Hydrochloric acid 
Iressa Gefitinib ;ZD1839; 
Isopropanol
Kaleidoscope prestained standards
Matrigel
MTT
PBS (non-sterile tablets)
PBS (sterile)
PD153035
Sigma Chemical Co., Poole, UK. 
Sigma Chemical Co., Poole, UK. 
Sigma Chemical Co., Poole, UK. 
Sigma Chemical Co., Poole, UK.
BD Biosciences, Oxford, UK,
Sigma Chemical Co., Poole, UK 
GIBCO/Invitrogen Corp., Paisley, UK. 
Sigma Chemical Co., Poole, UK. 
Sigma Chemical Co., Poole, UK. 
Sigma Chemical Co., Poole, UK.
PAA Laboratories, Somerset, UK. 
Sigma Chemical Co., Poole, UK 
Sigma Chemical Co., Poole, UK. 
Biolitec Pharma. Ltd, Edinburgh, UK. 
Sigma Chemical Co., Poole, UK. 
Sigma Chemical Co., Poole, UK.
VWR International,
AstraZeneca, UK.
VWR International,
Bio-Rad, Herts,UK,
Becton Dickinson (Oxford, UK). 
Chemicon int., Temecula, CA 
Oxoid, Hampshire, UK, 
GIBCO/Invitrogen Corp.,
Calbiochem; UK
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Penicillin/streptomycin
Plasminogen
Protein assay reagent kit BCA 
Quantikine ELISA kits (MMP-2 and-9 and 
VEGF)
Scion image software
SDS
TEMED
Triton X-100
Trizma Base
Trizma Hydrochloride
Trypsin-EDTA
Tween 80
UVP Image store 5000
GIBCO/Invitrogen Corp.,
Sigma, UK,
Pierce & Wariner, UK,
R&D Systems, Oxfordshire, UK, 
Scion Corp; USA,
VWR International,
Sigma Chemical Co.,
Sigma Chemical Co.,
Sigma Chemical Co.,
Sigma Chemical Co., 
GIBCO/Invitrogen Corp.,
Sigma Chemical Co., 
Ultra-Violet Products, UK,
2.1.2  Antibodies
All primary antibodies were monoclonal mouse anti-human.
a5p 1, clone PID6  Chemicon International Inc.,
avP6, clone 10D5  Chemicon International Inc.,
EGFR, clone 102618  R&D systems,
HGFR, clone 35309  R&D systems,
FITC. F(ab')2 Rabbit anti-mouse  Dako,
2.1.3  Drugs
The  photosensitive  drug,  meta-tetrahydroxyphenyl  chlorin  (m-THPC;  temoporfin; 
Foscan)  4  mg/ml  stock  was  kindly  provided  as  gift  by  Biolitec  Pharma  Ltd. 
(Edinburgh,  UK).  Foscan was  stored  according to  the  manufacturer’s  instructions. 
Cisplatin (cis-dichlorodiammineplatinum (II); CDDP; Sigma, UK), was prepared by
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dissolving  lOOmg  powder  in  5ml  dimethyl  formamide  (DMF)  to  give  20mg/ml 
stock. The tyrosine kinase inhibitors (TKIs), Gefitinib (Iressa; ZD 1839) provided by 
AstraZeneca Pharmaceuticals (London, UK) and PD153035 (Calbiochem; UK) were 
dissolved in dimethylsulfoxide (DMSO) at stock concentration 10 mM and stored at 
-20°C.  Further dilution  of all  drugs  was performed  in  serum  free  medium  (SFM; 
Appendix  I).  Control  cells  were  treated  with  the  medium  containing  an  equal 
concentration of DMSO.
2.2  Cell culture
All cells were grown in a humidified atmosphere at 37°C and 5% C02/95% air. 
Solutions and media used can be found in the Appendix I.
2.2.1  Routine cell cultures
A series of keratinocyte cell lines were used as PDT targets in this study. They were 
H376-human oral  squamous  cell  carcinoma cell  line  (Prime et al.,  1990);  VB6-p6 
transformed  oral  SCC  cell  line  (Thomas  et  al.,  2001a)  and  KB-human  cervical 
cancer cell line (gifts from Professor O.  Irwin; UCL Eastman Dental Institute, UK) 
and UP-human benign  skin keratinocytes cell line (papilloma 16 virus-transformed), 
served as a control (Pei et al.,  1991). Table 2.1  shows the origin and characteristics 
of each cell line.
Cells were retrieved from liquid nitrogen by thawing and cultured to confluence in 
keratinocyte  growth  medium  (KGM;  Appendix  I).  The  cultures  then  were 
maintained in a humidified incubator at 37°C with 5% CC>2/95% air atmosphere. All 
cells were allowed to attach for 24 h before replacing the medium with fresh culture 
medium. The medium was changed every 2-3 days until cells were reaching the end 
of log phase (semi-confluent).
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Table 2.1  Clinical features of cell lines used in studies.
Cell Line Site of Tumour Pathology of Primary Tumour
UP Skin Well differentiated
KB Cervix Poorly differentiated
VB6 Tongue Well differentiated
H376 Floor of the mouth Well differentiated
2.2.2 Passage of cells
Once  the  cells  became  confluent,  the  culture  medium  was  removed  and  the 
monolayer was washed twice with phosphate buffered saline (PBS). The cells were 
then removed using 0.25% (w/v) trypsin with 0.05M ethylenediaminetetraacetic acid 
(EDTA). The cells were kept in a humidified incubator at 37°C with 5% CO2 for 5 
min or until cells were detached. Four times the volume of KGM was then added to 
each flask to inhibit further trypsin activity.  The cell suspension was collected in a 
sterile  15ml tube and centrifuged at  1 lOOrpm for 5 min. The medium was discarded 
and the cell pellet was re-suspended in fresh culture medium. The cells were seeded 
at 3xl05 cells per 80 cm2 Falcon tissue culture flask.
2.2.3 Cell freezing
The cells were examined under a phase light microscope to rule out any microbial 
contamination and then washed with PBS, trypsinized and centrifuged for 5  min at 
1  lOOrpm.  Supernatant  was  discarded  and  the  pellet  was  washed  in  1ml  of fresh 
KGM  prior  to  cell  counting  (section  2.6.1).  Approximately  2xl06  cells  were  re­
suspended  in  900pl  of  culture  medium  containing  lOOpl  dimethyl  sulfoxide 
(DMSO).  The  1   ml solution was transferred into a cryovial, labelled and transferred
o
to an insulated container containing isopropyl alcohol and stored at -80 C overnight 
before being transferred to a liquid nitrogen tank for long term storage.
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2.2.4 Cell thawing
The vials of frozen cells from liquid nitrogen were quickly thawed in a water bath set 
at  37°C.  The  thawed  cell  suspension  was  rapidly  re-suspended  in  a  pre-warmed 
culture medium in a sterile  15  ml tube and centrifuged at  1 lOOrpm for 3  min.  The 
medium was discarded and the cell pellet was re-suspended in  1ml of fresh culture 
medium and transferred to an 80 cm2 flask containing  10ml of culture medium. The 
flask was maintained in the incubator, as described in section 2.1.
2.2.5 Cell density and viability
Cell  density  was  determined  using  an  improved  haemocytometer  (Assistent, 
Germany)  viewed  under  a  phase-contrast  light  microscope  at  X I0  magnification. 
Cells  were  trypsinized  and  re-suspended  in  1ml  growth medium.  lOpl  of the  cell 
suspension was placed at the edge of the haemocytometer glass coverslip. The cells 
were  counted within the  four major squares  and the average value was calculated. 
The viable  cells  were  determined  under the  light microscope,  at the  same time  of 
each  passage  by  mixing  lOpl  of cells  suspension  with  an  equal  volume  of 0.4% 
trypan blue  (prepared in  0.81%  sodium chloride  and 0.06% potassium phosphate). 
Unstained cells were counted and considered viable and cell viability percentage was 
determined by the ratio of viable cells to the total number of cells.
2.2.6 Cell viability assay
Cell  viability  was  determined  both  by  the  trypan  blue  dye  exclusion  test  (section 
2.1.4)  and  MTT  colorimetric  assay.  MTT  is  based  on  cellular  conversion  of the 
tetrazolium  compound  (3-(4,  5-dimethylthizol-2-yl)-2.5-diphenyl-2H-tetra-zolium 
bromide; MTT) into a purple formazan product. Optical readings were performed at 
570 nm using a microplate reader (Multiscan, MCC/340; Flow Laboratories, Herts,
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UK). Appropriate blanks were subtracted from the test absorbance figures. As results 
for  the  two  methods  were  well  correlated  for  all  cell  lines,  the  MTT  assay  was 
subsequently used routinely.
2.2.7  Cell growth assays
Cell lines were trypsinized, counted and re-suspended in KGM and seeded into 96- 
well  plates  at  a cell  concentration  of 2x10  cells  per well.  Cells  were  allowed  to 
attach for 24 h in a humidified incubator at 37°C with 5% CO2.  MTT solution was 
added to wells and the total number of cells was calculated from the standard curve 
(previously prepared from a known number of cells). Readings were taken every 24 
h for 7 days.
2.3  Photodynamic therapy
2.3.1 Photosensitisation
Sub-confluent cells were harvested, counted and seeded into 96-well plates in KGM 
at cell concentration of 3xl04 cells per well. Cells were allowed to attach for 24 h at 
37 C  before  Foscan  was  added  at  concentrations  of 0.25,  0.5,  1,  2  and 4pg/ml  in 
serum free KGM.  The cells were incubated with Foscan in darkness at 37°C in 5% 
CO2 for 3 h and 24 h unless otherwise stated. Cells not exposed to Foscan were used 
as controls.
2.3.2 Cell irradiation
Cells were washed three times in PBS and new serum free KGM was added.  Cells 
were then exposed to  652  nm diode red laser (Diomed Ltd,  Cambridge, UK).  The 
laser beam was transmitted through a microlens fibre, giving a fluence (energy) rate 
of 25mW/cm2. The distance from the distal end of the fibre to the bottom of the well 
and  the  exposure  time  were  automatically  adjusted  by  the  laser  machine
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microprocessor to obtain various energy densities (fluence) of 0.25, 0.5,  1, 2, 3  and 
4J/cm . Percentage phototoxicity was determined by the MTT assay after 3 and 24 h.
2.4  Combination treatment
2.4.1  PDT and CDDP cytotoxicity assay
Cytotoxicity of CDDP combined with PDT was also determined by MTT assay. The 
UP, VB6 and H376 cells were seeded into 96-well plates at a cell concentration of 
3xl04 cells per well and allowed to attach for 24 h at 37 C before KGM was replaced 
with serum free KGM containing CDDP (2, 4 and 8pg/ml) and Foscan (0.5pg/ml). 
After 24 h of incubation at 37°C, cells were washed with PBS and new serum free 
KGM  was  added.  Cells  then  were  exposed  to  0.5  J/cm  (20  s)  of  red  light. 
Cytotoxicity for each cell line was then determined by MTT assay after 24 h.  Cells 
not exposed to treatment were used as controls.
Cytotoxicity of CDDP and PDT, each alone was also determined by MTT assay. For 
CDDP alone, the UP, VB6 and H376 cells were seeded into 96-well plates at a cell 
concentration of 3x104 cells per well and allowed to attach for 24 h at 37 C. A range 
of concentrations between 2 and 40pg/ml of CDDP in serum free KGM were added 
for 24 h before cytotoxicity by MTT assay was determined.  Cells not exposed to 
CDDP were used as controls.  For PDT alone, cells were incubated with Foscan at 
0.5pg/ml.  After 24  h  of incubation  at  37°C, new Foscan free  culture  medium was 
added before exposure of the cells to red light at 0.5 J/cm  (20 s).  Cytotoxicity for 
each cell  line was then determined by MTT assay after 24 h.  Cells not exposed to 
PDT were used as controls.
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2.4.2  PDT and TKI cytotoxicity assay
Cytotoxicity of Iressa or PD153035  combined with PDT was determined by MTT 
assay. The UP, VB6 and H376 cell lines were harvested, counted and seeded into 96- 
well plates at a cell concentration of 3xl04 cells per well and for 24 h at 37 C. After 
attachment, KGM was replaced with serum free KGM contained Iressa between 0.05 
and lOpM or PD153035 between 0.5 and 20pM and 2 doses of Foscan (0.25pg/ml; 
PDT-1) or (0.5pg/ml;  PDT-2) were added for 24 h at 37°C.  After incubation, new 
drugs  free  medium  was  added  and  cells  then  exposed  to  0.5  J/cm  of red  light. 
Cytotoxicity for each cell line was then determined by MTT assay after 24 h.  Cells 
not exposed to treatment were used as controls.
Cytotoxicity of Iressa and PD153035, each alone, was also determined by MTT. For 
Iressa or PD153035, the UP, VB6 and H376 cell lines were harvested, counted and 
seeded into 96-well plates at a cell concentration of 3xl04 cells per well for 24 h at 
37 C.  Following  attachment,  KGM was replaced with  serum  free KGM  contained 
Iressa between  0.05,  and  50pM  or PD153035  between  0.5  and 20pM  was  added.
o
After 24 h of incubation at 37 C, Iressa and PD153035 cytotoxicity was determined 
by MTT assay.  Cells not exposed to any treatment were used as controls. For PDT 
alone, Foscan at (0.25pg/ml; PDT-1) or (0.5pg/ml; PDT-2) was added for 24 h cells 
then were exposed to 0.5 J/cm2 of red light. Cytotoxicity for each cell line was then 
determined  by  MTT  assay  after  24  h.  Cells  not  exposed  to  PDT  were  used  as 
controls.
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2.5 Cell detachment assay
The detachment assays of control and treated cells were studied on 24-well culture 
plates  (Falcon;  Becton  Dickinson,  UK).  Cells  were  seeded  at  a  density  of  lxl05  
cells/well in 1ml of KGM. The cells were allowed to attach and grow until confluent. 
The  medium  was  aspirated  and  the  cultures  were  then  washed  twice  in  PBS. 
Thereafter 0.1ml  of trypsin/EDTA was  added.  The  cells were then re-incubated at
o  0
37 C for 5 mm. The number of detached cells was counted using a haemocytometer. 
The results were expressed as the ratio of treated cells that had detached compared to 
the untreated control.
2.6 Cell adhesion assay
The  adhesion  assays  of control  and treated  cells to  fibronectin,  collagen type  I  or 
Matrigel were studied on 96-well microtiter plates (Falcon; Becton Dickinson, UK). 
Wells were coated with 50pl of lOpg/ml of fibronectin, collagen type I, or Matrigel 
and allowed to  dry  for  1  h  in a humidified  incubator at 37°G  in 5%  CC>2/95%  air 
atmosphere.  The  wells  were  subsequently washed  with PBS  containing  10%  FCS 
and then blocked by incubation in PBS containing 0.5% (w/v) bovine serum albumin 
(BSA; Sigma, UK). The wells were then returned to the humidified incubator for 30 
min before being washed with PBS containing  10% FCS.  Treated and control cells 
were harvested and plated into the coated wells at a concentration of 4xl04 cells per 
well in 1  OOpl of SFM. Plates were incubated for 1  h to allow cells to adhere.
Following  incubation,  the  medium  and  non-adherent  cells  were  removed  by 
immersion the plate gently twice in PBS supplemented with ImM CaCh and 0.5mM 
MgCb. To each well,  lOOpl of SFM was then added and allowed to equilibrate for 1  
h at 37 C  with 5%  CO2.  Thereafter  lOpl of MTT solution was added to each well 
and cells were incubated for 4 h. The relative absorbance of the coloured product of 
MTT was  measured  at  570  nm and the relative  number of cells  in each well  was 
calculated from a standard curve prepared by measuring the optical density of known
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number of cells. The non-specific adhesion (Adhesion to BSA coated wells) reading 
was subtracted and the results were expressed as mean percentage of attached cells 
in each well compared to the number of original seeded cells, which was expressed 
as 100%.
2.7  Protein assay
2.7.1 Preparation of supernatants
The treated and control cells were detached with trypsin/EDTA and seeded into 24- 
well  tissue  culture  plates,  at  a  concentration  of  lxl05  cells  per  well  in  0.5ml  of 
additive free medium (AFM; Appendix I) supplemented with  10% FCS  for 24 h at 
37 C. Culture medium in each well  then was replaced with  new 0.5ml of serum free 
AFM and supernatant of each cell line sampled after 24 h, at which time conditioned 
medium  was  cleared  of cells  and  debris  by  centrifugation  at  4000  g  for  10  min, 
followed  by  protein  estimation  using  the  colorimetric  BCA  protein  assay  reagent 
(Pierce  Warriner,  UK).  Cell  media  of  non-treated  cultures  was  considered  as 
controls.
2.7.2 Determination of total protein
The  amount  of total  protein  concentration within each cell  sample  in conditioned 
medium  was  determined  using  a  colorimetric  BCA.  Briefly,  a  series  of protein 
concentrations  for a  standard  curve  was  prepared  by  dilution  of BSA  at  1:2,  1:5, 
1:10,  1:100 or 1:1000 v/v in PBS. Working reagent was prepared by mixing 50 parts 
of Reagent A with  1   part of Reagent B. Then  lOpl of conditioned medium samples 
or  standard  were  added  into  each  well  of a  96-well  microtiter plate,  followed  by
    o
200pl  of working reagent.  The plate was then incubated at 37 C  for 30 min.  The 
relative  absorbance  at  652  nm  was  determined  using  a  plate  reader  (Multiscan, 
MCC/340;  Flow  Laboratories,  Herts,  UK).  The  standard  curve  was  created  by
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plotting the protein concentrations versus absorbance, and the protein concentrations 
of test samples were calculated from this.
2.7.3  Zymography 
Introduction
Zymography  is  a  simple,  sensitive,  quantifiable,  and  functional  approach  used  to 
investigate  and  quantify  the  expression  of  matrix-degrading  metalloproteinases 
(MMPs).  The  standard  method  for  zymography  is  based  on  the  use  of  SDS- 
polyacrylamide gels co-polymerized with a protein substrate, in particular gelatin, or 
casein. Proteases that have the ability to renature after removal of SDS and to exert 
proteolytic activity on a co-polymerized substrate can be analyzed with this method. 
MMP-2 (gelatinase A, 72 kD) and MMP-9 (gelatinase B, 92 kD) can be detected on 
gelatin zymograms and MMP-7 on casein gels. Staining of the gel with commassie 
blue  allows the  bands  of proteolytic  activity to  be detected as clear bands of lysis 
against a blue background (Figure 2.1). Based on the molecular weights, these bands 
reflect  inactive and  active  MMP-2  and  inactive  and  active  MMP-9,  and  the  band 
intensity is related to the amount of protein loaded.
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Digestion band
Blue background
Figure 2.1  Representative picture of gelatin zymography (clear area represent 
areas of enzymatic digestion of gelatin gel).
Electrophoresis of supernatant samples
In the present study, MMP-9 and MMP-2 activities were analysed using SDS-PAGE 
substrate  gels.  Gelatin  (BLOOM  300,  Sigma,  UK)  was  added  to  12%  acrylamide 
separating gel at a final concentration of 1  mg/ml, and poured using a pre-assembled 
vertical  gel  electrophoresis  apparatus  (Mini-PROTEAN® II cell;  Bio-Rad).  The gel 
was immediately overlaid with isopropanol to inhibit the air interface, and allowed to 
set for about 30 min at room temperature. After checking the setting of the gels, the 
isopropanol was discarded and the tops of gels were rinsed with distilled water and 
dried with filter paper.  The stacking gels (Appendix  1) were poured into the top of 
the resolving layer. Again, the stacking gels were poured and the proper comb was 
seated before being allowed to set for 20-30 min.  The comb was removed and the 
gels were fitted into the electrophoresis tank before an appropriate amount of SDS- 
running buffer (Appendix  1) was added. The supernatant samples with equal protein 
were  diluted  1:1  in non-reducing  sample  buffer (Appendix  1)  and  loaded  into  the 
wells  using  capillary  disposable  pipette  tips.  The  molecular  weight  marker 
(Kaleidoscope  pre-stained  standards)  was  prepared according to  the  manufacture’s
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instructions  and  loaded  into  one  well.  Samples  were  run  at  100V  through  the 
stacking gel  stage  and the current then elevated to  120V  for approximately 2 h or 
until the samples approached the resolving bottom gel.
Renaturing, developing and staining of gels
The gels were separated from the plates with care and washed twice in 2.5% Triton 
X-100 for 30 min at 37 C to remove SDS. The gels were then allowed to equilibrate 
in  developing  buffer  containing  50mM  Tris-HCL,  0.2mM NaCl,  5mM  CaCl2  and 
0.02% Triton X-100.  The buffer was discarded and changed with fresh developing 
buffer and incubated overnight at 37 C. Following development, the gels were gently 
immersed  in  Coomassie  Blue  stain  (Appendix  1)  for 30  min  at room temperature 
before  being  de-stained  with  Coomassie  de-stain (Appendix  1)  for 3-4  h until  the 
enzyme  activity  bands  were  obviously  clear  as  white  bands  against  a  blue 
background.  Stained  gels  were  captured  under  illumination using the  UVP  Image 
store  5000  (Ultra-Violet  Products,  UK)  and  obtained  Images  saved  on  a personal 
computer  (PC).  The  images  were  analysed  quantitatively  using  the  Scion  image 
software (Scion, USA).The intensity bands was measured by densitometric analysis, 
and  comparisons  were  made  within  each  gel  to  determine  the  relative  changes  in 
MMP activity. Data for each zymogram were expressed as a relative change in MMP 
activity, and these relative changes were compared with repeat experiments.  Direct 
comparison  between  separate  gels  was  not  made  as  the  intensity  of background 
staining was variables.
2.7.4  ELISA
To quantify the amount of specific protein in cell culture supernatants, commercial 
ELISA  kits  for human  MMP-2  (total)  ,  MMP-9  (total)  ,  pro  MMP-13  and VEGF 
(R&D  Systems,  Inc.  Europe)  were  used.  The assay is  based  on a two  site  ELISA 
‘sandwich’  format  and  performed  according  to  the  manufacturer’s  instructions. 
Briefly, cell supernatants were prepared as for zymography, and  lOOpl sample was
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added  to  each  well  and  immobilized  MMP  or VEGF  detected by the  horseradish 
peroxidase labelled Fab’ antibody directed to MMP-9, MMP-2, MMP-13 or VEGF. 
The  reaction  was  stopped  by  addition  of an  acid  solution  (2  N  H2S04)  and  the 
intensity  of the  resultant  colour  change  read  at  450  nm  on  a  spectrophotometer 
(Multiscan,  MCC/340;  Flow  Laboratories,  Herts,  UK).  The  concentration  was 
determined  by  interpolation  from  a  standard  curve  using  known  concentration  of 
MMP-9, MMP-2, MMP-13 or VEGF standards as supplied.
2.7.5  Assay of plasminogen activator (PA)
The activity of PA in  50pl  of cell  supernatants  (prepared as for zymography) was 
indirectly estimated by hydrolysis of a specific chromogenic substrate H-D-Val-Leu- 
Lys-paranitroanilide 2HC1 (2.5mg/ml; Cs -2251; Chromogenix, UK) in the presence 
of  Human  Glu-plasminogen  (15pM;  Enzyme  Research  Labs,  UK)  in  Tris-HCl 
buffer,  150 mM, pH 7.4) at 37°C for 2 h. The intensity of formed H-D-Val-Leu-Lys- 
OH  +  pNA  was  measured  spectrophotometrically  at  405  nm  using  a  microplate 
reader (Multiscan, MCC/340;  Flow Laboratories, Herts, UK).  The concentration of 
uPA (This assay measure both tPA and uPA, However, since monolayer cells were 
tested, this experiment assumed that most of secreted PA was uPA) was estimated by 
interpolation from standard curve using known concentrations of uPA standards.
2.8  Migration assay
The haptotactic assay of malignant cells, which implicates the liability of migrating 
cells  to  move  towards  a  gradient  of coated  ligand,  was  studied  using  a  modified 
Boyden chamber assay system. The two clamberers were divided by a tissue culture 
treated  poly  carbonate  filter  with  8-pm  pore  size,  6.5  mm  diameter  and  lOjim 
thickness  (Transwell®;  Costa).  The  lower  surface  of the  filter  was  coated  with 
fibronectin (lOpg/ml) or collagen type I (40pg/ml), both diluted in PBS, and left to 
dry for 1   h at 37 C. Non-specific sites on the filter of each chamber were blocked by 
adding  lOOpl  of migration  buffer  (DMEM,  FI2  3:1  and  5%  BSA)  into  the  upper
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chamber and 600pl of migration buffer into the lower chamber for 1  h at 37 C. The 
buffer in the upper chamber of triplicate wells was replaced with lOOpl of migration 
buffer containing  lx l0 5   of treated cells.  The untreated cells were used as controls. 
The  lower chamber had migration buffer replaced with fresh buffer.  The chambers 
were incubated for 3  h at 37 C with 5% CO2.  Following this incubation period, the 
filters were fixed for 10 min in  10% neutral buffered formalin. The filters were then 
stained with 0.5% crystal violet in ethanol (w/v) for 10 min and washed in deionised 
water. The cells on the upper surfaces of the filters were wiped off with cotton swabs 
and the filters left overnight to air-dry. The filters were cut and mounted in DPX on 
glass slides for microscopy. The number of remaining cells was counted in random 
high powered fields (X40) (at least 6 random positions per filter, as determined by 
cumulative  frequency  analysis).  The  results  were  expressed  as  mean  values  per 
microscope field ± standard deviation.
Insert
SFM
Cells
24-well 
culture plate
Microporous membrane (8pm). 
underside coated with fibronectin
Figure 2.2  Schematic illustration of cell migration assay. SFM=serum free 
medium
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2.9  Invasion assay
Chemotaxis  assay  of tumour cells,  which  implies  cell  movement toward a soluble 
chemo-attractant gradient, was studied using poly carbonate membranes with 8-pm 
pore  size,  6.5mm  diameter  and  10pm  thickness  (Transwell®;  Costa).  The  inserts 
were  coated  with  40pg/cm2  of Matrigel  diluted  in  PBS.  The  gel  was  allowed  to
o
polymerize  for  1  h  at  37 C.  The  treated  and  control  cells  were  trypsinised  and 
counted.  1x10s cells in 200pl of SFM were added to the upper chamber of triplicate 
wells. The lower chambers were filled with KGM, which would behave as a chemo- 
attractant.  Cells then were incubated for 72 h at 37°C in 5% CO2 atmosphere. Cells 
that had invaded the lower chamber,  including those bound to the under-surface of 
the filter, were trypsinised and counted.  To ensure that the reduction of invasion of 
PDT treated cells was not due to the loss of initial cell attachment, the cell adhesion 
assays on Matrigel were carried out at the same time as the invasion assays.
Matrigel  layer
Cells Insert 24-well 
culture plate KGM
Microporous membrane (8pm) 
underside coated with fibronectin Migrated cells
Figure 2.3  Schematic illustration of cell invasion assay
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2.10  Photomicrography
The UP, VB6 and H376 cells were washed with PBS, trypsinized and counted. The 
cells were then added to  a 25cm2 tissue culture flasks  at a concentration of 2xl05  
cells per flask. The flasks were incubated at 37°C with 5% CO2 until confluent. The 
morphology  of control  and  treated  cells  was  determined  by  viewing  the  cultured 
cells under a phase-contrast-microscope (Olympus CK2) at a magnification of X20. 
The pictures were taken by digital camera (Nikon Coolpix 4500) at 0, 24 and 48 h 
post treatment. Untreated cells served as controls and photographed at the same time 
points as the test cells.
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2.11  Flow cytometry
Flow cytometry uses the principles  of light  scattering,  excitation,  and  emission of 
fluorescent light from molecules in or attached to cells. Cells are focused in a sheath 
of PBS  before  intercepting  an  optimally  focused  laser  light  source.  The  cells  are 
excited with light with a specific wavelength. Following excitation, the light photons 
can be emitted as fluorescence or scattered either in a forward direction (FSC) with
o
low angle (<2 ) to the light axis (proportional to cell size), or at scatter angle (90°) 
known as  ‘side  scatter’  (SSC)  (proportional to cell  granularity).  The released  light 
from the cells  is then converted into electrical pulses and processed by a series of 
linear and log amplifiers.  Logarithmic amplification is most often used to measure 
fluorescence signals in cells, which is considered to be proportional to the amount of 
target antigen attached via the fluorophores (Mandy et al., 1995). The data were then 
stored on computer for future analysis.
2.11.1  Preparation of cells for analysis
Treated  and  control  cells  from  confluent  or  late  log-phase  cultures  were  washed 
twice with PBS and released by trypsin/EDTA (0.25% w: v,  5 mM EDTA) used to 
reduce  the  proteolytic  breakdown  of the  extracellular  domain  of surface  proteins. 
The cells were then centrifuged,  counted and washed once in washing buffer (PBS 
solution  supplemented  with  10%  v/v  FCS)  at  llOOrpm  for  5  min.  The  cells  were 
pelleted  into  round  bottom  polystyrene  fluorescence  activated  cell  sorting  (FACS) 
tubes (Becton Dickinson) in  100 pi washing buffer at a concentration of lxl05 cells 
per tube. Cells were incubated with primary antibodies to EGF, HGF, a5pl and avp6 
cell receptors (1:200 dilution) for 40 min at 4°C, control cells were incubated with 
washing buffer only.  Following incubation, cells were washed twice with washing- 
buffer.  Fluorescein  isothiocyanate  (FITC)-conjugated  rabbit  anti-mouse  anti-sera 
secondary  antibody  (1:250  dilution)  was  added to the  cells  for  30  minutes at 4 C. 
The cells were then washed twice in washing-buffer and resuspended immediately in 
0.5 ml of washing-buffer. The size, granularity and fluorescence intensity of 10,000
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individual  cells  were  analysed  using  the  FACScan  flow  cytometer  (Becton 
Dickinson) for duplicate samples from three separate experiments.
2.11.2  Data acquisition and processing
Labelled cells were passed through the flow chamber and each individual cell was 
then subjected to the laser beam of a specific wavelength that matched the excitation 
wave  length  of the  attached  label.  Emitted  signals  (FCS,  SCC  and  fluorescence) 
were  transmitted  from  the  flow  cytometer  and  the  scatter-window  was  set  to 
eliminate  dead  cells  (usually  about  6%  in  control  cells  and  up  to  20%  for  PDT- 
treated  cells).  Foscan  fluorescence  intensity  in  FL3-H  and the  expression  of a5pi 
and  avp6  integrins,  EGF  and  HGF  receptors  in  FL1-H  were  analysed  and  stored 
digitally  on the  attached  computer  (Quadra  650,  Apple  Macintosh).  For  each  cell 
label, two separate tubes were analysed. A dot plot was created and FSC versus SCC 
was produced following manual gating, the arbitrary units obtained by the software 
programme. The intensity of sample-emitted fluorescence in FL1-H and FL3-H was 
represented  by  a  frequency  distribution  histogram  and  gated  in  accordance  with 
negative controls. The mean fluorescence value was calculated.
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2.12  Detection of oral premalignancy
It  has  become  universally  known  that  early  detection  of premalignant/  malignant 
lesions can substantially reduce the risk or improve the prognosis in oral cancer.
2.12.1 Fluorescence spectroscopy (FS)
2.12.1.1 Patients
Seventy-one  patients  (mean  age  59  years,  range  37-81  years)  with  clinically 
suspicious  oral  leukoplakia  took  part  in  this  study  in  the  Maxillofacial  Unit, 
University College Hospital (UCH), London. The trial protocol was approved by the 
UCH Joint Research and Ethics Committee. An information sheet explaining the aim 
of our study in simple non-scientific terms was given to each patient and those who 
then consented were examined. FS was then used to examine the suspicious area for 
each of those patients prior to surgical biopsy.  Inclusion criteria were patients over 
18 years of age who presented with suspicious oral leukoplakia, while the exclusion 
criteria were women who were or might have been pregnant. However, there are no 
known teratogenic effects that FS might induce.  The main reason behind this is the 
anxiety that might be triggered during the examination.
Two  hours  prior  to  examination,  a  topical  application  of  0.4%  (w/v)  5-ALA 
(supplied by the UCH pharmacy) has applied to the oral mucosa via an oral rinse. 
This  was  prepared  by  dissolving  200mg  5-ALA  in  50ml  of mineral  water.  The 
patient  is  required  to  rinse  the  mouth  for  15  min,  and  maintain  3 x 5   min  of 
continuous  contact  to  achieve  the  maximum  saturation  of the  mucosa  with  the 
solution.  The  solution  was  prepared  shortly  before  application  to  avoid  unwanted 
effects reported from the instability of such solutions (Novo et al.,  1996). Following 
this, the patients were allowed to rinse with mineral water prior to examination but 
they were warned to avoid illumination and brushing of teeth.  We have considered 
this relatively short incubation period to be applicable for routine clinical diagnosis;
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Leunig  A  et  al.  found  that  the  absolute  fluorescence  intensities  in  tumour  tissue 
decreased 3  h following the 5-ALA application and this could lead to the reduction 
of contrast between pre-malignant/malignant and healthy tissue (Leunig et al., 1996).
2.12.1.2  The system
The  apparatus  (Figure  2.4)  consisted of a light optical power output light delivery 
system that includes a xenon-arc lamp (Medical Light Technologies Ltd, UK) whose 
output  was  filtered  by  a  long  pass  filter  (BG12,  Schott  Glass,  Germany)  and  a 
bandpass  filter  centred  at  425(±17)  nm  (Corion  Corp.,  MA,  USA).  An  optical 
endoscope was used for both illumination and detection of the tissue fluorescence. 
The fluorescence image of the tissue was acquired by a high sensitivity single chip 
charge-coupled device (CCD) colour camera (Sensicam, Personal Computer Optics, 
Germany)  integrated  with  red/green/blue  (RGB)  mosaic  filter  and  coupled  to  the 
endoscope  to  facilitate  examination  of all  tissues.  The  images were  captured  by  a 
frame-grabber  (0.6  s  integration  time)  fitted  with  an  analogue/digital  converter 
(ADC)  and  analysed  and  displayed  by  personal  computer  loaded  with  software 
(Sensicam, Personal Computer Optics, Germany). This allowed fast computation and 
analysing  times.  In  addition,  the  RGB  system  provides  wavelength  separation 
allowing  only red  and  green  detection for ratio  imaging.  The  output power of the 
blue light at the endoscope tip was kept to approximately 2mW/cm2; this was found 
to minimise the photobleaching of the photosensitiser (Scott et al., 2000).
78Chapter 2: Materials and Methods
Flexible
fibre optic endoscope
Halogen
Lamp
CCD camera & 
R:G:B filters 
Red 600-700 nm 
Green 500-550 nm
Computer& Printer
Aminoluvelinic acid
(ALA)
mouth wash/cream
Figure 2.4  Schematic diagram of the fluorescence spectroscopy system.
2.12.1.3  Measurement procedures
All  measurements  were  taken  at  the  Maxillofacial  Surgery  Unit,  UCH.  All 
histopathological  samples  were  examined  by  the  Histopathology  department  at 
UCH,  London.  The  premalignant/malignant  and  normal  tissue  accumulated  PpIX 
was excited via an endoscope with a blue light generated by a filtered high optical 
power  output  xenon-arc  lamp,  following  excitation,  PpIX  and  tissue 
autofluorescence  were  detected  by  a  sensitive  single  chip  CCD  colour  camera 
connected  to  a  personal  computer.  Following  examination,  the  images  produced 
(Figure  2.5)  were  analysed  by  the  computer  to  identify  the  area  of the  highest 
fluorescence signal.  Then this area was marked with blue ink in a diamond pattern. 
Subsequently,  the  area  was  subjected  three  times  to  fluorescence  spectroscopy  in 
order to reduce the error and ensure the reproducibility at each biopsy site by quick 
calculation of red-to-green intensity ratio.  To prevent any optical interference, care 
was taken not to capture any fluorescence image after marking.
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2.12.1.4  Data classification and analysis
The  images  obtained  were  displayed  in  black  and  white  and  the  intensity  of 
whiteness  was  proportional  to  the  fluorescence  intensity.  The  captured  image  was 
intensified  and red-to-green was  calculated.  Within  0.2s,  the  data processing  stage 
was  complete;  this  involved  digital  analysis  of  the  12-bit  red,  green  and  blue 
fluorescence images. A dimensionless spatial variable (R) was calculated according 
to the pixel coordination of x and y.  The red channel described PpIX fluorescence 
and  red  tissue  autofluorescence.  The  green  channel  recorded  the  green  tissue 
autofluorescence, while the blue channel showed diffusely back scattered excitation 
light (Figure 2.6).  To exclude distance dependence of the signals, a red fluorescent 
spot within normal mucosa was recorded at a different distance and fixed integration 
time.
Following  fluorescence  imaging,  71  acquired  biopsies  (from  71  patients)  were 
obtained from various oral sites and sent for histopathology studies. These biopsies 
were  examined  histopathologically  and  were  found  to  be  either  normal  (normal, 
inflammatory or hyperkeratotic) or potentially malignant (mild, moderate or severe 
dysplastic).  To  allow the  correlation of fluorescence  images and histology, the red 
PpIX fluorescence  and green tissue  autofluorescence for each site were calculated. 
Histopathological  reports  were  considered  as  standard  and  correlated  with  red  to 
green ratios measured in terms of oral changes. The ratios (red/green) were set at 1.2 
and 1.3 as the threshold values for demarcation between normal and dysplastic.
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Figure 2.5  Black and white tissue fluorescence image. Bright area represent the 
highest fluorescence intensity whereas low intensity in black area
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Figure 2.6  Example of magnified pixel colour fluorescent intensity values.
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2.12.2  Elastic scattering spectroscopy (ESS)
2.12.2.1 Patients
Twenty-five patients (13 male and  12 female), mean age 52 years, age range 41-67 
years,  with  clinically  suspicious  oral  leukoplakia  took  part  in  this  study  in  the 
Maxillofacial  Unit,  UCH,  London.  The  trial  protocol  was  approved  by  the  Joint 
Research and Ethics Committee of UCH. An information sheet explaining the aim of 
the  study in  simple non-scientific terms was given to  each patient,  and those who 
consented were further examined.  ESS was used to examine the suspicious area of 
each of those patients prior to surgical biopsy.  Inclusion criteria were patients over 
18 years of age who presented with one or more suspicious oral lesions;  while the 
exclusion criteria were women who were pregnant, since this group of patients are 
usually more anxious when attending hospitals.
2.12.2.2 The system
The ESS apparatus (Figure 2.7) have been described in previous publications, (Bigio 
et al., 2000; Jerjes et al., 2004) is a prototype that was designed and built at the Los 
Alamos National Laboratory, USA. The system consists of a pulsed xenon-arc lamp 
for the light source, a PC-compatible spectrometer, which employs a linear charged 
coupled  device  (CCD)  array  for  detection,  an  optical  fibre  (graded-index)  based 
probe,  and a laptop  computer for system control and data display.  The wavelength 
range of the system is 300-900 nm, but the range used for these studies was 330-750 
nm, which covers the near UV and visible part of the electromagnetic spectrum; the 
range of the  spectrum  usually covers the light emitted by cellular and  sub-cellular 
organelles. The output of the arc lamp is coupled to the illumination fibre, which has 
a  core  diameter  of  400pm.  A  second,  200pm  diameter  fibre  alongside  the 
illuminating  fibre,  collects  the  scattered  light  from  the  tissue  and  guides  it  to  the 
spectrometer where an optical spectrum is generated for further processing; centre-
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Figure 2.7  Schematic illustration of the elastic scattering spectroscopy system.
The  system probe  (Figure  2.8) was  designed to  be used  in (gentle)  optical  contact 
with tissues,  and  incorporates two  optical  fibres, one to transmit the  light into the 
tissue and the other one for collecting the scattered light from tissue; the two probes 
are built-in one bigger probe so the viewer can see only the latter. Placement of the 
probe in direct contact with the tissue avoids interference with specularly reflected 
light. With this probe geometry, the volume of tissue visited by the collected photons 
occupies  ~lmm3.  This  has  been determined  from  computational  simulations using 
Monte  Carlo  code,  which  incorporates  Mie theory  for the  details of the  scattering 
events.
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Figure 2.8  Schematic diagram of the fibre optic probe
2.12.2.3  Measurement procedures
In clinical use, the suspected tissue areas were marked and the tip of the fibre probe 
was  momentarily  placed  in  direct  contact  with  the  suspected  lesion.  The 
measurement then was activated at the keyboard.  The system automatically takes a 
background measurement without firing the lamp, followed immediately (within-100 
ms)  by  an  ESS  measurement  with  the  pulsed  lamp  was  been  triggered,  and  then 
subtracts the background spectrum from the ESS spectrum. The entire measurement 
processes (activating the spectrometer, triggering the arc lamp, reading the detector 
array with an analogue/digital (A/D) converter etc.) were computer controlled by a 
laptop  PC.  This  allowed  both  accurate  and reproducible  measurements  within the 
clinical  setting.  It  provides  also  the  clinician  with  the  advantage  of  rapid  data 
acquisition and a display time of less than  1  s for each site measured. Three optical 
measurements were  acquired from  each of the suspected  lesions;  1st measurement 
from  the  centre,  2nd  from  the  periphery  of the  lesion  and  in  between  the  two 
measurements the 3rd was acquired.
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Following the optical readings, a surgical biopsy was taken, preserved in formalin, 
processed in H&E stain and examined by the histopathologist; digital pictures have 
been taken and sketches have been made for all the suspected sites to ensure that all 
sites are  easily identified by the pathologist and hence reduce  any chance  of false 
results.  The  tissue  samples  (25  biopsies  in  total)  were  graded  as  normal, 
hyperkeratotic,  mild  dysplastic,  moderate  dysplastic,  severe  dysplastic  and 
carcinoma in situ. The elastic spectrum of each lesion was correlated to its histology.
In  this  study,  spectra  were  combined  together  although  they  originated  from 
histologically different oral sites (floor of mouth, tongue, cheek); before doing this, 
each acquired spectrum from a particular site was compared to a spectrum acquired 
from  a  histology-similar  normal  oral  site;  the  intention  here  was  to  reduce 
discrepancies in the readings.
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2.13  Monitoring of PDT
2.13.1 Patients
Fourteen patients (mean age 66 years, range 39-78 years) treated with ALA-PDT for 
superficial BCC of the scalp and the face took part in this study at the Maxillofacial 
Unit,  UCH,  London.  The  trial  protocol  was  approved  by  the  Joint  Research  and 
Ethics Committee of UCH. An information sheet explaining the aim of the study in 
simple non-scientific terms was given to each patient who was then consented prior 
to examination. Inclusion criteria were patients over 18 years of age diagnosed with 
superficial BCC. Excluded from the study were pregnant or breastfeeding women. A 
full written informed consent was obtained from each patient who entered the trial.
Prior to  PDT,  a freshly prepared  cream  containing  20%  ALA  (prepared  locally at 
UCLH pharmacy) was applied with a margin of approximately 1cm beyond the skin 
tumours and then covered with plastic adhesive dressing.  The ALA was left on the 
skin  and  the  patients  were  instructed  not  to  expose  the  creamed  area  to  direct 
sunlight for 3  h.  The plastic adhesive was removed, cream was then wiped-off, and 
the  tumour demarcated  with  5  mm  margins  of macroscopically normal  skin.  This 
shielded all normal  surrounding skin and allowed optimal tumour illumination. All 
lesions were illuminated through a fixed perpendicular coupled lens fibre to deliver 
100 J/cm2 at a fluence rate of 150mW/cm2, generated from 635 nm diode red laser 
(Diomed Ltd, Cambridge, UK) at a distance to cover the whole target area.
2.13.2 The systems
PDT  was  monitored  by  FS  and  ESS  systems  (previously  described  in  sections
2.12.1.2 and 2.12.2.2).
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2.13.3  Monitoring procedures
Three fluorescence readings and ESS spectra were acquired from each patient: “pre- 
PDT” (5  min before the PDT),  “peri-PDT” (333  s after starting PDT), “peri-PDT” 
(660 s after starting PDT, marks the end of treatment) and “post-PDT” (15 min after 
PDT). The primary treatment outcome was evaluated by visual inspection and palpation 
when patients returned for their follow-up visit at 6 weeks and later at approximately 6 
months. Complete response was defined as the disappearance of the disease (i.e. treatment 
site  was  macroscopically  normal  with  no  evidence  of tumour).  Partial  response  was 
defined as a decrease of at least 50% in the total tumour size relative to pre-treatment size
2.14  Statistical analysis
2.14.1 In vitro studies
Data were entered into the Microsoft Office Excel 2003  database, and expressed as 
the mean of observation ± standard deviation (SD). The difference in values between 
groups was determined by analysis of variance (ANOVA) and Student /-test unless 
otherwise stated.  Results were considered significant when the value ofp< 0.05.
2.14.2 In vivo studies
2.14.2.1  Fluorescence spectroscopy
The red-to-green values of the  suspected areas were calculated and correlated with 
the  histopathology.  A  Student’s  /-test  was  used  to  test  the  viability  of the  ratios 
regarding its ability to discriminate between different disease stages.  Sensitivity and 
specificity  determination,  histopathological  reports  (normal,  inflammation, 
hyperkeratosis, mild dysplasia, moderate dysplasia,  severe dysplasia and carcinoma 
in situ) were considered as standard and correlated with red-to-green ratios measured
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in  terms  of oral  changes  in  this  clinical  trial.  Results  were  considered  significant 
when the value ofp< 0.05.
2.14.2.2  Elastic scattering spectroscopy
The number of dimensions in the data (wavelengths) greatly exceeded the number of 
observations  (spectra),  and  so  a  naive  analysis  of the  raw  data  would  result  in  a 
model that was vastly over-fitted and would be much more sensitive to noise in the 
training  data  set.  To  avoid  this  problem,  the  data  was  cropped  between  340  and 
800 nm to remove those parts of the spectrum with low signal-to-noise ratio. Spectra 
were  smoothed  using  a  Savitsky-Golay  linear  filter  (to  remove  the  noise)  with  a 
smoothing width of 30 points  (10 nm),  and normalised  so that each spectra had a 
mean  intensity  of zero  and  a standard deviation of unity with virtually no  loss  of 
information;  by  doing  this  we  were  able  to  compare  and  analyse  spectra  with 
different intensities.
In  this  clinical  trial,  to  test  the  system,  all  types  of dysplasia  were  classified  as 
‘malignant’  whereas  all  other  reports  (normal,  inflammation,  and  hyperkeratosis) 
were considered “non-malignant or benign” changes. A linear discriminant analysis 
was  used to  find  a transformation that maximised the  difference between the  data 
belonging  to  the  dysplastic  and  the  benign  groups.  In  order  to  determine  how 
successful  this  algorithm  was  at  discriminating  between  the  novel  benign  and 
dysplastic  spectra,  leave-one-out (or “jacksnipe”) validation was used. All analyses 
were  performed  in  R  (R Development  Core  Team,  2005),  using  software  libraries 
from (Venables and Ripley, 2002).
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2.14.2.3  Monitoring of PDT
For  the  fluorescence  data,  the  image  obtained  was  intensified  and  PpIX  and  red 
tissue  autofluorescence  intensity  was  calculated.  For  the  ESS  data,  the  acquired 
spectra  were  first  smoothed  with  a  Savitzky-Golay  linear  filter  with  a  smoothing 
width of 30 points (10 nm).  Then the spectra taken during, at the end of, and after 
PDT were each log-ratioed against the mean spectra taken from that patient prior to 
PDT.  The relative  change  in the absorbance of ALA was estimated by calculating 
the area under a peak centred at 408 nm with a width of 10 nm. To test whether the 
ESS instrument detected significant differences in the relative absorbance over time, 
ANOVA was used where the integrated area under the curve was explained by time 
period (a factor with three levels: “during”, “at the end o f’ and “after”, depending on 
when the measurement was taken).
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Chapter 3
Results I
Photodynamic Efficacy in OSCC Cells
3.1  Introduction
The relationship between the degree of photodamage occurring in tumour tissue and 
photosensitiser  uptake  and  light  dose  is  controversial.  Early  studies  indicated  a 
reciprocal relationship between the photosensitiser and light, but this balance can be 
lost when using an excessive amount of the photosensitiser, which suggests shielding 
of the delivered light (Bown et al.,  1986; Barr et al.,  1990). In contrast, Teiten et al. 
showed that there is no significant correlation between tumour drug levels and PDT 
response in vitro, when measuring the amount of drug in human breast cancer cells 
(Teiten  et  al.,  2001).  In  addition  to  photosensitiser  and  light,  other  groups  have 
suggested the rule of tissue threshold (Lilge and Wilson,  1998); the same group also 
suggested that doses below the lethal level can repair cell damage caused by PDT. 
However, it is important to deliver the proper drug and light dose to the target area in 
order to  initiate the photochemical reaction.  Thus, minimum drug and power light, 
sufficient  to  achieve  tumour  ablation  without  causing  side  effects,  i.e.  long-term 
toxicity and thermal damage, are required.
The purpose of the  experiments described in this chapter was to  investigate, using 
various doses of both Foscan and light, in an attempt to determine whether treatment 
could  potentially  improve  the  outcome.  A  further  purpose  was  to  determine  the 
sublethal PDT dose for each cell line to be used for subsequent chapters.
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3.2 Foscan-dark toxicity
To  determine  the  safety  of  Foscan  on  cell  viability,  cells  were  incubated  with 
concentrations of the Foscan (0,  1, 5,  10, and 15pg/ml) for 72 h prior to analysis by 
MTT assay.  It was noted that sensitisation of KB,  UP, VB6 and H376 cells with 
5|ig/ml  of Foscan  for  up  to  5  days  in  the  dark  had  no  significant  effect  on  the 
viability of the cells. At higher dose concentrations, the cell viability was decreased 
slightly  in  a  dose  and  time  dependant  manner.  For  example,  at  15pg/ml,  which 
represents a 15- fold increase of the normal in vitro dose, the percentage survival in 
VB6 cells was 97% ±1.2 and 90% ±2.7 by day  1   and day 3, respectively, compared 
to the untreated controls (data not shown).
3.3 Effects of laser light
To  determine  the  safety  of red  light  on cell  viability,  cells  were  illuminated  with 
doses of the 652 nm red light (0,  1, 5,  10 and 15J/cm ), and incubated for 72 h prior 
to analysis by MTT assay.  It was noted that exposure of cell lines up to 5J/cm  of 
red  laser  had  no  effect  on  cell  survival.  At  the  higher  doses  (>10J/cm2),  the 
proliferation  of  cells  was  increased  slightly.  For  example,  in  H376  cells,  the 
proliferation was  10% ±2 higher than controls when cells were exposed to  lOJ/cm 
of red light (data not shown).
3.4 Phototoxicity of Foscan-PDT
To  analyse  Foscan-PDT  induced cytotoxicity,  KB,  UP,  VB6  and H376  cells were 
subjected to various doses of PDT. Thus, when cell lines were subjected to Foscan at 
concentrations of 0.25, 0.5,  1, 2, and 4pg/ml for 3 h and 24 h, and then illuminated 
with 0.5,  1,  2  and 4J/cm2  of red light,  the levels  of phototoxicity were  induced  in 
dose-dependant manner by both the drug and light and time of incubation (Figures 
3.1-4).  Compared  to  untreated  control,  the  results  showed  a  very  significant  (p< 
0.001) phototoxicity was found for all cell lines sensitised with 4pg/ml of Foscan for
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24 h and then  illuminated with 4J/cm2  light.  When cell  lines were  incubated with 
2pg/ml Foscan for 24 h and illuminated with 2J/cm2, the phototoxicity was maximal 
in  KB  cells  and  lesser  in  UP  cells  resulted  in  11%  ±  1.2  and  66.3%  ±  6.4  cell 
survivals, respectively. These cell survivals were reduced to 8.3% ± 6.3 and 58.3% ± 
3.4,  respectively  when  cells  incubated  with  Foscan  for  24  h  only.  Control 
experiments  show  that  both  drug  and  light  were  required  for  any  significant 
cytotoxicity to any of the cell lines. The sublethal doses causing approximately not 
more than 15% cell death in UP, VB6 and H376 cells are summarized in Tables 3.1. 
In order to determine the effects of PDT on metastasis, each cell line was subjected 
to this subtoxic dose, as reported in Chapter 4.
Table 3.1  Approximate sublethal doses of Foscan-PDT
Incubation Foscan Fluence Fluence rate Exposure Survival
time (h) (pg/ml) (J/cm2) mW/cm2 time (s) (%)
UP 24 1.0 0.5 25 20
88±3
VB6 24 0.5 0.5 25 20
87±2
H376 24 0.25 0.5 25 20 85±3
Control 24 0.0 0.0 0.0 0
Normalized 
to  100
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Figure  3.1  Phototoxicity  on  KB  cells  treated  with  various  concentration  of 
Foscan 0.25 A ,  0.5 (®),  1  (O), 2 (□) and 4 (®) pg/ml for 3 h (A) and 24 h (B).
The  cells were  exposed to  652  nm red light at 0.5,  1, 2, or 4J/cm2.  Controls were 
cells without treatment. Data represent the % of surviving cells relative to controls (= 
100). Error bar represent standard deviation of triplicate wells. The experiment was 
repeated twice with similar results.
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Figure  3.2  Phototoxicity  on  UP  cells  treated  with  various  concentration  of 
Foscan 0.25 (®), 0.5 (■), 1  (O), 2 (□) and 4 (■) jig/ml for 3 h (A) and 24 h (B).
The cells were  exposed to  652  nm red  light at 0.5,  1,  2,  or 4J/cm2. Controls were 
cells without treatment. Data represent the % of surviving cells relative to controls (= 
100). Error bar represent standard deviation of triplicate wells. The experiment was 
repeated twice with similar results.
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Figure  3.3  Phototoxicity  on  VB6  cells  treated  with  various  concentration  of 
Foscan 0.25 (O), 0.5 (^ , 1 (D), 2 (O) or 4 m jug/m 1  for 3 h (A) or 24 h (B). The
cells were exposed to 652 nm red light at 0.5,  1, 2, or 4J/cm2. Controls were cells 
without  treatment.  Data  represent  the  %  of surviving  cells  relative  to  controls  (= 
100). Error bar represent standard deviation of triplicate wells. The experiment was 
repeated twice with similar results.
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Figure 3.4  Phototoxicity  on  H376  cells  treated  with  various  concentration  of 
Foscan 0.25 (■), 0.5 <■), 1 <□), 2 <□) or 4 <■> fig/ml for 3 h (A) or 24 h (B). The
cells were  exposed to 652 nm red light at 0.5,  1, 2, or 4J/cm2. Controls were cells 
without  treatment.  Data  represent  the  %  of surviving  cells  relative  to  controls  (= 
100). Error bar represent standard deviation of triplicate wells. The experiment was 
repeated twice with similar results.
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3.5  Cell line dependence of Foscan-uptake
In order to determine whether the difference in sensitivity to PDT between the cell 
lines was  a result of the increased uptake of Foscan, the amount of Foscan within 
cells was analysed by flow cytometry. Figure 3.5  shows that the mean fluorescence 
intensities of Foscan at 24 h of incubation were varied.  In H376 cells, there was a 
4.9-fold  (p<  0.001)  and  1.7-fold  (p<  0.05) higher content compared with UP  and 
VB6 cells, respectively (Figure 3.6).
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Figure 3.5  Flow  cytometer  analysis  of Foscan  uptake  by  UP,  VB6  and  H376 
cells.  Cells  were  incubated  with  0.5pg/ml  of Foscan  for  24  h.  Cells  were  then 
released by trypsin/EDTA. Foscan was detected by measuring its red fluorescence in 
FL3-H.  Negative  controls  of all  cells  (first  left  solid  histogram) had no treatment. 
Figure represents results for one experiment run in duplicate.
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Figure  3.6  Mean  fluorescence  of cells  shown  in  Figure 3.5.  The  values were 
calculated by subtracting the mean fluorescence of the peaks of untreated cells from 
mean fluorescence of the peaks of Foscan treated cells. Fluorescence is measured in 
arbitrary units (a.u). Error bars represent standard deviation.
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3.6 Discussion
In this study, both the cytotoxicity and phototoxicity effects of Foscan mediated PDT 
were evaluated. Foscan has proved to be an efficient photosensitiser and has recently 
been  approved  in  clinical  practice  for the  treatment  of various  cancers,  including 
head and neck tumours (D’Cruz et al., 2004). The main disadvantage of the drug is 
its chronic phototoxicity which compels patients to avoid light for up to four weeks 
(Biel,  1995).  Dark  toxicity  is  one  of the  most  common  criteria  used  to  assess 
photosensitiser  safety  and  activity.  The  present  study  employed  various  doses  of 
both light and drug to  series of established cancer cell lines. Foscan,  in this study, 
showed  no  toxicity  and  the  illumination  of the  cell  lines  to  red  light  alone  (no 
photosensitiser) resulted in slight stimulation of growth. This is consistent with other 
authors who found that a stimulatory effect is produced by low intensity laser light 
(Pe  et  al.,  1994).  The  increased  growth  was  explained  as  an  increase  in 
mitochondrial  transmembrane  electrochemical  proton  gradient,  which  in  turn 
enhanced  calcium  release  in  cytoplasm,  while  excess  light  can  deplete  cellular 
energy and stimulate production of the proteases and lipases (Homung et al.,  1997). 
Currently,  the  red  laser  is  used  to  stimulate  wound  healing.  This  is  based  on  its 
stimulatory  effect  on  fibrous  tissue  to  initiate  release  of growth  factors  (Pe  et al., 
1994).
The results of the present  study revealed that cell  survival  was dependent on both 
drug and light, and this has been demonstrated in several other studies, both in vitro 
and in vivo (Yow et al., 2000; Teiten et al., 2001; Jones et al., 2003). Upon exposure 
to the red  laser, the reduced  sensitivity to  PDT when cells were incubated for 3  h 
indicates  either  a  reduction  of  the  intracellular  Foscan  concentration,  or  the 
possibility that the drug is not effectively distributed in the cell, as has been reported 
(Melnikova et al., 1999).
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Flow cytometry was used in this study to quantify the intracellular concentration of 
Foscan,  which indicated that Foscan was taken by all  investigated cells.  UP, VB6 
and  H376  cells  showed  different  drug  uptakes  and  were  inversely proportional  to 
their  size  and  positively  related  to  their  sensitivity  to  PDT.  This  difference  in 
response  to  PDT  could  be  explained  in  part  by  their  Foscan  uptake.  This  is 
contrasted  Moan  et  al.  who  indicated  that  normal  cells  and  cells  of  varying 
malignancy  potential  takeup  similar  levels  of photosensitiser  (Moan  et  al.,  1992). 
Another  explanation  for  different  sensitivity  to  PDT  could  be  the  result  of their 
degree  of  differentiation.  The  poorly  differentiated  cells  (KB)  were  the  most 
sensitive  line  to  PDT.  This  was  in  contrast  with  another  report  concerning 
erythroleukemia  cells,  where  reduction  in  HpD  sensitiser  uptake  by  differentiated 
cells  was  reduced,  but  without  changes  in  sensitivity  to  PDT  (Lejbkowicz  and 
Salzberg,  1992).  Furthermore,  UP  cells  are  keratinocyte-like  (papilloma  virus 
transformed cells)  and not an established cancer cell line, which may explain their 
low response in spite of their large size compared to the other cell lines used in the 
study. This is in agreement with other study on human colon carcinoma cells which 
were  divided  into  sensitive  and  resistant  according  to  the  cell  volume  (West  and 
Moore, 1992).
Many  studies  have  shown  a  relationship  between  photosensitiser  localization  and 
uptake and the killing effects of PDT (Sharman et al., 2004; Endlicher et al., 2001; 
Teiten et al., 2003; Fabris et al., 2001; Biel,  1995). The modulation of the sensitiser 
or light dose could  lead to  an enhanced killing effect,  for example,  decreasing the 
Foscan dose or incubation time and increasing the light dose could result in fewer 
adverse effects, therefore improving the outcome.  Clinically, this protocol has now 
been partially applied with promising results here at UCLH.
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Chapter 4
Results II
The  Effects  of  Photodynamic  Therapy  on  the 
Expressions of Invasion Promoting Factors in Head 
and Neck Carcinomas
4.1 Introduction
PDT is currently under clinical investigation for the treatment of early cancer. The 
biological  effects  of  PDT  are  primarily  mediated  by  the  generation  of reactive 
oxygen species, such as singlet oxygen, which result in cytotoxic effects on treated 
cells  with  the  initiation  of signal  transduction  pathways  (Margaron  et  al.,  1997; 
Runnels et al.,  1999; Almeida et al., 2004). In vitro, cell death is mainly due to the 
singlet oxygen reactions with the cellular organelles and membranes (direct killing), 
while in vivo, in addition to the direct effect, there is also significant microvascular 
damage  which  greatly  contributes  to  tumour  cell  destruction  (Fingar  et  al.,  1999; 
Triesscheijn  et  al.,  2005).  Apart  from  a  death  response,  cells  can  also  undergo  a 
rescue response after PDT and restore their activities (Kessel and Luo,  1999; Mitra 
et al., 2003).  PDT is mainly used for treatment of early cancer without metastases, 
yet it is crucial to determine the influence of PDT on the metastatic process.
The purpose of the experiments in this chapter was to describe the results of PDT on 
migration  and  invasion  capacity  including  its  effect  on  the  secretion  of MMP-2 
MMP-9, MMP-13, uPA, VEGF and expression of avpi and avp6 integrin receptors 
by human oral carcinoma.
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4.2  PDT decreases migration towards ECM substrates
The effect of PDT on the migration of UP,  VB6  and H376  cells was investigated 
using modified Boyden chamber assays.  Cells were allowed to migrate for 4 h on 
membranes precoated with one of two ECM proteins, fibronectin or type I collagen. 
The  obtained  data  (Figure  4.1)  shows  that the  migratory  activity  of all  cells  was 
varied,  depending  on  the  cell  line  and  coated  matrix  proteins.  Overall,  both 
fibronectin  and  type  I  collagen  promoted  the  migration  of all  lines.  VB6  cells 
showed a relatively higher migratory affinity towards fibronectin, approximately 2- 
fold, compared to the UP or H376 cells.
Compared to the untreated control, treatment of cell lines with PDT (Figure 4.1-A) 
had  down  reduced  the  affinity  of UP,  VB6  and  H376  cells  to  migration  toward 
fibronectin  by  5.8,  8.5,  and  18-fold,  respectively  (p<  0.001  for  all).  Migration 
toward type I collagen, (Figure 4.1-B) was approximately equally reduced by all cell 
lines; 3.4, 3.6 and 3.4-fold by the UP, VB6 and H376 cells, respectively (p<  0.001 
for all).
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Figure  4.1  The  Effect  of PDT  on  the  migration  of UP,  VB6  and  H376  cells 
towards fibronectin (A) or collagen type I (B). Following sublethal dose of PDT, 
cells were plated on Transwell membranes coated with  lOpg/ml of collagen type I 
and  allowed  to  migrate  for  3  h.  The  cells  that  migrated  and  bound  to  the 
undersurface of the filter were stained and counted by light microscopy using X40 
objective. Data is expressed as the mean number of migrating cells per high power 
field  (hpf)  in each membrane.  Error bars  represent the  standard deviation of three 
assays. The experiment was repeated twice with similar results.
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4.3  PDT decreases Matrigel invasion
To examine the effect of PDT on the invasiveness of squamous cell carcinoma, the 
cells were plated on Matrigel-coated Transwell insert.  Cells initially formed a layer 
covering the  entire  surface of the  gel before penetrating the  gel to reach the lower 
chamber. At 72 h after plating, the invasive potential of all cells varied (Figure 4.2), 
depending on the cell line. H376 cells showed a relatively higher ability to penetrate 
the gel, approximately 2.5-fold higher than UP. Around  15%, 22% and 46% of the 
UP, VB6 and H376  cells,  respectively, had migrated through the gel.  Treatment of 
cells  with  a  sub-lethal  dose  of  PDT  (Table  3.1)  resulted  in  a  decrease  of cell 
invasion,  approximately  1.9-fold,  5.6-fold  and  6-fold  by  the  UP,  VB6  and  H376, 
respectively (p< 0.001 for all), compared to untreated control cells.
8000
7000
6000 —
g  5000 
°  4000 
|   3000 
2   2000 
1000 
0
p<0.001
UP
p<0.001
n
p<0.001 n
□ Control 
■ PDT
VB6 
Cell line
H376
Figure 4,2  Effect of PDT on the invasion of UP, VB6 and H376 cells. Following 
treatment with  sublethal  dose  of PDT  (Table  3.1),  cells were  plated  on  Transwell 
membranes coated with 40jig/cm2 of Matrigel diluted in PBS and allowed to invade 
for 72 h. Cells that invaded the lower chamber, including those bound to the under­
surface of the filter, were trypsinized and counted using light microscopy.  Data is 
expressed as the number of invading cells per well and represent a mean ± standard 
deviation of three wells. The experiment was repeated twice with similar results.
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4.4  PDT decreases cell detachment.
There was no significant effect from either Foscan or red light treatment alone on the 
detachment  of cells  from  the  plastic  substratum  (data not  shown).  When the  cells 
were  treated  with  PDT,  the  percentage  of detached  UP,  VB6  and  H376  cells was 
significantly  reduced  (Figure  4.3).  For example,  at 24  h post-PDT,  the  number of 
detached  cells  was  reduced  by  73%  (p<  0.001),  29%  (p<  0.05)  and  18%  by  UP, 
VB6 and H376 cells, respectively, in comparison to untreated controls (100%).
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Figure 4.3  A  representative bar chart showing detachment assay  of UP, VB6 
and H376 cells. Following treatment with sublethal dose of PDT (Table 3.1), cells 
were detached by trypsin/EDTA over a variable time; 0 (■),  1  (□), 3(0), 24 (O) or 
48  (D)  h,  and the  number of detached cells was counted.  Data represent the  % of 
detached cells relative to the untreated control (=100). Error bars represent standard 
deviation of triplicate wells from one of three similar independent experiments.
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4.5 PDT modulates cell attachment
The effect of PDT on the attachment properties of UP, VB6 and H376 was examined 
in  short-term  adhesion  assays.  The  extracellular  matrix  proteins  fibronectin  and 
collagen  type  I,  Matrigel  or  plastic  substrate  were  used.  Figure  4.4  shows  no 
significant  difference  in the  adhesion  of UP,  VB6  and  H376  to  any  of the  ECM 
proteins except to Matrigel by H376 cells (p< 0.05). In contrast, the adhesion to the 
plastic substratum was significantly reduced by approximately 2.4-fold, 3.5-fold and 
2.7-fold by the UP, VB6 and H376 cells, respectively, following PDT (p<  0.05 for 
all).
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Figure 4.4  Adhesion  assay  of UP (A), VB6  (B)  and  H376  cells  (C).  Following 
treatment with PDT, cells were plated to fibronectin, collagen type I, Matrigel coated 
and plain wells. Data is expressed as the number of attached cells determined by the 
growth curve of each cell  line, as determined by MTT assay.  Error Bars represent 
standard  deviations  of triplicate  wells.  The  experiment  was  repeated  twice  with 
similar results.
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4.6  PDT regulates MMP-2 and MMP-9 activity
To find whether the treatment of oral carcinomas with PDT had an effect on MMP-2 
production, The UP, VB6 and H376 cells were subjected to sublethal dose of PDT. 
At  24  h  post  PDT,  the  supernatant  samples  of equal  protein  were  run  in  12% 
acrylamide separating gel and stained with Coomassie blue. The MMP-2 and MMP- 
9  bands  (Figures  4.5-10)  revealed  various  profiles  of MMP-2  and  MMP-9  lysis 
zones  corresponding  to  the  molecular  weight  expressed  by  each  cell  line.  In 
supernatants of control cells, gelatinases of 72 kDa corresponded to the pro-MMP-2 
were found to be highly expressed by VB6 cells (Figure 4.7) and H376 (Figure 4.9), 
while  UP  cells  showed  a  relatively  low  expression  (Figures  4.6).  No  band  of 
gelatinases was  detected  corresponding to  62 kDa active-MMP-2  for all  cell  lines 
(Figures 4.5, 7, 9). After exposure to PDT, the activity of  total (both pro and active) 
MMP-2 was down-regulated  1.8-fold (p<  0.05% 4.3-fold (p<  0.001) by UP (Figure 
4.6)  and  H376  cells  (Figure  4.10),  respectively,  while  in VB6  cells,  total  MMP-2 
(Figure 4.9) was upregulated 1.8-fold (p< 0.05). Exposure of H376 cells to PDT had 
resulted  in  significant  partial  activation  of latent  MMP-2  approximately  14.3-fold 
(p< 0.001; Figure 4.10).
A similar profile of MMP-9  lysis zones corresponding to molecular weights of 92 
kDa (latent form) and 84 kDa (active form) gelatinases were observed (Figures 4.5- 
10). In the untreated control samples, gelatinases of 92 kDa were highly expressed 
by VB6 cells (Figures 4.7) and only slightly by the H376 cells (Figures 4.9), while 
the  84  kDa  was  expressed  by  the  VB6  cell  line  alone  (Figures  4.7).  After  PDT 
treatment,  both  92  kDa  and  84  kDa  MMP-9  were  reduced,  with  a  significant 
decrease in expression by VB6 cells (p< 0.001; Figures 4.7).
In order to support zymography results, ELISA kit against MMP-2 and MMP-9 was 
used, taking care to ensure that the same protein loading concentrations were used as 
in the zymography. The results showed that, following PDT treatment, the levels of 
total  MMP-2  proteins  (Figure 4.11 A) were reduced by  9.6-fold only by the  H376
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(p< 0.001) compared to the control. For UP and VB6 cells, no significant differences 
between control and PDT treated samples were evident. For MMP-9, the total MMP- 
9 levels (Figure 41 IB) were 5.4 times less in VB6 cells compared to the control (p< 
0.001). No  significant differences between the control and PDT treated samples of 
UP cells were evident.
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92kDa pro-MMP-9  ------
72kDa pro-MMP-2  ____
Control
84kDa activated-MMP-9
62kDa activated-MMP-2
Figure 4.5  Zymogram showing PDT effect on MMP-2 and MMP-9 expression 
by  UP  cells.  After treatment with  sublethal  doses  of PDT  (Table  3.1),  cells were 
grown for 24 h before supernatant sampling and cell counting.  Samples containing 
equal  protein  were  run  on  each  gel  with  m.w  markers.  Control  samples  were 
supernatants  of the  untreated  cells.  The  intensity  of the  bands  was  measured  by 
densitometric analysis, as shown in Figure 4.6.
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Figure 4.6  Representative chart of densitometric analysis of zymogram shown 
in  Figure  4.5.  Comparisons  were  made  within  each  gel  to  determine  relative 
changes  in  MMP-2  and  MMP-9  activity  measured  in  arbitrary  units  (a.u).  Data 
represents  the  mean  of  relactive  activity  in  2  lanes.  Error  bars  =  ±  standard 
deviations. Comparison between zymograms should not be made due to variation in 
intensity of background staining.
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Figure 4.7  Zymogram showing PDT effect on MMP-2  and MMP-9 expression 
by VB6  cells. After treatment with sublethal  doses of PDT (Table 3.1),  cells were 
grown for 24 h before supernatant sampling and cell counting.  Samples containing 
equal  protein  were  run  on  each  gel  with  m.w  markers.  Control  samples  were 
supernatants  of the  untreated  cells.  The  intensity  of the  bands  was  measured  by 
densitometric analysis, as shown in Figure 4.8.
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Figure 4.8  Representative chart of densitometric analysis of zymogram  shown  in  Figure 4.7. 
Comparisons were made within each gel to determine relative changes in MMP-2 and MMP-9 
activity measured in arbitrary units (a.u). Data represents the mean of relactive activity in 
2 lanes. Error bars = ± standard deviations. Comparison between zymograms should 
not be made due to variation in intensity of background staining.
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Figure 4.9  Zymogram showing PDT effect on MMP-2 and MMP-9 expression 
by H376 cells. After treatment with sublethal doses of PDT (Table 3.1), cells were 
grown for 24 h before supernatant sampling and cell counting. Samples containing 
equal protein were run on each gel with m.w markers. Control samples were 
supernatants of the untreated cells. The intensity of the bands was measured by 
densitometric analysis, as shown in Figure 4.10.
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Figure 4.10  Representative chart of densitometric analysis of zymogram shown 
in  Figure  4.9.  Comparisons  were  made  within  each  gel  to  determine  relative 
changes  in  MMP-2  and  MMP-9  activity  measured  in  arbitrary  units  (a.u).  Data 
represents  the  mean  of  relactive  activity  in  2  lanes.  Error  bars  =  ±  standard 
deviations. Comparison between zymograms should not be made due to variation in 
intensity of background staining.
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Figure 4.11  ELISA for MMP-2  (A)  and  MMP-9 (B). Following treatment with 
sublethal  doses  of  PDT  (Table  3.1),  cell  supernatants  were  prepared  as  for 
zymography.  Sample  (100pi)  was  added  to  each  well  and  the  concentration 
determined  by  interpolation  from  standard  curve  using  known  concentrations  of 
MMP  standards.  Control  samples were  supernatants of the untreated cells.  Figures 
show  representative  experiments.  Error  Bars  represent  standard  deviations  of 
triplicate samples. Experiments were repeated twice with similar results.
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4.7  PDT modulates secretion of MMP-13
Commercial ELISA kit against pro-MMP-13, were used on wells loaded with cells’ 
supernatant  following  PDT.  The  result  revealed  that  in  the  untreated  controls, 
MMP13  was  markedly  expressed only by the  H376  cells.  After exposure to PDT, 
MMP-13  levels were  19.5  times less in the H376 cells (p<  0.001) and  1.5 and  1.6 
times (p<  0.05) higher in UP and VB6 cells, respectively, compared to the control 
samples (Figure 4.12).
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Figure  4.12  ELISA  for  MMP-13.  Following  treatment  with  sublethal  doses  of 
PDT  (Table  3.1),  cell  supernatants  were  prepared  as  for  zymography.  Sample 
(lOOpl) was  added to  each well  and the  concentration determined by interpolation 
from  standard  curve  using  known  concentrations  of  MMP  standards.  Control 
samples  were  supernatants  of  the  untreated  cells.  Figure  show  representative 
experiment.  Error  Bars  represent  standard  deviations  of  triplicate  samples. 
Experiment was repeated twice with similar results.
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4.8  PDT decreases secretion of VEGF
The effect of PDT on VEGF levels in the conditioned medium was determined by an 
ELISA assay.  The  results  showed that the  level  of VEGF  in the  medium of PDT 
treated cells, compared to the untreated controls over the 24 h culture period (Figure 
4.13A), were 3.3 and 3.8 times less in VB6 and H376 cells, respectively (p< 0.05 for 
both).  This  was  reduced to  2.4-fold and 4-fold  (p<  0.01  for both)  when the  cells 
were  cultured  for  48  h  (Figure  4.13B).  For  UP  cells,  no  significant  difference  in 
VEGF expression over any of the experiment times was found (Figure 4.13A-B).
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Figure 4.13  ELISA for VEGF. After treatment with sublethal doses of PDT, UP, 
VB6  and  H376  cells  were  grown  for  24  h  (A)  and  48  h  (B)  before  supernatant 
sampling  and  cell  counting.  Cell  supernatants  were  prepared  as  for  zymography. 
Sample  (100pl)  was  added  to  each  well  and  the  concentration  determined  by 
interpolation from standard  curve using known concentrations of VEGF  standards. 
Control  samples  were  supernatants  of  the  untreated  cells.  Figures  show 
representative  experiments.  Error  Bars  represent  standard  deviations  of triplicate 
samples. Experiments were repeated twice with similar results.
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4.9  PDT decreases secretion of uPA
To  quantify  uPA  activity  by  UP,  VB6  and  H376  cells,  a  chromogenic  assay was 
performed  on  supernatants  of PDT  treated  and  control  cells  over  a  72  h  culture 
period.  In  comparison  to  the  untreated  controls,  the  assay  revealed  that  the  uPA 
activity was significantly (p<  0.05) decreased only by the VB6 cells (Figure 4.14). 
For UP  and H376  cells,  no  significant difference  in uPA expression between PDT 
treated and control supernatants was found.
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Figure  4.14  Chromogenic  assays  for  uPA.  Cells  were  grown  for  24  h before 
being exposed to  a sublethal  dose  of PDT.  Cell  supernatants were prepared as  for 
zymography.  Sample  (50pl)  was  added  to  each  well  and  the  concentration 
determined  by  interpolation  from  the  constructed  standard  curve  prepared  using 
range  of human  uPA  substrate  standards.  Figure  show  representative  experiment. 
Error  Bars  represent  standard  deviations  of  triplicate  samples.  Experiment  was 
repeated twice with similar results.
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4.10  PDT regulates expression of a5pi and avP6
As  the  expression  of adhesion  receptors  is  an  important  event  in  the  metastasis 
process, it was decided to investigate whether treatment of keratinocytes with PDT 
had  an  effect  on  the  expression  of  a5pl  integrin  receptor.  An  analysis  flow 
cytometry data indicated that exposure of the cells to sublethal doses of PDT caused 
an enhancement of a5pl receptor (Figures 4.15-4.16). The receptor was enhanced by 
6.54 fold and 5.6 fold by the UP and H376 cells, respectively (p <0.01 for both). For 
VB6  cells,  no  significant  change  in  a5pl  receptor expression following PDT was 
found. Similarly in avp6 receptor (Figure 4.17-4.18), data indicated that exposure of 
the cells to  sublethal doses of PDT caused an enhancement of avp6.  The receptor 
was significantly enhanced  10  fold (p< 0.001) by H376 cell line only, whereas no 
significant difference was found in UP and VB6 cells.
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Figure 4.15  Histograms analysis of a5pl by UP, VB6, and H376 cells. Cells were 
released by trypsin/EDTA and labelled with a5pi  (P1D6). Bound a5pi was detected 
by FITC-conjugated rabbit anti-mouse anti-sera. Negative controls of both untreated 
and PDT treated cells (first left histogram of each) had secondary antibody only. The 
X-axis represents  fluorescence  intensity in log scale and the  Y-axis represents cell 
counts (no. of events).
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Figure 4.16 A representative chart bar of mean fluorescence values of receptor 
expression shown in Figure 4.15. Values were calculated by subtracting the mean 
fluorescence (arbitrary units) of the peaks of second antibody labelled of cells (both 
PDT and control cells) from mean fluorescence of the peaks of a5fll  labelled cells. 
Error bars are standard deviation of triplicate experiments.
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Figure 4.17  Histograms analysis of avp6 by UP, VB6, and H376 cells. Cells were 
released by trypsin/EDTA and labelled with avp6 (E7P6). Bound avp6 was detected 
by FITC-conjugated rabbit anti-mouse anti-sera. Negative controls of both untreated 
and PDT treated cells (first left histogram) had secondary antibody only. The X-axis 
represents fluorescence  intensity in log scale and the Y-axis represents cell counts 
(no. of events).
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Figure 4.18  A representative chart bar of Mean fluorescence values of receptor 
expression shown in Figure 4.17. Values were calculated by subtracting the mean 
fluorescence (arbitrary units) of the peaks of second antibody labelled of cells (both 
PDT and control cells) from mean fluorescence of the peaks of avp6 labelled cells. 
Error bars are standard deviation of triplicate experiments.
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4.11  PDT regulates EGFR
As the expression of growth receptors is an important event in the process of tumour 
growth and metastasis, it was decided to investigate whether the treatment of head 
and neck tumour cells with PDT has an effect on the expression of the EGF receptor 
(Figure 4.19). An analysis of flow cytometry acquired data indicated that EGFR was 
expressed  only  by  H376  cells.  When  cells  were  treated  with  PDT,  the  EGFR 
expression  was  enhanced  approximately  3-fold  (p  < 0.01)  by  UP  cells  only  and 
suppressed 7-fold (p  <0.001) by the H376 cells, compared to the untreated controls 
(Figure 4.19).
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Figure 4.19  Histogram of EGFR expressions by UP, VB6 and H376 cells.  Cells 
were either given no treatment (control) or treated with sublethal dose of PDT (Table 
3.1).  Cells  were  released  and  labelled  with  EGFR  (102618).  Bound  EGFR  was 
detected by FITC-conjugated rabbit anti-mouse anti-sera. Negative controls of both 
untreated cells and PDT treated cells (first left histogram) had secondary antibodies 
only.  The  X-axis  represents  fluorescence  intensity  in  log  scale  and  the  Y-axis 
represents cell counts (no. of events).
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Figure 4.20  A representative chart bar of Mean fluorescence values  of EGFR 
expression shown in Figure 4.19. Values were calculated by subtracting the mean 
fluorescence (arbitrary units) of the peaks of second antibody labelled of cells (both 
PDT and control cells) from mean fluorescence of the peaks of EGFR labelled cells. 
Error bars are standard deviation of triplicate experiments.
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4.12  PDT effects on the expression of HGFR
It was also decided to investigate whether the combined treatment has any effect on 
the expression of HGF receptors (Figure 4.21). An analysis of flow cytometry results 
indicated  that  HGFR  was  not  expressed  by  any  of the  cell  lines,  nor  were  any 
significant  changes  observed  following  treatment  with  sub-lethal  doses  of PDT 
(Figure 4.22).
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Figure  4.21  Histogram  of expression  of HGFR  by  UP,  VB6  and  H376  cells.
Cells were either given no treatment (control) or treated with sublethal dose of PDT 
(Table 3.1). Cells were released and labelled with HGFR (35309). Bound GFR was 
detected by FITC-conjugated rabbit anti-mouse anti-sera. Negative controls of both 
untreated cells and PDT treated cells (first left histogram) had secondary antibodies 
only.  The  X-axis  represents  fluorescence  intensity  in  log  scale  and  the  Y-axis 
represents cell counts (no. of events).
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Figure 4.22  A representative chart bar of Mean fluorescence values  of HGFR 
expression shown in Figure 4.21. Values were calculated by subtracting the mean 
fluorescence (arbitrary units) of the peaks of second antibody labelled of cells (both 
PDT and control cells) from mean fluorescence of the peaks of HGFR labelled cells. 
Error bars are standard deviation of triplicate experiments.
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4.13  Discussion
The precise mechanism by which PDT interferes with the metastatic process has yet 
to  be elucidated.  This  may be associated with changes  in metabolic  functions and 
signals, such as those triggered by the apoptotic effect of PDT, which converges to 
regulate MMP  synthesis and activity (Agostinis et al.,  2004).  In the present study, 
the  effect  of Foscan-PDT  on  the  synthesis  of  several  known  tumour  promoting 
factors in head and neck cancer was examined. It was found that PDT reduced the 
invasive  potential  of  malignant  head  and  neck  cells.  It  is  striking  that  this 
suppression of invasiveness was observed at sub-lethal doses, killing no more than 
15% of cells,  which implies the  feasibility of this emerging therapy.  This Chapter 
results showed for the first time that uPA and MMP-13 proteinases and cell surface 
integrin a5pi and avp6 expression can be modulated by PDT.
In this  study,  invasiveness  reduction was  associated with the  decreased activity of 
MMP-2 and MMP-9 in most of the cell models used. This conflicts with the findings 
of other researchers (Ferrario et al., 2004) who have explored the effect of PDT on 
the  expression  and/or activity  of MMP-2  and MMP-9  and found that exposure of 
mouse  mammary  tumour  to  Photofrin-mediated  PDT  has  increased  the  MMP-9 
activity,  but  without  significant  changes  in  MMP-2  profiles.  One  potential 
explanation  for  this  enhancement  of MMP-9  activity  could  relate  to  the  different 
protocol  applied,  i.e.  the  use  of broad  spectrum  fluorescence  bulbs  to  initiate  the 
photochemical reaction, which might included UVB bands, and has been shown to 
stimulate  the  expression  and  secretion  of different  MMPs  (Ramos  et  al.,  2004; 
Brenneisen et al., 2002).  In a recent in vitro report, it was demonstrated that when 
fibroblast  cells  were  treated  with  ALA-PDT,  no  change  in  MMP2  secretion  was 
observed, while the levels of MMP-1  and MMP-3  proteins increased up to 3-fold, 
suggesting  that  MMP-1  and  MMP-3  are  produced  by  fibroblasts  in  response  to 
photodynamic  therapy  (PDT)  and  may  be  involved  in  the  antisclerotic  effects  of 
ALA-PDT (Karrer et al., 2003). This effect was not obvious on keratinocytes, since 
neither enzyme, MMP-1  nor MMP-3, was altered significantly (Karrer et al., 2004).
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Du  et  al.  have  analysed  the  effect  of  hypericin-based  photodynamic  therapy 
(hypericin-PDT)  on  MMP-1  expression  in  two  nasopharyngeal  cancer  (NPC)  cell 
lines  and  in  an  animal  tumour model  (Du  et  al.,  2004).  They found MMP-1  was 
increased at both mRNA and protein levels  in well differentiated HK1  and poorly 
differentiated CNE-2 NPC cells.
On gelatinase  zymography,  MMP-2  and MMP-9  activity is occasionally seen as a 
doublet,  reflecting  the  inactive,  higher  molecular  weight  and  the  active,  lower 
molecular weight of the enzyme. Here, both the decrease and increase in intensity of 
both  bands  were  noted.  An  increase  of the  higher weight  inactive  form  by non- 
malignant  UP  cells  and  lowers  molecular  weight  active  form  by  H376  cell  line 
following  PDT  suggests  that  PDT  could  have  an  effect  on  local  factors,  e.g.  an 
imbalance between MMPs and their inhibitors, while the decrease in the upper band 
could be due to a reduction in the synthesis or secretion of the matrix protein. Also, 
the low secretion of MMP-13 by VB6 cells may be explained by recent findings on 
P6-transfected OSCC cells, that avp6 integrin has caused downregulation of  MMP- 
13 expression at both mRNA and protein level (Ylipalosaari et al., 2005).
In the  present  study,  the  levels  of uPA and  VEGF  were  reduced  by  invasive  cell 
lines. This agrees with the findings of Uehra et al., who reported a decrease in VEGF 
expression 24 h after PDT,  and attributed this reduction to tumour re-oxygenation 
(Uehara et al., 2001). It was also demonstrated that following exposure to PDT, the 
VEGF  expression  in  healthy  tissue  surrounding  rat  brain  tumour  was  highly 
expressed in comparison to the tumour tissue (Jiang et al., 2004).
A sub-lethal dose of PDT markedly reduced cell attachment to collagen, fibronectin, 
Matrigel and plastic tissue culture with a reduction of cell migration. The reaction of 
cells  with  their  surrounding  matrices  has  been  shown  to  promote  cell  migration, 
proliferation and the digestion of ECM (Kramer et al.,  2005).  It was demonstrated 
previously  that  the  prevention  of  cancer  metastasis  can  be  achieved  by  the
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prevention of tumour adhesion and migration (Liotta et al.,  1982),  and agents that 
inhibit cell attachment in vitro decrease the invasiveness and metastatic potential of 
cancer  cells  in  vivo  (Vollmers  et  al.,  1984;  Humphries  et  al.,  1986).This  study 
demonstrated that the  attachment of transformed and malignant cells to the type I 
collagen,  fibronectin,  Matrigel  and  plastic  substratum  decreased  following  pre­
treatment with a sub-lethal dose of PDT, and this depended on cell type and matrix 
proteins.  This  is  in  agreement  with  Vonarx  (1995),  who  found  that  treatment  of 
colonic cancer cells with hematoporphyrin photosensitiser caused a decrease in the 
adhesion of cells to the ECM proteins with subsequent reduction of their metastatic 
potential (Vonarx et al.,  1995). A similar result is reported in another study (Foultier 
et al.,  1994).  In addition, a recent report demonstrated that ALA-PDT resulted in a 
slowing  down  the  cell  attachment  process  at  both  toxic  and  non-toxic  PDT 
application (Uzdensky et al., 2004).
Trypsin  acts  by  digesting  the  bonds  between  the  cell  surface  proteins  and  the 
substratum and leads to cell detachment.  In the present study, it was demonstrated 
that the suppression effects of Foscan-PDT on trypsin-induced cell detachment and 
the reduction in enzyme activity showed differential effects in relation to cell lines 
and time after PDT treatment.  These observations are in agreement with Uzdensky 
[2004],  who  demonstrated  that  the  trypsin  releasing  efficiency  is  lost  when 
adenocarcinoma  cells  were  grown  on  plastic  substratum  and  treated  with  a  sub- 
lethal  dose  of  PDT  using  5-aminolevulinic  acid  (ALA),  disulfonated 
tetraphenylporphyrine  (TPPS2a),  or  a  MitoTracker  Red  (MTR)  as  photosensitiser 
(Uzdensky et al., 2004). However, this was in  contrast to Ball [2001], who reported 
no  resistance  to  trypsin  in  fibroblast  cells  when  m-THPC  was  used  as  a 
photosensitiser  but  a  significant  resistance  with  pyridinium  zinc(II)  pthalocyanine 
(PPC),  suggesting that the role of tissue transglutaminase may cause this resistance 
(Ball et al., 2001).
The role of integrins in the regulation of the adhesion of cells to the ECM is well 
established.  Integrin-mediated  cell  adhesion  can  trigger  Ca  influx,  activate  and
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deactivate  protein  tyrosine  kinases  (e.g.  focal  adhesion  kinase  (FAK)  and  Src 
tyrosine kinase ), serine/threonine protein kinases, e.g. MAP kinases, protein kinase 
C (Giancotti and Ruoslahti,  1999; Cordes and Meineke, 2004; Danen, 2005). In this 
study, the two subunits, a5pl  and avp6 integrins were examined. The data showed 
for  the  first  time  that  cell  surface  integrin  a5pi  and  avp6  expression  can  be 
modulated by Foscan-PDT.  This was clear in avp6 positive cell line (VB6), which 
was reduced by PDT.
The results demonstrated that Foscan based PDT markedly reduces the ability of UP, 
VB6  and  H376  cells  to  migrate  and  invade  through  artificial  membrane.  The 
mechanism  by  which  PDT  extensively  suppresses  cell  migration  and  inhibits  the 
invasive process is unclear. Invading cells must pass through an extracellular matrix, 
a  process  that  involves  attachment/detachment  and  enzymatic  degradation  of the 
components of the ECM. The results of this study shown that secretion of MMP-2, 
MMP-9,  MMP-13,  uPA  and  VEGF  was  reduced  following  PDT,  which  could 
explain  the  reduction  of cells  invasive  potential.  Many  studies  revealed  that  the 
enhanced  production  of  MMPs,  uPA  and  VEGF  correlates  with  the  invasion, 
metastasis and angiogenesis of the tumour cells (Franchi et al., 2002; Werner et al., 
2002; Culhaci et al., 2004; Pacheco et al., 2002; Chin et al., 2005; Benefield et al., 
1996).
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Chapter 5
Results III
Chemical Therapy: Its Implication for Combination 
Treatment with Photodynamic Therapy.
5.1  Introduction
Combination therapies have been shown to improve the treatment outcomes in many 
human  cancers,  including  head  and  neck  squamous  cell  carcinoma.  Using  this 
approach, drug resistance and limitation can be overcome. The most commonly used 
combinations  are  chemotherapy  regimens  whereby  different  agents  are  given 
concurrently,  i.e.  cisplatin/5-fluorouracil  and  combinations  of chemotherapy  with 
radiotherapy (Bradley et al., 2002), and more recently with tyrosine kinase inhibitors 
(Ciardiello et al., 2000; Raben et al., 2005; Zhu et al., 2005). PDT is characterised by 
low toxicity and cost, excellent cosmetic results and absence of significant morbidity 
(D'Cruz et al., 2004; Hopper et al., 2004b) but at the same time there are several side 
effects,  such  as  prolonged  photosensitization,  limited  depth  and  others,  which 
occasionally cause long-term follow-up results to be worse than for its conventional 
counterparts.
Nevertheless, at the time of writing, there has been no work on combinations of PDT 
with either ZD 1839  or PD153035  TKIs.  Therefore,  the  effects  of small molecules 
(ZD1839 and PD153035) or CDDP chemotherapy combined with Foscan mediated- 
PDT on the toxicity and anti-metastatic  effects of PDT, were evaluated using oral 
squamous carcinoma cell lines as ‘’targets” .
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5.2  CDDP augments PDT anti-tumour activity
To evaluate the effects of CDDP combined with PDT on cell toxicity, the cells were 
treated with combination doses of PDT and CDDP. Firstly, the effect of CDDP on 
the viability of transformed and malignant cells as a single treatment was evaluated. 
Compared to the untreated controls, cell growth (Figure 5.1) as evaluated by MTT 
assay revealed that CDDP suppressed the proliferation of UP, VB6 and H376 cells in 
a dose-dependent manner, with IC50 ranging between 6 and 12 pg/ml. Approximately 
90% inhibition of growth was observed at a dose of 4 pg/ml in UP cells and 2 jug/ml 
in both VB6 and H376.
Subsequently, the effect of the addition of CDDP to PDT was determined. Figure 5.2 
shows that additive  (no more than the addition of the efficiency of each treatment 
modality  alone)  and  synergistic  (exceeds  the  value  of each  modality)  inhibitory 
effects on growth were  achieved when PDT was combined with CDDP.  This was 
dependent on cell line and CDDP dose. In UP cells, only an additive inhibition effect 
was produced following combination of PDT with any of CDDP dose used (Figure 
5.2A-C).
In  H376  cells,  a  synergistic  inhibitory  effect  (Figure  5.2A-B)  was  produced  at  4 
pg/ml  of CDDP,  since  a  single  treatment  with  CDDP  or  PDT  reduces  the  cell 
survival to 57 ± 7.3% and 71±1%, respectively, whereas exposure to both treatments 
reduced cell survival to 8 ± 2%. When PDT was combined with 8 pg/ml of CDDP, 
an additive inhibitory effect on H376 cells was observed (Figure 5. 2C).
For VB6 line, an additive inhibitory effect (Figure 5.2A-B) was produced only when 
cells  were  treated  with  PDT  combined  with  8pg/ml  of  CDDP,  since  a  single 
treatment with CDDP or PDT reduces the cell survival to 39 ± 3.8% and 83± 6%, 
respectively and exposure to both treatments reduced cell survival to 14 ± 2.5%. 
Exposure of VB6 cells to combined doses of PDT and CDDP (2 and 4 pg/ml) caused 
a synergetic effect on cell survival.
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Figure 5.1  Toxicity of CDDP on UP, VB6 and H376 cells. Cells were incubated 
with CDDP at 2 (■), 4(d), 6(0),  10(0), 20 (0), and 40 <■> pg/ml for 24 h. Cells 
were  then  released  and  counted  using  MTT  assay.  The  data  represents  the  %  of 
surviving  cells  24  h  after  the  treatment  relative  to  the  untreated  controls  (=100). 
Error  Bars  represent  standard  deviations  of triplicate  wells.  The  experiment  was 
repeated twice with similar results.
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Figure 5.2  Toxicity of PDT combined with CDDP on UP, VB6 and H376 cells.
Cells were incubated with CDDP at 2 (A), 4 (B) or 8pg/ml (C) for 24 h. Cells were 
treated  with  small  dose  of PDT  (0.5|ig/ml  Foscan;  0.5J/cm2  light)  before  being 
released  and  counted  using  MTT  assay.  The  data  represents  the  %  of cells  that 
survived  24  h  after  the  treatment  in  comparison to  the  untreated  controls  (=100). 
Figure  represents  results  for  one  experiment  run  in  triplicate.  Error  bar  represent 
standard  deviation  of  triplicate  wells.  The  experiment  was  repeated  twice  with 
similar results.
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5.3  Iressa augments PDT anti-tumour activity
The cytotoxicity of Iressa, as a single drug or in combination with Foscan-PDT, on 
UP,  VB6  and  H376  cells was  determined using MTT assay.  The results  of Iressa 
alone (Figure  5.3)  show that the  survival  inhibition of the drug was dependent on 
both  cell  line  and  drug  concentration.  Compared  to  the  untreated  controls,  the 
incubation of UP, VB6 and H376 cells with a 5pM dose of Iressa caused maximum 
toxicity and the percentage  of surviving cells was reduced to  approximately  79%, 
72% and  50% respectively.  There was  a sequential  suppression of survival  in UP 
cells  only,  following  increases  doses  of  Iressa  drug  (0.05  to  50  pM),  but  this 
sequential suppression does not observed in VB6 and H376 cell lines. Fore example 
incubation  of  UP  cells  with  0.05,  0.5,  5  and  50pM  of  Iressa  suppressed  their 
survivals approximately to 93%, 86%, 79% and 63%, respectively, whereas in H376 
cells, approximately 50% suppression was achieved following incubation with  0.5, 
5  and  50pM  doses  of Iressa.  Moreover,  exposure  of cells  to  higher  doses  (up  to 
50pM) of Iressa had no further toxicity on any of cell line tested.
When cells were exposed to combined doses of PDT and Iressa, both additive and 
synergistic  inhibitory  effects  on  growth  were  achieved  (Figure  5.4A-C).  For 
example,  in UP  cells  a  single  treatment with PDT-2  (Foscan,  0.5pg/ml;  light  0.5 
J/cm2) and Iressa (0.05  pM),  each alone, resulted  in 97 ± 4% and 98 ±  11% cell 
survival, respectively (Figure 5.4-A).  If UP cells were treated with combined doses 
of PDT-2 (Foscan, 0.5pg/ml; light 0.5 J/cm2) and Iressa (0.05 pM), the cell survival 
was reduced (synergistically) to  73  % ± 6%.  In VB6 cells (Figure 5.4-B), a single 
treatment with PDT (Foscan,  0.5pg/ml;  light 0.5J/cm2) or Iressa (0.05 pM) reduced 
cell survival  approximately to 87 ± 2% and 85% respectively in comparison to the 
untreated controls (100%). Exposure of cells to combined doses of PDT and Iressa
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reduced the cell survivals to 35%.  Similarly in H376 cells, combined treatment had 
synergistically reduced the cell survivals to 25% (Figure 5.4-C).
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Figure 5.3  Toxicity of Iressa on  UP, VB6 and H376 cells.  Cells were incubated 
with Iressa at 0.05 (&), 0.5 (O), 5 (O) or 50 (D) pM. After 24 h, cells were released 
and  counted  using  MTT  assay.  The  data  represents  the  %  of surviving  cells  in 
comparison to the untreated controls (=  100). Error bar represent standard deviation 
of triplicate wells. The experiment was repeated twice with similar results.
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Figure 5.4  Toxicity of Iressa combined with PDT on UP (A), VB6 (B) and H376 
cells  (C).  Cells  were  incubated with  0.05,  (O),  0.1  <■),  i  A, and  lOpM  (Q)  of 
Iressa  and  PDT-1  (Foscan,  0.25pg/ml;  light  0.5  J/cm2)  and  PDT-2  (Foscan, 
0.5pg/ml;  light  0.5  J/cm2)  doses.  The  data  represents  the  %  of  surviving  cells 
compared to the untreated controls (=100). Error bar represent standard deviation of 
triplicate wells. The experiment was repeated twice with similar results.
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5.4  PD153035 augments PDT anti-tumour activity
To support the Iressa results, PDT was combined with another TKI drug, PD153035. 
The  results  of  PD153035  alone  indicated  that  the  toxicity  of  PD153035  was 
dependent on its concentrations.  The maximum suppression of survival in UP and 
VB6 cell lines was obtained at exposure of both cell lines to a 20pM dose, which 
reduced  the  percentage  of  cell  survival  approximately  by  27  %  and  26%, 
respectively, in comparison to untreated controls (100%). In contrast to UP and VB6 
cells, the toxicity in H376 cells was observed at smaller dose of PD153035  (lpM), 
which reduced  the  cell  survival  approximately  by  52%  (Figure  5.5).  Exposure  of 
cells to higher doses (up to 40pM) of PD 153035 had no further toxicity on any of 
cell line tested.
When UP, VB6 and H376 cells were exposed to combined doses of PD153035 and 
PDT, additive and synergistic inhibitory effects were observed, except in H376 cell 
line  where  an  antagonistic  toxicity  found;  this  was  dose  dependant  of  both 
PD153035  and PDT (Figure 5.6A-C).  For example, In UP cells, a single treatment 
with PDT-2  or PD153035  (lpM )  reduced  cell  survival  approximately by  3%  and 
15%,  respectively,  in  comparison  to  the  untreated  controls  (100%),  whereas 
exposure  to  both  regime  caused  synergetic  effect  on  cell  survival  and  resulted 
approximately in 54% toxicity (Figure 5.6A).  Similarly with UP cells, exposure of 
VB6  cells  to  PDT-2  or  PD 153035  (lpM),  each  alone,  reduced  cell  survival 
approximately  by  18%  and  21%,  respectively,  in  comparison  to  the  untreated 
controls (100%), whereas exposure to both regime caused synergetic effect on cell 
survival and resulted approximately in 76% toxicity (Figure 5.6B). In contrast to UP 
and VB6 cells, exposure of H376 cells to 0.5pM of PD153035  (27% toxicity) and 
PDT-1 (26% toxicity), resulted in an antagonist effect on cell toxicity (41% toxicity). 
This  antagonist effect become  synergetic  if PD 153035  was  combined with PDT-2 
dose  (31%  toxicity),  which  increases  the  toxicity  approximately  to  70%  (Figure 
5.6C).
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Figure  5.5  Toxicity  of  PD153035  on  UP,  VB6  and  H376  cells.  Cells  were 
incubated with Iressa at,  0.5  (O),  1   (O),  5  (O),  10  (D) and 20pM  (D). After 24 h, 
cells  were  released  and  counted  using  MTT  assay.  The  data  represents  the  %  of 
surviving cells in comparison to the  untreated controls (=100).  Error bar represent 
standard  deviation  of  triplicate  wells.  The  experiment  was  repeated  twice  with 
similar results.
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Figure 5.6  Toxicity of PD153035 combined with PDT on UP (A), VB6 (B) and 
H376 cells (C). Cells were either incubated with 0.5,  <■),  1   <■), 5  (□), and 20pM 
(□) of PD 153035  and then treated with PDT-1  and PDT-2. The data represents the 
%  of  surviving  cells  in  comparison  to  the  untreated  controls  (=100).  Error  bar 
represent standard deviation of triplicate wells.  The experiment was repeated twice 
with similar results.
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5.5  Iressa augments PDT down-regulation effect on VEGF 
activity
Since angiogenesis is an important step during tumour metastasis, it was decided to 
investigate, using an ELISA, whether PDT in combination with Iressa had an effect 
on secretion  of VEGF.  In  comparison to  untreated  controls,  results  (Figure  5.7A) 
indicated that Iressa, as a single treatment, reduced the secretion of VEGF over 48 h 
of culture  approximately by  1.1-fold,  1.4-fold and  1.5-fold in UP, VB6  and H376 
cells, respectively.
When cells were treated with combined doses of Iressa and PDT, VEGF  secretion 
was  significantly  (additively)  reduced  (p<  0.001  for  all).  In  comparison  to  PDT 
alone, VEGF secretion was also significantly reduced (p< 0.001 for all).
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Figure 5.7  ELISA  assay  of VEGF  activity  on  UP, VB6  and  H376  cells.  After 
treatment with Iressa (0.5pM for UP and 0.05pM for VB6 and H376 cells) and PDT 
(Table  3.1),  supernatant  sampling  of cells  was  collected  48  h  after treatment.  The 
amount of secreted VEGF/100000 cells is given in Figure 5.7A.  The percentage of 
secreted VEGF in treated supernatants compared to the untreated control (= 100) is 
given  in  Figure  5.7B.  Error  bar represent  standard  deviation of triplicate  samples. 
The experiment was repeated twice with similar results.
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5.6  Cell morphology
The morphological changes of UP and VB6 cells treated with PDT and CDDP, each 
alone or in combination were examined over time. In UP (Figure 5.8) and VB6 cells 
(Figure 5.9), the pictures revealed a healthy confluent layer of untreated control cells 
over  48  h  of  culture.  Treatment  of  UP  cells  with  CDDP  resulted  in  wavy 
morphological  changes, but intact intracellular connection. In contrast to UP cells, 
treatment of VB6 cells with CDDP reduced the intracellular contact, compared to the 
untreated controls.
When  cells  were  treated  with  PDT,  many  vacuoles  were  observed  without  any 
intracellular connection changes  in either cell  line.  Following combined treatment 
with CDDP and PDT, adhesion to plastic substrate was markedly reduced in both the 
UP at 48 h and VB6 cell lines at 24 h of culture.
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Figure  5.8  Morphology  and  adhesion  of UP  cells.  Cells  were  either  given  no 
treatment (control) or treated with small dose of CDDP (4jag/ml) or PDT (Table 3.1) 
as a single or in combination. Pictures were taken at 1, 24 or 48h after the treatment.
CDDP
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Figure  5.9  Morphology  and  adhesion  of VB6  cells.  Cells  were  either given  no 
treatment (control) or treated with small dose of CDDP (4jag/ml) or PDT (Table 3.1) 
as a single or in combination. Pictures were taken at 1, 24 or 48h after the treatment.
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5.7  CDDP regulates PDT effect on cell migration
The effect of CDDP on the PDT impact of the migration of normal and malignant 
head  and  neck  human  cell  lines  through  a  8-pm  pores  Transwell®  cell  culture 
chamber  pre-coated  with  either  fibronectin  or  collagen  type-I  ECM  protein  was 
examined. Migration experiments revealed that differences in the migration potential 
of the tested cell lines were dependent on both cell type and matrix proteins (Figure 
5.10-11).  For example,  in UP  and VB6  cells  in  comparison to  untreated controls, 
exposure  of cells  to  a  sublethal  dose  of PDT  alone  down-regulated the  migration 
toward  fibronectin  (Figure  5.10A-B)  by  approximately  56%  and  75% respectively 
(p<  0.001  for both), and toward type I collagen (Figure 5.11A-B) by 64% and 67% 
respectively {p<  0.001 for all), whereas treatment of cells with CDDP alone reduced 
the migration toward fibronectin by approximately  18% and  17% respectively, and 
toward collagen type-1 by 15% and 20%, respectively.
When cells were exposed to combined doses of CDDP and PDT, migration of UP 
and VB6 cells toward fibronectin (Figure 5.10A-B) was further reduced by 36% and 
22% respectively (p<  0.001  for both)  in comparison to PDT alone, and 70% and 
62% respectively (p<  0.001  for both)  in comparison to CDDP alone. A significant 
reduction in migration of UP,  VB6  and H376 cells toward collagen type I (Figure 
5.11A-B) was also observed following exposure to PDT (p< 0.05 for all).
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Figure  5.10  Effect  of PDT  and  CDDP  on  UP,  VB6  and  H376  cell  migration 
towards fibronectin. After treatment with small dose of CDDP (4pg/ml for UP and 
VB6  cells,  and  2pg/ml  for  H376  cells)  and  PDT  (Table  3.1),  as  single  or  in 
combination,  cells  then  were  detached  and  plated  on  Transwell  membranes  sub­
coated with  lOpg/ml  of fibronectin and allowed to migrate  for 4  h.  Cells that had 
migrated and bound to the under-surface of the filter were stained and counted using 
light microscopy at X40.  The number of migrating cells is given in Figure 5.10A. 
The percent of migrating cells per high power field in each membrane compared to 
untreated  control  (=  100)  is  given  in  Figure  5.1 IB.  Error  bar  represent  standard 
deviation of triplicate membranes.  The  experiment was repeated once with similar 
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Figure 5.11  Effect of PDT and CDDP on the migration of UP, VB6 and H376 
cells  towards  collagen  type-I. After treatment with  small dose of CDDP  (4pg/ml 
for UP and VB6 cells, and 2pg/ml for H376 cells) and PDT (Table 3.1), as single or 
in combination, cells then were detached and plated on Transwell membranes sub­
coated with  10  pg/ml of collagen type-I and allowed to migrate for 4 h.  Cells that 
had migrated and bound to the under-surface of the filters were stained and counted 
using  light microscopy  at X40.  The  number  of migrating  cells  is  given  in Figure 
5.11 A.  The  percent  of migrating  cells  in  each  membrane  compared to  untreated 
control  (=  100) is given in Figure  5.1 IB.  Error bar represent standard deviation of 
three assays. The experiment was repeated once with similar results.
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5.8  CDDP augments PDT invasion inhibition
Invasion  is  one  of  main  pathophysiological  characteristics  of  head  and  neck 
squamous  cell  carcinoma cells.  To  evaluate the  effect of PDT with CDDP  on the 
invasive potential of malignancy in normal and malignant head and neck cell lines, 
invasion  assays  were  performed  using  Matrigel  coated  Transwell  inserts.  The 
number of cells that invaded the lower chamber, including those bound to the under­
surface of the  filter,  was varied.  Figure  5.12A-B  shows that the treatment of cells 
with  CDDP  significantly reduced the  invasion of the UP  and VB6  cells  28%  and 
31% respectively (p<  0.05 for both) and enhanced the invasion of H376 cells 9%, 
compared to the untreated controls.
Combined treatment with both  CDDP  and PDT caused further invasion inhibition 
effects  on  UP  and  VB6.  Invasion  of UP,  VB6  and  H376  cells  was  significantly 
reduced  further by approximately 39%, 40% and 90% respectively, compared to the 
CDDP treated cells. An insignificant antagonist effect was also observed in VB6 and 
H376 cells of approximately 9% and 2% respectively, compared to the PDT treated 
cells.
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Figure  5.12  Effect  of PDT  and  CDDP  chemotherapy  on  the  invasion  of UP, 
VB6 and H376 cells. After treatment with small dose of CDDP (4pg/ml for UP and 
VB6  cells,  and  2pg/ml  for  H376  cells)  and  PDT  (Table  3.1),  each  alone  or  in 
combination,  cells then were  detached and plated on Transwell membranes coated 
with 40pg/cm2 of Matrigel diluted in PBS for 72 h. Following incubation, cells that 
had invaded the lower chamber plus those bound to the under-surface of the filters 
were  trypsinized  and  counted.  The  number  of invading  cells  is  given  in  Figure 
5.12A.  The percent of invading cells compared to untreated control (= 100) is given 
in  Figure  5.12B.  Error  bar  represent  standard  deviation  of  three  assays.  The 
experiment was repeated once with similar results.
152Chapter 5: Results III
5.9  Iressa  and  PD153035  augment  PDT  migration  down- 
regulation
To  determine  whether  Iressa  can  modulate  the  impact  of  PDT  on  normal  and 
malignant head and neck cell migration, the UP, VB6 and H376 cells were treated 
with Iressa and PDT. The results show that, in comparison to the untreated controls, 
the migration toward fibronectin following exposure to Iressa alone (Figure 5.13A- 
B) was significantly only reduced by the H376 cells (p< 0.001).
Compared  to  PDT  treated  cells,  Iressa with  PDT  reduced migration  significantly 
only  by  VB6  (p<  0.001),  whereas  UP  and  H376  cells  showed  an  insignificant 
migration,  whereas  comparison  to  Iressa treated  cells,  treatment  of UP,  VB6  and 
H376  cells  with combined  doses  of PDT and Iressa further reduced the migration 
approximately 62%, 66% and 36% respectively (p< 0.001 for all).
Like  Iressa,  treatment  of  H376  cells  with  PD153035  significantly  reduced  the 
migration potential (p<  0.01) and no action on the other cell lines was observed, in 
comparison to the untreated control (Figure 5.14A-B).  Also, exposure to both PDT 
and  PD153035  caused  further  inhibition  in  VB6  and  H376  cell  migration  and 
reduced  their  migration  further  by  approximately  15%  {p<  0.05)  and  10% 
respectively, compared to PDT treatment alone (78% and 87% respectively).
Compared to treatment with PD 153035 alone, an extreme inhibition was observed in 
all the three lines tested (p< 0.001 for all).
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Figure 5.13  Effect of PDT  and Iressa on the migration  of UP, VB6 and H376 
cells towards fibronectin. After treatment with Iressa (0.5pM for UP and 0.05pM 
for VB6 and H376 cells) and PDT (Table 3.1), each alone or in combination, cells 
then were detached and plated on Transwell membranes sub-coated with 10fig/ml of 
fibronectin and allowed to migrate for 4 h. Cells that had migrated and bound to the 
under-surface of the filter were stained and counted using light microscopy at X40. 
The number of migrating cells is given in Figure 5.13A.  The percent of migrating 
cells per high power field in each membrane compared to untreated control (=100) is 
given in Figure  5.13B.  Error bar represent standard deviation of three  assays.  The 
experiment was repeated twice with similar results.
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Figure  5.14  Effect  of PDT  and  PD153035  on  the  migration  of UP,  VB6  and 
H376 cells towards fibronectin. After treatment with PD  153035 (lpM for UP and 
0.5 pM for VB6 and H376 cells) and PDT (Table 3.1), as single or in combination, 
cells  then  were  detached  and  plated  on  Transwell  membranes  sub-coated  with 
lOpg/ml of fibronectin and allowed to migrate for 4 h. Cells that had migrated and 
bound  to  the  under-surface  of  the  filter  were  stained  and  counted  using  light 
microscopy at X40. The number of migrating cells of control and Iressa treated cells 
is  given  in  Figure  5.14A.  The  percent  of  migrating  cells  in  each  membrane 
compared to untreated control (100%) is given in Figure 5.14B.  Error bar represent 
standard deviation of three assays. The experiment was repeated twice with similar 
results.
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5.10  Iressa augments PDT invasion down-regulation
To  determine  whether  Iressa  TKI  could  modulate  PDT  effects  on  head  and  neck 
cancer invasion, the UP, VB6 and H376 cells were used. It was found that invasion 
following Iressa treatment was significantly reduced, approximately 1.8-fold  and 2- 
fold  by  VB6  and  H376  cells  respectively  (p<  0.01  for  both),  compared  to  the 
untreated controls (Figure 5.15A).
When cells were exposed to combined doses of Iressa and PDT, the percentage of 
UP, VB6 and H376 cells invading the Matrigel was further reduced by  15%,  11% 
and  13% respectively (p<  0.05 for both) compared to treatment with PDT, whereas 
these percentages were 49%, 46% and 44%, in comparison to the invasion inhibition 
percentage caused by Iressa alone (Figure 5.15B).
To support these effects on invasion,  another EGFR-specific inhibitor (PD153035) 
was tested. Like Iressa, here the invasion potential of VB6 and H376 cells were also 
significantly  reduced  1.6-fold  (p<  0.05)  and  1.8-fold  (p<  0.01)  respectively, 
compared to the untreated controls (Figure 5.16A).
When  UP,  VB6  and  H376  cells  were  treated  with  combined  doses  of PDT  and 
PD153035,  further  invasion  inhibition  was  observed,  50%,  56%  and  46% 
respectively,  in  comparison  to  PD 153035  alone.  In  comparison  to  PDT,  UP  and 
H376  cells  showed  significant  reduction  (p<  0.05  and p<  0.01%  respectively, 
(Figure 5.16B).
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Figure  5.15  Effect  of PDT  and  Iressa  on  the  invasion  of UP, VB6  and  H376 
cells.  After treatment with  Iressa  (0.5 pM  for UP  and  0.05 pM  for VB6  and H376 
cells) and PDT (Table 3.1), each alone or in combination, cells then were detached 
and  plated  on  Transwell  membranes  coated  with  40pg/cm2  of Matrigel  diluted  in 
PBS for 72 h.  Following incubation, cells that had invaded the lower chamber plus 
those  bound to  the  under-surface  of the  filters  were  trypsinized and  counted.  The 
number of invading  cells  is given in Figure  5.15A.  The percent of invading cells 
compared to untreated control (= 100) is given in Figure 5.15B. Error bar represent 
standard deviation of three assays. The experiment was repeated twice with similar 
results.
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Figure 5.16  Effect of PDT and PD 153035 on the invasion of UP, VB6 and H376 
cells. After treatment with PD  153035 (lpM for UP and 0.5pM for VB6 and H376 
cells) and PDT (Table 3.1), each alone or in combination, cells then were detached 
and  plated  on  Transwell  membranes  coated with  40|ig/cm2 of Matrigel  diluted  in 
PBS for 72 h.  Following incubation, cells that had invaded the lower chamber plus 
those  bound  to  the  under-surface  of the  filters  were trypsinized  and counted.  The 
number of invading cells  is given in Figure  5.16A.  The percent of invading cells 
compared to untreated control (=  100) is given in Figure 5.16B. Error bar represent 
standard deviation of three assays.  The experiment was repeated twice with similar 
results.
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5.11  Discussion
Drug combination strategies have been applied clinically with a promising outcome. 
Small  molecules  are  currently  used  in  clinical  trial  stage  III  for  the  treatment  of 
human cancer and are considered safe for long-term oral treatment exhibiting mild 
toxicity without affecting chemotherapy efficiency (Baselga et al., 2005; Veronese et 
al., 2005;  Giaccone et al., 2004).  Cisplatin, a common platin analogue, is the most 
widely used cytotoxic  agent for the treatment of head and neck cancers  (Kim and 
Glisson,  2003).  The  combination  of  PDT  plus  receptor  target  molecules  and 
chemotherapy  seems  beneficial,  since  each  has  a  relatively  different  target  and 
mechanism  of action,  thus  reducing  the  potential  for  cross  resistance.  Moreover, 
tumour  treatment  can  involve  PDT  alone,  but  this  can  be  at  the  expense  of 
undesirable  local  or systemic phototoxicity.  Also  PDT is a local treatment and,  in 
order to control any unseen metastases, a systemic treatment is needed.
In the present study, the effects of the combination of two small molecule tyrosine 
kinase inhibitors,  Iressa and PD153035,  and cisplatin chemotherapeutic agent with 
PDT,  on the toxicity and metastatic potential of human squamous cell carcinomas 
were evaluated. This was examined after the exposure of cells to a sub-lethal dose of 
the drugs tested, since the sub-toxic reactions to the sub-lethal treatment using the in 
vitro  model  are  considered to  mirror the  reactions that occur in  surviving tumour 
cells and their surrounding normal tissues at tumour sites in patients.
The results of this study using head and neck squamous cell carcinomas and normal 
transformed keratinocytes demonstrated that selective tyrosine kinase inhibitors, as a 
single treatment, reduced cellular viability, and that their combined application with 
PDT induced a cytotoxic effect.  It is difficult to propose a satisfactory explanation 
for this enhancement, but it may be explained, in part, by an earlier finding of this 
thesis (reported in Chapter 4), that EGFR expression was reduced following PDT in
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the  H376  cell  line.  This  is  in  agreement with EGFR  stimulation being  lost when 
human  squamous  carcinoma  cells  were  treated  with  PDT  (Ahmad  et  al.,  2001). 
Another possible explanation could be the effect of apoptosis, as reported on several 
tumours including squamous cell carcinoma cell lines exposed to CDDP (Kuwahara 
et al., 2000), PD153035 (Faust et al.,  1999; Modjtahedi et al.,  1998; Mimeault et al., 
2003), PDT (Chiu and Oleinick, 2001; Plaetzer et al., 2005) and  Iressa (Shintani et 
al., 2004).
Nonaka et al. demonstrated an additional effect of PDT and CDDP on the survival of 
lymphoma cells in vitro using Photofrin as a photosensitiser (Nonaka et al., 2002). A 
significant  elevation  of apoptotic  cell  numbers  compared to  CDDP  or PDT  alone 
was found, and two apoptotic signal pathways, one for PDT and the other for CDDP, 
were  suggested.  Similarly,  Canti  et  al.  reported  a  significantly  positive  result  on 
combinations of PDT and CDDP  in mice bearing tumours (Canti et al.,  1998) i.e. 
enhanced toxicity was evident in combination treatment. Recent data by Crescenzi et 
al., using breast cancer cells as “targets”, demonstrated that the enhanced cell-killing 
produced by PDT and CDDP was due to apoptotic effects (Crescenzi et al., 2004). 
Moreover,  this  latter  group  found  that  PDT  mainly  killed  cells  in  the  G1  phase, 
whereas CDDP mostly kills in the S-phase of the cell cycle
Several  studies  on  the  combination  of  Iressa  with  ionizing  radiation  and 
chemotherapy have suggested an enhanced cytotoxic effect on tumour cells (Zhu et 
al.,  2005;  Raben  et  al.,  2005).  The  preliminary  clinical  data  suggests  that  the 
combination of radiation and PDT is feasible and encourages anti-tumour activity. A 
pilot study evaluating radiation with PDT has shown that 13 out of 15 patients with 
locally  advanced  head  and  neck  cancer  experienced  a  long-lasting  and  complete 
response  following combined treatment(Suhr et al.,  2001).  In addition, the authors 
noted that the anti-tumour effect was dependent on the sequence of treatment.
Another  important  step  during  cancer  metastasis  was  investigated  in  the  present 
Chapter.  It is well  demonstrated that tumour invasion requires interaction between
160Chapter 5: Results III
invading tumour cells and the ECM, as well as the surrounding microenvironment 
(Bogenrieder and Herlyn,  2003).  Following treatment with CDDP  alone, a marked 
reduction  of adhesion  and  migration  of tumour  cells  was  observed.  This  can  be 
explained as  changes  in cell morphology and membrane  conformation which may 
have affected the cell attachment, and suggested that further specific studies would 
be needed to  elucidate this.  Both small molecules and chemotherapy were able to 
reduce migration and invasion and their combined application with PDT induced a 
more inhibitory effect of cell  invasion.  This inhibition of invasion is in agreement 
with a previous report on ovarian adenocarcinoma cells, treated with small molecule 
(ZD 1839), where both growth and invasion of cells were inhibited (Fujimura et al.,
2002). It is difficult to explain why, but it may be attributed to the observation that 
stimulation of c-Src tyrosine kinase pathways is the major signal transduction factor 
involved  in  growth  receptor  signals  for  proliferation  and  differentiation,  and 
reorganization  of  the  cytoskeleton,  which  allows  increased  tumour  invasiveness 
(Irby and Yeatman, 2000). Yang et al. demonstrated that EGFR mediated signalling 
pathway was a potent inducer of c-Src and Pakl  pathways, and the Iressa drug was 
able to suppress c-Src, which in turn reduced cancer cell invasion in head and neck 
cancer cells (Yang et al., 2004).  Also they found that the invasion reduction effect 
was not dependent on EGFR expression and.  Invading cells must pass through an 
extracellular matrix,  a process that involves attachment/detachment and enzymatic 
degradation  of the  components  of the  ECM.  According  to  findings  of this  thesis 
(demonstrated  earlier,  in  Chapter  4),  that  avp6  integrin  expression  was  reduced 
significantly by the VB6 cell line following PDT which may explain the invasion of 
VB6 cells following treatment with combined treatment of PDT and TKIs.
The enhanced effect of Iressa on PDT inhibitory effect on the metastatic potential of 
squamous cell carcinoma cells was accompanied by a reduction in tumour induced 
angiogenesis,  as  assessed  indirectly by measuring  the  secreted  VEGF.  This  result 
indicated  that  Iressa  or  PDT,  as  a  single  treatment,  has  reduced  the  secretion  of 
VEGF, and that combined treatment induced a further reduction of VEGF activity in 
human  head  and  neck  cancers.  This  result  was  in  agreement  with  previous  work
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(Perrotte  et  al.,  1999),  which  showed  that  after  48  h  of continuous  exposure  of 
transitional  carcinoma  cells  to  monoclonal  antibody  C225  (EGFR  Ab),  VEGF 
secretion was reduced.
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Chapter 6
Results IV
Photodynamic Diagnosis of Oral Tumours
6.1  Introduction
Clinical  differentiation  of lesions  is  usually  based  on  morphological  changes  in 
tissue.  However,  this  technique  is  quite  difficult  to  implement  and  experience  is 
usually considered to be a major factor in its success. However it can be found to be 
less  sensitive  in  differentiating  between  lesions  with  similar  clinical  and 
morphological characteristics,  e.g.  dysplasia and carcinoma in situ.  Several groups 
have  investigated  the  use  of native  tissue  fluorescence  in  the  early  detection  of 
malignant tissues (de et al., 2005; de et al., 2003; Betz et al.,  1999). The results are 
encouraging,  but  vary  greatly  between  patients  and  appear  insufficient  for  others 
(Betz et al., 1999).
ALA is a precursor of the highly photosensitive  PpIX, which can be administered 
systemically or applied topically to the oral mucosa and facial skin. The principle of 
ALA induced PpIX is that, in excess, it results in the accumulation of intracellular 
porphyrins, especially of PpIX, which increase tissue fluorescence (Onizawa et al.,
2003).  Subsequent  irradiation  of the  lesion  with  visible  light  matching  the  main 
absorption peak  of PpIX,  405  nm,  leads to  its transfer into  an electrically  excited 
molecular state, which rapidly returns to a more stable and less energetic state after 
the emission of red fluorescent light at around 635 nm.
The difference in fluorescence intensity between normal and premalignant/malignant 
tissue makes detection and analysis by fluorescent light more applicable (Zheng et 
al.,  2002b).  This  intensity  is  governed  by  many  conditions,  however,  such  as
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variations  in  sensitiser  rinsing  procedure,  tumour  site  and  type  in  each  patient 
undergoing light interrogation (Betz et al., 2002b; Kennedy et al., 1996).
The aim of this clinical study was twofold: to clinically investigate the ability of 5- 
ALA  induced  PpIX  fluorescence  to  distinguish  between  benign  and  potentially 
malignant  tissues  and  to  develop  an  applicable  algorithm  that  can  be  used  as  a 
standard for the subsequent analysis of “unknown” lesions.
6.2  Patients
Seventy-one  patients  (mean  age  59  years,  range  37-81  years)  with  clinically 
suspicious  oral  lesions  took  part  in  this  study  in  the  Maxillofacial  unit,  UCH, 
London. The 71  biopsies were obtained from various oral sites. The majority came 
from the tongue, buccal mucosa and floor of the mouth (Table 6.1). These biopsies 
were examined histopathologically and were found to be either benign or potentially 
malignant (Table 6.2).
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Table 6.1  Number and percentage of surgical biopsies from different 
anatomical sites
Site of biopsy Number of lesions Percentage
Tongue 18 25.4%
Buccal mucosa 25 35.2%
Floor of mouth 14 19.7%
Alveolus 9 12.7%
Hard palate 5 7.0%
Table 6.2  Type and percentage of surgical biopsies with different 
histology
Histology Number of biopsies Percentage
Lichen planus 7 9.9%
Inflammation 9 12.7%
Hyperkeratosis 22 31.0%
Mild dysplasia 14 19.7%
Moderate dysplasia 9 12.7%
Severe dysplasia 8 11.3%
Carcinoma in situ 2 2.8%
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6.3  Distance effect on fluorescence ratio
To  exclude  distance  dependence  of the  fluorescence  signals,  a spot within normal 
mucosa was recorded at a different distance and fixed integration time. The data in 
this  experiment  showed that the  intensity of red  (IR)  and green  (IG)  fluorescence 
was directly related to the distance between the endoscope tip and the tissue surface. 
Thus,  by  increasing  the  distance,  the  intensity  declined,  whereas  the  red-to-green 
fluorescence ratio remained constant (Figure 6.1).
Distance (cm) from the lesion
Figure 6.1  The distance dependence of the red-to-green ratio signals evaluated 
at various observation distances. Error bars represent the standard deviation of 
three readings.
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6.4  Red fluorescence of dysplastic tissue
All of the images were displayed on the system monitor in black and white, and the 
degree of severity of the lesions was proportional to the brightness of the colour. For 
example, an increase in brightness suggested the presence of dysplastic lesion (see 
Figure 2.5). By using the computer programme, a quick analysis of the bright area 
reproduced the intensities of RGB fluorescence for that area (see Figure 2.6).
When  comparing  the  red  PpIX  fluorescence  to  the  green  tissue  fluorescence,  a 
marked increase of the red fluorescence over the green fluorescence in dysplastic 
lesions and carcinoma in situ was found (Figure 6.2).
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Figure 6.2  Fluorescence intensity versus histopathological stages of oral lesions.
Topical  ALA  was  applied  on  mucosa  for  15  min  and  fluorescence  measurements 
were taken after 2 h.  The data represents the % of fluorescence intensity in red and 
green  fluorescence  in  arbitrary  units  (a.u).  The  error  bar  represents  the  standard 
deviation of the  same  diagnostic  group.  INF  =  inflammatory;  HK=hyperkeratosis; 
MI-DYS=mild  dysplasia;  MO-DYS=moderate  dysplasia;  S-DYS=severe  dysplasia; 
CIS=carcinoma in situ.
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6.5  Significant red-to-green ratio
The  red-to-green  ratio  was  found  to  increase  when  the  lesions  were  identified  as 
dysplastic or carcinoma in situ (Figure 6.3).
The red-to-green ratio of normal and pathological tissues has been compared (Table 
6.3); p-values have been found to be highly significant when comparing the ratio of 
normal  tissue  to  that  of mild  dysplasia  (p=0.002),  moderate  dysplasia  (p=0.039\ 
severe dysplasia (p=0.018) and carcinoma in situ (p=0.027).
A threshold line was set at red-to-green ratio of 1.2 in order to discriminate between 
normal  and  dysplastic  lesions.  A  sensitivity  of 90%  and  specificity  of 79%  were 
obtained. A higher specificity value (89%) was obtained when the threshold line was 
shifted to 1.3; but this reduced the sensitivity of the results by 7% (Table 6.3).
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Figure  6.3  Red  to  green  ratio  versus  histopathological  stages  of oral  lesions.
LP=lichen  planus;  INF=inflammation;  HK=hyperkeratosis;  MI-DYS=mild 
dysplasia;  MO-DYS=moderate  dysplasia;  S-DYS=sever  dysplasia;  CIS=carcinoma 
in situ. The error bar represents the standard deviation of the same diagnostic group.
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Table  6.3  Significance  of  correlation  of  red-to-green  ratio  with 
histopathology of oral lesions.  Figures  represent p values  as  calculated by 
student /-test
LP INF HK MI-DYS MO- DYS S-DYS
LP
_ _ _ _ _ _
INF
0.0207 - - _ _ _
HK NS NS - - -
MI-DYS 0.002 0.020 0.041 - - -
MO- DYS 0.039 NS 0.004 NS - -
S-DYS 0.018 0.051 0.000 0.053 NS -
CIS 0.027 0.074 0.001 0.073 NS NS
NS = non significant; LP=lichen planus;  INF=inflanimation; HK=hyperkeratosis; 
MI-DYS=mild dysplasia; MO-DYS=moderate dysplasia; S-DYS=sever dysplasia; 
CIS=carcinoma in  situ .
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Table 6.4  Classification of oral tissue red-to-green fluorescence ratios
Red-to-green ratio 
1.2  1.3
Number of biopsies showing dysplasia 
(confirmed by histology)
32 32
Number of dysplastic sites diagnosed by optical 
fluorescence ratio as dysplasia (True positive)
29 26
Number of dysplastic sites diagnosed by optical 
fluorescence ratio as normal (False negative)
3 5
Sensitivity (%) = *TP/(TP+FN) 90% 83%
Number of biopsies found to be normal histologically 39 39
Number of normal fluorescence ratios found to be 
normal (True negative)
31 35
Number of normal fluorescence ratios found to be 
dysplastic (False positive)
8 4
Specificity (%) = *TN/(TN+FP) 79% 89%
*  Where TP, TN, FP, FN represent true positives, true negatives, false positives and 
false negatives respectively
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6.5  Discussion
Optical diagnostics have proved to be a reliable source that can be used to give an 
instant diagnosis of soft and, more interestingly, hard tissues. In the field of head and 
neck malignancy, most of the experimental  spectroscopy work has been performed 
using  fluorescence,  Raman,  ESS  and  tri-modal  techniques,  which  involve  the 
combination of these  techniques that  showed a marked increase  in  sensitivity and 
specificity.  Currently,  there  is  continued  development  not  only  in  spectroscopy 
technology  and  data  acquisition  but  also  in  the  data  analysis  methods  used.  The 
ultimate aim of all this development is to be able to provide diagnostic algorithms 
that may be used instantaneously in the clinical setting.
Alfano et al.  [1984]  first described the use of autofluorescence spectroscopy in vivo 
to  differentiate between normal  and malignant tissues  (Alfano  et al.,  1984).  Since 
then, several authors have registered their findings with this technique (Gillenwater 
et al.,  1998; Heintzelman et al., 2000; Badizadegan et al., 2004). The technique has 
also  recently  been  used  to  map  out  the  individual  characteristics  of healthy  oral 
mucosa at  several  anatomical  sites within the  oral  cavity,  which can be used as  a 
baseline  for  further  studies  (de  et  al.,  2003).  Onizawa et  al.  [1999]  examined the 
usefulness  of fluorescence  spectroscopy  for  oral  cancer  diagnosis.  One  hundred- 
thirty oral  lesions  from  130  patients  were  subjected to  fluorescence  spectroscopy; 
72/79 (91.1%) and 6/7 (85.7%) of carcinoma and epithelial dysplasia were identified 
respectively. This suggested that fluorescence spectroscopy was a potentially useful 
tool in oral tissue pathology diagnosis (Onizawa et al., 1999).
Current routine methods  applied for the detection of oral neoplasms are limited to 
the  appearance  of  the  suspected  tumour  area  and  it  appears  difficult  for  even 
experienced  clinicians  to  differentiate  between  different  disease  stages.  Therefore, 
the  development  of  an  enhanced  fluorescence  imaging  system  for  non-invasive 
demarcation  between  normal  and  altered  tissues  may  revolutionize  early  clinical
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diagnosis. The imaging technique applied in this study was initially developed at the 
National Laser Centre and a few preliminary tests performed on very few patients.
In the present study, more detailed clinical  digital  fluorescence images were used, 
with  a  correlation  to  the  conventional  histological  results  for  different  oral 
anatomical sites following the topical application of an ALA solution. Two channels, 
red  and  green,  and  their  ratio  diagnostic  algorithm  were  used  to  quantify  the 
fluorescence intensities.
The clinical data obtained demonstrated that dysplastic positive fluorescence lesions 
have  significantly  higher  red  fluorescence  than  fluorescence  positive  benign  oral 
lesions  without  changes  in  green  autofluorescence.  This  is  in  agreement  with 
previous reported studies (Leunig et al., 2000; Zheng et al., 2002b). In clinical trials, 
a combination of autofluorescence and ALA-induced PpIX fluorescence caused an 
enhanced demarcation between malignant and healthy tissues  (Betz  et al., 2002a). 
Many  physiological  mechanisms  have  been  proposed  in  order  to  explain  the 
enhanced  intensity  of PpIX  in the  abnormal  tissues,  such as  deficiency in iron or 
ferrochelatasse  (the  enzyme  required  for conversion of PpEX to heme)  in tumours 
results  in  accumulation  of PpIX  relative  to  benign  host  tissue  and  the  increased 
percentage of tumour vasculature (Reinhold and Endrich, 1986; Reddi, 1997; Pottier, 
1990).
The  application of a red-to-green ratio  algorithm  set to  1.2  cut threshold between 
normal  and  abnormal  tissues  results  to  90%  sensitivity  and  79%  specificity,  in 
discriminating between malignant dysplastic lesions and benign lesions. A possible 
explanation for a slightly low specificity is the number of false positives, probably 
due to superficial necrotic tissues and porphyrin synthesised by oral microrganisms 
present in the plaque (Betz et al., 2002a; Leunig et al., 2000). The  10% reduction in 
sensitivity (90%) could be related to the limited (< 1mm) penetration depth (Leunig 
et  al.,  2001),  which  may  have  led  to  poor  registration  of  all  cytological  and 
biochemical changes occurring in dysplastic tissues.
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The  present  study  supports  the  data  from  previous  studies.  Thus,  Zheng  et  al. 
investigated  ALA  induced  PpIX  fluorescence  on  28  patients  with  suspicious 
malignant  oral  lesions,  combining  both  red  to  green  and  red  to  blue  ratios,  and 
reported a high sensitivity and specificity of 95% and 97%, respectively (Zheng et 
al., 2002b). Similarly, others found high specificity by applying a red to blue ratio to 
discriminate between malignant and pre-malignant bladder lesions, although the red 
to green ratio was less applicable (Zaak et al., 2001).
In order to  enhance  specificity,  a  1.3  cut threshold between malignant and benign 
tissues  was  applied.  Nevertheless,  there remains the  possibility of false negatives, 
such as insufficient tissue fluorescence due to the improper application of ALA. It is 
difficult to  compare quantitatively the ratio  imaging with the other systems due to 
the inter-system variation in many factors, such as spectral width, background noise 
and  sensitivity.  Although  the  results  suggest,  that  the  criteria put  forward  for  the 
diagnostic  purposes  described  in  this  chapter,  indicate  a  promising  method  of 
distinguishing/clarifying tumour grades.
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Chapter 7
Results V
The  Scattering  Properties  of Potentially  Malignant 
Oral Lesions
7.1 Introduction
ESS  has  been  shown  to  be  sensitive  to  nucleus  size,  chromatin  content  and 
nuclear/cytoplasmic  ratio,  which are  all  criteria that the  histopathologist  looks  for 
when establishing malignancy within a tissue (Mourant et al.,  1998; Perelman et al., 
1997; Wallace et al., 2000; Mourant et al., 2000; Drezek et al., 2003; Mourant et al., 
2000).  ESS  has,  in  a  number  of studies,  been  combined  with  extracted  intrinsic 
fluorescence  and  diffused  reflectance  forming  a  “tri-modal  spectroscopy”  device, 
which has been shown to have a higher sensitivity and specificity when examining 
premalignant and malignant lesions (Badizadegan et al., 2004). Therefore, the aim of 
this  clinical  trial  was  to  evaluate  the  ability  of the  ESS  system  to  discriminate 
potentially malignant lesions from normal oral tissues and to develop an algorithm 
for the precise analysis of retrieved tissue signals.
7.2 Patients
Twenty-five patients (17 male and 8  female), mean age  52 years, age range 41-67 
years, with clinically suspicious oral leukoplakia took part in this study. Twenty five 
biopsies  were  taken  from  various  oral  sites  (Table  1),  and  examined 
histopathologically (Table 2). All types of dysplasia were classified as “malignant”,
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whereas all other reports (normal, inflammation and hyperkeratosis) were considered 
“non-malignant” or “benign” changes.
Table 7.1  The number of biopsies from each region of oral tissue
Site in oral cavity No. of biopsies
Buccal Mucosa 9
Floor of Mouth 3
Sublingual 2
Tongue 11
Total  25
Table 7.2  The number of histological grades in the dataset
Histology
Number of 
occurrence
Normal 4
Hyper Keratosis 10
Mild Dysplasia 6
Moderate Dysplasia 3
Severe Dysplasia 1
Carcinoma in Situ 1
Total 25
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7.3  Elastic spectroscopy detects oral premalignancy
In this study, the aim was to determine the ability of an ESS system to discriminate 
between benign and dysplastic oral lesions, with the development of the subsequent 
analysis methods.  Results of this  study represent the first assessment of the use of 
ESS  for  oral  tissues  classification.  A total  of 75  spectra  (3  for  each  lesion)  were 
taken.  The  mean  spectra  of dysplastic  and  normal  sites  are  shown  in  Figure  7.1. 
Moreover, the standard deviations of the spectra were large and tended to overlap, 
although differences in the shape of the mean scattered spectra were apparent.  The 
application  of the  ROC  Curve  (Receiver-Operator  Curves)  in  Figure  7.2  suggests 
that  the  trade-off  between  optimal  sensitivity  and  specificity  is  0.73  and  0.75, 
respectively.  Table 3  shows the true positive, true negative, false positive and false 
negative  values  of tissue  spectra.  A  sensitivity  of 73%  and  specificity  of 75% to 
discriminate between normal and dysplastic lesions were obtained.
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Figure 7.1  A representative ESS spectra plot of the mean dysplastic and benign 
spectra (solid lines), with one standard deviation plotted either side of the mean 
(dashed lines).
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Figure  7.2  A  ROC  Curve  (Receiver-Operator  Curve)  computed  for 
distinguishing  between  benign  and  dysplastic  oral  lesions  by  the  trade-off 
between  sensitivity  and  specificity.  Optimal  sensitivity  is  (0.727),  optimal 
specificity (0.75).
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Table 7.3  Classification of oral tissue spectra (dysplastic vs. normal)
Number of biopsies showing dysplasia histologically 11
Number of dysplastic sites diagnosed by ESS as 8
dysplasia (true positive)
Number of dysplastic sites diagnosed by ESS as normal 3
(False negative)
Sensitivity (%) = *TP/(TP+FN) 73%
Number of biopsies found histologically to be normal 14
Number of normal ESS spectra found histologically to be 3
normal (true negative)
Number of normal ESS spectra found histologically to be 1
dysplastic (False positive)
Specificity (%) = *TN/(TN+FP) 75%
*  Where TP, TN, FP, FN represent true positives, true negatives, false positives and 
false negatives respectively
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7.4  Discussion
The  development  and  use  of a  new  diagnostic  instrument  for  diagnosis  of oral 
dysplasia is a real challenge, particularly as currently there is no database available. 
The  oral  tissue,  which  includes  keratinized,  non-keratinized,  glandular  and  fatty 
tissue, results in variable signals when measured by ESS. These render the plotting 
and correlation of the obtained data sets more complicated. In this study, ESS spectra 
were combined together, although they originated from geographically and therefore 
histologically different oral sites (floor of mouth, tongue, cheek). However, prior to 
combining spectra, each acquired spectrum from a particular site was compared to a 
spectrum acquired from a histologically-similar normal oral site; the intention here 
was to reduce discrepancies in the readings.
Recently,  there  has  been  increasing  interest  in  the  use  of  optical  spectroscopy 
systems  to  be  able  to  provide  tissue  diagnosis  in real-time,  non-invasively.  These 
systems  rely  on  the  fact  that  the  optical  spectrum  derived  from  any  tissue  will 
contain information about the histological and biochemical make up of that tissue. 
The technique has not only been shown to have a role in the detection of dysplasia 
and malignancy but also in performing guided biopsies, monitoring of haemoglobin 
tissue  perfusion  in  free-flaps  and  therapeutic  drug  levels  during  chemo-  and 
photodynamic  therapy  (Mourant  et  al.,  1999;  Bigio  et  al.,  1999;  Johnson  et  al., 
2004).
Epithelial dysplasia in the gastrointestinal tract, in particular Barrett’s esophagus, is 
an important disease state, which is currently being investigated by ESS (Lovat and 
Bown, 2004). A number of promising clinical studies have shown some unequivocal 
results,  suggesting that this technique  can be used as an adjunct to histopathology 
since  it  is  a  cheap,  simple-to-use  tool  and  can  give  rapid  and  accurate  diagnoses 
(Bohorfoush,  1996; Geboes et al.,  1999; Van Veen et al., 2002; Badizadegan et al., 
2004; Lovat and Bown, 2004; Badizadegan et al., 2004; Lin et al., 2001).
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Georgakoudi and Feld (2004) used tri-modal spectroscopy in patients with Barrett’s 
esophagus and obtained higher sensitivity and specificity when compared with one 
of the  combined  techniques  (Georgakoudi  and  Feld,  2004).  Work  by  Haringsma 
(2002),  on  Barrett's  oesophagus  found  that  ESS  was  superior  to  other  optical 
diagnostics  in terms  of early detection of low-grade dysplasia,  based on structural 
information of the mucosa, in which the size and crowding of nuclei in the epithelial 
layer play a key role (Haringsma, 2002).
The  study  of  malignancy  and  dysplasia  of  the  oral  cavity  using  ESS  is  in 
development.  Ex-vivo  work  by  Jeijes  et  al.  (2004)  used  the  technique  to  study 
formalin-fixed  specimens  of cervical  lymph  nodes  and  bony  margins  taken  from 
patients with oral squamous cell carcinoma. Using linear discriminant analysis, they 
showed  a  sensitivity  and  specificity  of 98%  and  68%  respectively  for  the  lymph 
nodes, and 87% and 80% for the bone margins (Jeijes et al., 2004). Jeijes et al. also 
suggested  that  ESS  had  the  potential  to  perform  a  full  optical  mapping  of the 
suspicious  area,  thus  eliminating the need for  subsequent pathological  verification 
(Jerjes et al., 2005).
Muller et al. used diffuse reflectance spectroscopy to look at normal versus abnormal 
tissue,  and  dysplastic  versus  cancerous  lesions  in  the  oral  cavity.  By  comparing 
spectroscopy to histopathology, the accuracy for normal tissues was 91.6% (22/24), 
compared to 97% (33/34) for abnormal tissues.  These figures fell when examining 
dysplasia, 64.3% (9/14) and carcinoma 50% (5/10). However, when using tri-modal 
(fluorescence, diffuse reflectance and light scattering)  spectroscopy, they showed a 
sensitivity  and  specificity  of  96%  and  96%  respectively,  when  comparing 
cancerous/dysplastic  tissues  from normal tissues,  and  obtained values  of 64%  and 
90% when comparing dysplastic with cancerous tissues, respectively (Muller et al., 
2003).
Compared  with  previous  studies  using  light  to  differentiate  between  normal  and 
benign lesions on other human tissues and despite the small number of cases plus the
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heterogeneity of the  oral tissues,  our results yield a reasonable outcome.  A small 
trial  examining  the  combination  of  diffuse  reflectance  spectroscopy  with 
fluorescence spectroscopy for the detection of cervical pre-cancer suggests that the 
two  techniques  provide  complementaiy  diagnostic  information  (Nordstrom  et  al., 
2001).
Overall, the results of this study support the hypothesis that ESS was able to provide 
accurate oral dysplasia demarcation and can potentially be used as an effective tool 
that may replace  invasive  surgical biopsy.  Although this  early result is promising, 
one  must  consider  when  more  data  is  added  to  the  analyses,  since  in  this  small 
dataset, patient,  site,  and histological grade are  significant variable, and it is likely 
that the high level of discrimination between benign and dysplastic tissues is due to 
the  correlation  between  histological  grade  and,  for  example,  patient  specificity. 
Further work is required in the form of the collection of more data sets, and careful 
analysis  using  multivariate  statistical  techniques  on  all  the  available  spectral 
information, which can potentially improve the accuracy of detection. This requires 
multiple samples within each tissue category and a large number of patients before it 
can be used in routine oral diagnosis. Some of the reduction in the sensitivity (28%) 
and  specificity  (25%)  from  100%  can  be  accounted  for  by  the  possibility  of 
discrepancy occurring from combining spectra from different anatomical sites.
182Chapter 8: Results VI
Chapter 8 
Results VI
Monitoring Photodynamic Therapy by Fluorescence 
and Elastic Scattering Spectroscopy
8.1 Introduction
A  problem  of  continuing  interest  in  the  study  of  PDT  is  the  definition  and 
measurement of photodynamic dose. For efficacy of PDT, optimal protocols in terms 
of sensitiser and light doses have been devised for many tumour types. Nevertheless, 
the actual amount of sensitiser exists in target tissues is largely variable and could 
lead to variation in treatment outcome (Amelink et al., 2005). As a consequence, this 
of course, carries a potentially unfavourable outcome and the patient in some cases 
may  need  to  undergo  further  treatment  or,  excess  damage  may  take  place, 
particularly  to  surrounding  normal  tissues.  It  is  believed  that  the  majority  of 
photosensitisers accomplish their cytotoxic effect through the production of lC > 2 and 
other reactive oxygen species (Dougherty et al.,  1998).  For ALA,  like many other 
sensitisers,  the  same  or  similar mechanism  is  also  responsible  for  its  degradation, 
which is observable as irreversible photobleaching (Wilson et al., 1997). Therefore a 
method  for real-time monitoring  of relevant parameters  other than pre-determined 
sensitiser and light doses would be of great benefit for patients.
It  was  shown  that  sensitiser  photobleaching  process  is  oxygen-dependent  process 
(Ericson et al.,  2003;  Mang  et al.,  1987),  mediated predominantly by  lC > 2 and the 
degradation  of  drug  is  reflected  as  the  bleaching  of  the  loaded  sensitiser 
(Georgakoudi  and  Foster,  1998).  However,  the  monitoring  of  sensitiser 
photobleaching via fluorescence measurement can therefore provide a means of real­
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time  dosimetry.  This  concept  was  introduced  by  Wilson  et  al.,  and  involves 
measuring sensitiser photobleaching rate to determine the  *02 concentration during 
PDT (Wilson et al.,  1997). A number of studies have explored the feasibility of this 
approach.  Robinson  et  al.  demonstrated  that  the  rate  of  PpIX  photobleaching 
increased  with  decreasing  fluence  rate  (Robinson  et  al.,  1998).  Using  m-THPC 
sensitiser, a positive relationship between fluorescence photobleaching and toxicity 
during in vitro PDT was established, and suggested the usefulness of applying this 
concept  as  a  predictor  of  tissue  damage  (Dysart  et  al.,  2005).  However,  if 
photobleaching  is  to  be  used  as  a  surrogate  measure  of damage  (i.e  an  enhanced 
tumour  response  can  be  reflected  by  rapid  bleaching),  which  very  often  can  be 
revealed by fluorescence changes, then by monitoring photobleaching through non- 
invasive recording of the accumulated PpIX in the target tissue before the exposure 
to PDT and evaluating the changes occurring during and after PDT, could result in 
better understanding of the PDT process and increase its effectiveness. The objective 
of this study, therefore was to investigate the feasibility of using fluorescence and 
elastic scattering systems as real-time monitors of PDT in patients with BCC lesions.
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8.2  Patients
Measurements  of PpIX  fluorescence  and  scattering  spectra  were  taken  from  14 
patients  treated  with  ALA-PDT  for  BCC  located on the facial  area,  including the 
scalp. Details of the tumours from these patients are given in Table 8.1.  The mean 
age of the patients was 66 years (range 39-78 years). All of the subjects enrolled in 
this study were 18 years or older, with histologically confirmed BCC. Excluded from 
the study were pregnant or breastfeeding women. All of the patients were treated and 
followed-up  at the  Maxillofacial  Unit,  University  College  London Hospitals,  UK. 
All treatment and measurements were performed under a protocol approved by the 
Ethical Review Board of University College London Hospitals. All patients received 
written and oral information about the study, which included the aim of the trial and 
assurance that the procedure would be non-invasive. A full written informed consent 
was obtained from each patient who entered the trial. Complete response to PDT was 
defined as the disappearance of the disease (i.e. treatment site was macroscopically 
normal with no evidence of tumour). Partial response was defined as a decrease of at 
least 50% in the total tumour size relative to pre-treatment size.
Table 8.1  The number of BCC lesions from each facial region
Site No. of lesions Percentage
Cheek 4 29%
Temple 4 29%
Nose 3 21%
Scalp 3 21%
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8.2  PpIX photobleaching measured by FS
The  fluorescence-emission  signals  of PpIX  from  BCC  lesions  before,  during,  and 
some time (15 min) after light exposure during PDT treatment were measured in the 
red zone after excitation with blue light. Figure 8.1  shows that PpIX photobleaching 
was started immediately after the beginning of exposure to 100 J/cm2 of red light. At 
333  s  (partway  through  treatment)  after  exposure  to  red  light,  PpIX  was 
photobleached in lesions  of cheek, temple,  nose  and  scalp approximately by 35%, 
36%, 22% and 31%, respectively, in comparison to their initial fluorescence values. 
At  666  s  (end  of treatment)  of  exposure,  no  further  PpIX  photobleaching  was 
observed in comparison to fluorescence at 333  s of illumination, whereas at 15 min 
after the end of light exposure, PpIX fluorescence has partially recovered in cheek, 
temple, nose,  and scalp BCC tumours approximately by  12%,  29%,  30% and  8%, 
respectively, in comparison to those values obtained at the end of light illumination. 
This recovery in cheek, temple, nose and scalp represents approximately 28%,  17%, 
1% and 26%, respectively, of PpIX initial intensity measured prior to light exposure.
Collectively, when one considers the readings of all BCC lesions together, Figure 8.2 
showed  that  approximately  31%  of  PpIX  had  bleached  when  tumours  were 
illuminated  for  333  s  (p=  0.0018),  also  and  in  comparison  to  the  end  of light 
exposure (666  s),  approximately 20% (p<  0.05) of fluorescence intensity had been 
restored 15 min after light exposure had ended.
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Figure 8.1  PpIX photobleaching and  reappearance  as  function  of time during 
PDT of SCC tumours located in patient’s cheek, scalp, temple and nose. Values 
were calculated from fluorescence images acquired during PDT (333 s), at the end of 
PDT  (666s)  and  15  min  after the  PDT treatment had  ended.  The  control  readings 
were  obtained  before  light  illumination  (time  zero).  Data  represent  the  mean 
fluorescence  values ±  SD  for each tumour site  at  different time  point during PDT 
treatment.
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Figure 8.2  PpIX  photobleaching and  reappearance  as function  of time during
PDT  of SCC  (n  =14).  Values were  calculated  from  fluorescence  images acquired 
during PDT (333  s), at the end of PDT (666s) and  15 min after the PDT treatment 
had ended. The control readings were obtained before light illumination at time zero. 
Data  represents  the  mean  fluorescence  values ±  SD  at different time point during 
PDT treatment.
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8.3  PpIX photobleaching measured by ESS
To determine whether the ESS could detect differences in absorbance of PpIX over 
time, the relative change in absorbance was determined. The photobleaching of PpIX 
during  PDT  was  monitored  by  recording  the  PpIX  absorbance  within  the  treated 
lesion area. Figure 8.3 shows the acquired spectra for 14 BCC lesions which seem to 
indicate  a  close  resemblance  in  shape,  indicating  that there  is  no  large  difference 
between  initial  absorbance  and bleaching during illumination.  As can be  seen, the 
shape  of the  PpIX  dips  at  wavelength  of 408  nm,  which  represents  the  peak  of 
absorbance for PpIX,  and had decreased slightly during PDT illumination and was 
reflected  by  the  increase  of the  scattering  slope.  After  the  PDT  illumination  is 
removed,  the  PpIX  absorbance  had  slightly  recovered.  When  ESS  spectra  were 
smoothed  and  normalized,  the  photobleaching  parameters  for  all  patients  were 
evaluated and absorbance scattering means were determined for all acquired spectra 
during PDT and compared (Figure  8.4).  Using ANOVA test (Appendix 2),  only a 
marginal significant correlation between PpIX photobleaching at the start and during 
PDT process was found (p= 0.053).
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Figure  8.3  Acquired  spectra  as  function  of time  during  PDT  shown  for SCC 
lesions (n = 14) during PDT. Data shows the absorbance dips and scattering slope 
for  each  time  point  during  PDT  process  over  the  region  of 320-  910  nm.  The 
standard  deviation  for  each  spectrum  was  omitted  for  clarity.  The  spectra  are 
coloured according to when they were taken.  Blue spectrum was taken at time zero 
(before the PDT treatment); pink spectrum at 333  s (during PDT); yellow spectrum 
at 666  s  (the  end  of PDT treatment)  and  green  spectrum at  15  min after the PDT 
treatment had ended. Arrow indicates PpIX peak absorbance.
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during
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Figure 8.4  Box-plot analysis  of results  of the fitted  spectra  as function  of time 
during  PDT  for  SCC  lesions  shown  in  Figure  8.3.  All  spectra  underwent 
smoothing (each intensity point was replaced by the average of the 20 neighbouring 
points.  Each  smoothed  spectrum  was  then  standardized  by  subtracting  the  mean 
intensity of the spectrum from each data point. Each point was then divided by the 
standard deviation of the smoothed spectrum; this gave spectra a mean intensity of 
zero and standard deviation equal to one. The spectra were compared over the region 
of 408  nm  which  represents  the  peak  absorbance  of PpIX).  Data are  presented  as 
mean values of PpIX absorbance expressed as relative values to normalized pre-PDT 
treatment at 408 nm ± SD (error bars), 25th and 75th quartiles, and circles denoting 
the  outliers/anomalies  data.  During  =  at  333  s  during  PDT;  end  =  end  of light 
exposure  (666  s);  later  =  15  min  after  PDT  had  ended  (i.e  15  min  after red  light 
turned off).
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8.4  ALA-PDT
The clinical outcome of ALA-PDT in  14 patients with BCC at the follow-up visit 
(6 months) was varied from ‘no response’ to ‘complete ablation’ of the lesion (Table 
8.2).  This was unexpected because each patient with BCC lesion was treated using 
the same treatment parameters. The data obtained showed that cosmetic results were 
achieved  in  all  patients.  The  number of patients  with  complete  remission was  11 
(78.6%), partial remission in 2 patients (14.3%) and no response in one case (7.1%), 
as represented by a nasal BCC case. A positive correlation between photobleaching 
and the response of BCC lesions to PDT treatment was seen (Table 8.2 and Figure 
8.1).
Table 8.2 BCC responses to ALA-PDT
Site CR* (/i) PR*  (n) NR* (n) % of CR
Cheek 4 - - 100%
Nose 1 1 1 33%
Temple 3 1 - 75%
Scalp 3 - - 100%
*  Where CR, PR, NR, represent complete response, partial response and no response, 
respectively.
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8.6  Discussion
PDT is an important treatment method for skin lesions such as superficial BCC and 
AK.  Monitoring the  relevant parameters,  such as  sensitiser photobleaching rate or 
decay time, to determine the concentration of l0 2 formed during PDT and comparing 
them to the treatment response. An optimal and reproducible treatment outcome then 
may be achieved. It has previously been shown that PpIX fluorescence spectroscopy 
is  a useful  tool  for  monitoring  PDT  dose  and  determining the  lesion response to 
therapy (Rhodes et al., 1997).
A study by Ericson et al. included 37 patients undergoing PDT for AK of the head, 
neck and upper chest and aimed to investigate the impact of fluence rate and spectral 
range on primary treatment outcome and bleaching rate when ALA was used as a 
photosensitiser. They concluded that both photobleaching rate and primary treatment 
outcome were dependent on fluence rate.  They also suggested that low fluence rate 
appeared preferable when performing PDT on AK using non-coherent light sources 
(Ericson et al., 2004).
Amelink  et  al.  (2005)  correlated  changes  in  the  local  tissue  optical  properties 
(absorption  and  scattering  coefficients)  during  ALA-PDT  and  changes  in  PpIX 
fluorescence by using superficial reflectance spectroscopy, which employed a single 
fibre for the delivery and collection of white light to and from the tissue (Amelink et 
al., 2005). The spectra acquired were modulated with blood saturation, relative blood 
volume  fraction,  scattering  intensity and wavelength dependence  of the  scattering. 
Except for blood volume, the study showed a marked correlation between the other 
parameters  and  photobleaching  of PpIX.  This  suggests  that  these  parameters  can 
predict PDT-response.
In the present study, the red PpIX fluorescence signals were detected after the topical 
application of PDT.  These  signals were lost over time during PDT, which may be 
due to the fact that most PpIX was photobleached.  After a cumulative time of 333 s 
with fixed fluence of 100 J/cm2 and fluence rate of 150mW/cm2, no significant additional
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photobleaching was recorded.  This may indicate that current PDT time was excessive, 
since slow bleaching may result in higher oxygen levels in tissues during treatment, which 
in turn results in a better treatment response. Numerous studies have demonstrated that 
the  amount  of PpIX  synthesised  after  ALA  administration  is  proportional  to  its 
emitted fluorescence, as a prediction of PDT success (Jeffes et al., 1997; Mang et al., 
1987;  Spikes,  1992;  Calin  et  al.,  2004).  Another  study  by  Fijan  et  al  found  no 
significant correlation between fluorescence intensity and response to PDT (Fijan et 
al.,  1995). This is perhaps not surprising as no two studies using PDT are currently 
comparable with respect to patient selection, drug/light doses, equipments etc.
Since PpIX is manufactured by tumour cells and surroundings normal tissue cells, 
ALA cream was applied to the target area with extended margins that were partially 
shielded during PDT. This may explain the post-PDT re-fluorescence. In the present 
study,  a  difference  between  the  PpIX  fluorescence  at  the  beginning  of PDT  and 
response  to  PDT  was  found.  However,  the  amount  of PpIX  photobleaching  was 
observed in tumours that showed complete response rate; less bleaching was seen in 
tumours  that  showed  no  response.  Several  studies  have  shown  a positive  relation 
between  both  PDT-induced  damage  and  PpIX  photobleaching  rate  and  the 
concentration  of sensitiser  and  oxygen  availability  during  exposure  to  PDT  light 
(Georgakoudi  and  Foster,  1998;  Georgakoudi  and  Foster,  1998;  Langmack et  al., 
2001).
ESS  was  applied to  clinically presented lesions  in order to discover whether there 
was a significant  difference  in the  absorbance  of the  active  form of ALA (PpIX), 
which has a relatively sharp absorbance peak at 408 nm (Georgakoudi and Foster, 
1998; DaCosta et al., 2003). This latter study did not have spectra taken prior to the 
drug being administered,  so the degree of intensity in this region in the absence of 
PpIX  could  not  be  reconstructed.  What  could  be  examined,  however,  were  the 
changes  in  absorbance  over  time  as  the  treatment  progressed.  If photobleaching 
occurred, then it might be expected that there may have been more absorbance at the 
start of the treatment and less absorbance at the end. The outcome was approaching 
significance,  which  could  be  due  to  the  small  cohort  of patients  and  different
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measurement sites and different lesion types, thus, future studies should consider the 
control of these variables.
The PDT response was achieved in most tumours, since the same dose of PDT was 
applied with the same fluence and fluence rate. This agrees with a previous clinical 
study (Svanberg et  al.,  1994).  The  small percentage with no response,  or a partial 
response, could be due to the limited depth of ALA penetration and the nature of the 
tumours. A similar finding was reported in relation to oesophagus tumours (Boere et 
al., 2003), and the incorporation of iron chelator to enhance the production of PpIX 
and subsequently enhanced PDT, was suggested (Cumow et al., 1998).
This study has  explored the  feasibility of using ESS  and FS,  as monitors of PpIX 
photobleaching  during  PDT.  It  was  found  that  red  fluorescence  value  decreased 
markedly during PDT, and was considered to be significant when compared to pre-PDT. 
The PpIX photobleaching was higher in lesions with high response rate, and less in those 
with low response rate to PDT; this may be useful indicative of the response rate of 
tissue to therapy.
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Chapter 9
General Discussion
The research presented in this thesis explored the use of light techniques with regard 
to the control of head and neck cancers at the cellular and clinical levels.  It was a 
unique opportunity to compare both scenarios. Surprisingly, little is known about the 
relationship  between  PDT  and  distant  metastases,  a consequence  that may  not be 
explored  for  years  after  the  primary  treatment.  The  motivation  for  such  a  study 
emanated  from  the  fact  that  PDT  is  mainly  indicated  for  tumour  lesion  without 
metastasis. However, it is important to establish what the effects of PDT might be on 
metastasis. Therefore, the primary aim of the present study was to explore some of 
the metastasis related biological consequences of PDT at the cellular and molecular 
levels using OSCC  cells  as  an appropriate  in vitro model.  The second aim was to 
evaluate, clinically, the ability of an optical system based on fluorescence and elastic 
scattering  spectroscopy,  to  distinguish  between  normal,  potentially  malignant  and 
malignant  tissues  and  to  develop  an  applicable  algorithm  that  may  be  used  as  a 
standard for the subsequent analysis of ‘unknown lesions’; in an attempt to control 
head  and  neck  squamous  cell  carcinoma  (HNSCC)  recurrence  and  established  an 
early  detection  before  spread  of tumour  cells.  The  failure  to  achieve  complete 
ablation of tumours that were previously treated with PDT might be a leading cause 
of their recurrence  and  distance  metastases.  Thus,  in  order to  fill  this  gap  in the 
knowledge and, in order to ensure complete removal of tumour, a sufficient dose of 
PDT  must  be  delivered.  Therefore,  this  study  also  explored  the  applicability  of 
fluorescence  and  elastic  scattering  spectroscopy  systems  for  monitoring  PDT  in 
patients  with  superficial  BCC,  and to  compare  this  to  treatment  outcome.  To  this 
end,  several  experiments were conducted to determine the applicability of  ‘optical 
biopsy ’ and  ‘optical monitoring’.
Throughout of this thesis, both in vitro and in vivo studies have been considered in 
their own right.
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9.1  The i n   v it r o  studies
The biochemistry of tumour cell biology covers a vast area, and tumour invasion is a 
complex process that requires interactions between the invading tumour cells and the 
ECM,  as  well  as the  surrounding microenvironment beyond the  ECM.  This  study 
found  that  PDT  has  the  capacity  to  regulate  the  behaviour  of  squamous  cell 
carcinomas, and reduce their metastases phenotype.  The human oral SCC cell lines 
were H376 and VB6.  The VB6 cell line was transfected with a P6 integrin subunit 
and expressed predominantly avp6 integrin receptor. The control cell line used was 
represented by UP cells (human papilloma virus 16-transformed skin keratinocytes), 
which are not a cancer line.  They are however, more “normal” than the SCC lines. 
Nevertheless,  this  research  focuses  on comparing the  influence of PDT in various 
scenarios, and the same cell line may fulfil this purpose.
Foscan-PDT is currently in clinical use for the treatment of head and neck cancers. 
In  the  1990s,  the  published  research  misled  the  clinicians  regarding  the 
photosensitiser selectivity of tumour cells. It was thought that the sensitivity to PDT 
is related to the cell type, and malignant cells are more sensitive to this than normal 
keratinocytes  (Dougherty  et  al.,  1998).  This  concept has now been changed,  since 
both  malignant  and  normal  cells  can  retain  the  sensitiser,  and  the  present  study 
findings  support  this.  The  UP  cells  used  in  this  study  were  a  transformed  skin 
keratinocyte  cell  line,  and  not  SCC,  and  were  less  sensitive  to  Foscan  possibly 
because  of their larger size,  compared to  H376  and VB6  SCC, which may need a 
longer time to take up/saturate  Foscan in vitro.  This was  clearly explained by this 
study which found that UP cells  sensitiser take-up was less compared to the other 
OSCC  lines.  Therefore,  in order to  examine this  concept more fully, two types of 
cells (normal vs. malignant) with relatively equal size, might be used.
This thesis found that the PDT toxic effect on cells was dependent on both Foscan 
concentrations and light intensity. It is well known that efficient cell death following 
PDT requires light, oxygen and photosensitiser quantity not to be limited. When one
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of these  components  is  limited,  most  of the  cells  do  not  immediately  undergo 
apoptosis/necrosis, and rather than their growth being arrested, causes activation of 
several  transduction  pathways.  However,  in  this  study  it  was  possible  to  achieve 
lethal  effects  on  cell  survival  by  increasing  the  light  dose  rather  than  sensitiser 
concentration.  This  may  be  of clinical  value,  since  decreasing  the  sensitiser  dose 
clinically means  reduction  of adverse  effects  of sensitiser e.g.  patients’  long time 
shielding from sunlight and also treatment costs will be reduced. Nevertheless, using 
a high dose  of sensitiser can also activate anti-apoptotic signalling,  e.g.  eukaryotic 
transcription factor (NF-kB) dependant pathway (Granville et al., 2000).
As discussed in Chapters 4 and 5, the observed suppressive effect of PDT on cellular 
behaviour  towards  malignancy  was  reflected  by  a  decreased  affinity  of cells  to 
migrate towards extracellular proteins. The reason behind this reduction is not clear, 
but according to the findings in this thesis, activities of the tumour promoting factors 
MMP-2, -9 and -13, uPA and the VEGF were significantly reduced in some of the 
cell lines tested. At the time of writing, this is the first report to explore the effects of 
Foscan-PDT on MMP-2,  -9,  and  -13,  uPA  and  VEGF activities in head and neck 
carcinomas.  In addition, the present data showed for the first time that cell surface 
integrin a5pl  and avp6 expression were enhanced by Foscan-PDT, especially a5pi 
receptor which was significantly increased by PDT in UP and H376 cells.
It  was  reported  that  migration  of  human  keratinocytes  is  mediated  by  specific 
integrins  (Pilcher  et  al.,  1997;  Lange  et  al.,  1995),  growth  factor  receptors  and 
MMPs.  In this  study,  PDT  had  suppressed  migration  in  UP  and  H376  cells  with 
decreased secretion of MMP-9, MMP-13, VEGF, increased expression of a5pi  and 
avP6  integrin  and  decreased  expression  of  EGFR  receptors.  MMP-2  was 
significantly activated by H376 cells following PDT, this activation may explain the 
recurrence in some cases treated here at UCH, London. MMP-2 was reported to be 
related to the HNSCC tumour metastases to the lymph nodes, while MMP-9 was not. 
Therefore,  MMP-2  was  considered  as  a useful  marker  for the  degrees  of tumour 
invasion and metastases  (Kawata et al.,  2002).  Accordingly,  in those tumours,  the
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administration of anti MMP-2 might enhance the clinical outcome. Moreover, it is 
not  fully understood whether the  integrins,  a5pl  and av|36,  are  implicated  in cell 
migration.  In  VB6  cells  (which  expressed  high  levels  of avj36),  expression  was 
reduced after PDT. However, investigating the effect of PDT on integrin expressing 
cells using a range of PDT doses rather than sublethal doses (as used in this study), 
might  answer  the  latter  question.  It  seems  that  other  mediators  or  pathways  are 
involved.  Expression of av(36  leads to  a phenotype  which is more migratory,  less 
differentiated  and  upregulated  expression  of MMP-2  and  MMP-9  (Thomas  et  al., 
2001b). However, it is not hard to imagine how these processes could contribute to 
invasion  of tumour  cells  in  vivo.  Therefore,  further  studies  would  be  required  to 
elucidate these mechanisms involved in cell migration.
By combining PDT with chemotherapy (cisplatin) and small molecules (Iressa and 
PD153035; further enhancement of PDT antimetastatic effects were achieved. At the 
time  of  writing,  no  published  reports  on  the  combination  of  PDT  with  small 
molecules could be found, and only a few recent reports on the combination of PDT 
with  chemotherapy  and  radiation  therapy  effects  on  toxicity.  The  expression  of 
EGFR  by  flow  cytometry  revealed  an  obvious  suppression  with  enhanced  anti­
tumour  PDT  activity  when  small  molecules  were  added.  On  the 
immunohistochemical  study  of HNSCC  cases,  EGFR was  significantly  correlated 
with the lymph node metastasis; this was connected to MMP-2 and MMP-9 (Do et 
al.,  2004).  Accordingly,  correlation  between  invasiveness  of  HNSCC  and 
overexpression of both EGFR and MMP-9 was reported using an in vitro Matrigel 
invasion  model  (charoenrat  et  al.,  2000).  In  combination,  these  findings  are 
important when looking for PDT as an early treatment of cancer lesions that do not 
lead  to  established  metastases.  Also,  these  observations  may help  to  enhance  the 
prognosis of head and neck carcinoma patients undergoing surgical resection of large 
tumour  masses  where  at  times  it  is  difficult  to  discern  the  safe  margins.  By 
combining  surgery  and  illumination  of the  margins  with  PDT,  this may  lead to  a 
decrease in, or may even prevent, recurrence and metastases forming.
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9.2  Clinical studies
The  results  of this  study  represent  the  first  assessment  of the  use  of ESS  in the 
classification of oral tissues. Optical biopsy techniques are based on the idea of light 
being  used  for  illumination.  In biological  tissues,  the  light may both be  absorbed 
with  fluorescence  emission  and  subsequently  scattered,  either  elastically  or 
inelastically.  The intensity of these events depends on the type of the tissue under 
investigation.  Tools  that  are  sensitive  to  these  changes  could  therefore  have  the 
potential to classify each lesion with a high degree of accuracy, which, if validated, 
can contribute positively to cancer management.  Optical biopsies can be useful not 
only  for  oral  malignancy,  but  also  for  other  clinical  applications,  such  as 
dermatological  conditions,  breast  cancer,  and  cervical  dysplasia.  In  addition,  it  is 
possible that optical biopsies may be applicable anywhere in the body where other 
image guidance techniques are applied.
There  is  currently  no  database  relating  to  optical  biopsies  in  oral  tissues,  which 
makes the precise correlation of the obtained samples more difficult. In the clinical 
trial described in this thesis,  optical biopsies were taken from specific tissue areas 
and  the  acquired  spectra  were  derived  from  different  anatomical  sites  in the  oral 
cavity with different structures and volume thicknesses; this highlights the necessity 
for close co-operation between the clinicians, pathologists and the data interpreter. In 
addition, little is known by patients and GPs concerning these optical processes, and 
this may have contributed to the low cohort of patients in this study. In order to help 
in establishing appropriate controls and the characteristics of the normal spectra, and 
make the true differences in the ESS  spectra,  several normal acquired spectra were 
obtained  from  different  oral  anatomical  sites.  Nevertheless,  the  FS  obtained  data 
were  presented  with  a  great  degree  of accuracy  regarding  calculated  red-to-green 
diagnostic  ratios/algorithms,  since  the  captured  images  were  analysed  and  the 
intensity of emitted red and green fluorescence obtained immediately in real time by 
the  PC.  Thus,  the  clinician was  able to  decide which areas  of mucosa were to be 
captured.
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In  this  study,  the  application  of a red-to-green ratio  algorithm  set to  1.2  actually 
reduced  thresholds  between  normal  and  abnormal  tissues  and  resulted  in  90% 
sensitivity  and  79%  specificity  in  discriminating  between  malignant  dysplastic 
lesions  and  benign  lesions.  By  implicating the  1.3  threshold,  the  number of false 
positive results were reduced by 50% with 10% increase in specificity and only 7% 
reduction in sensitivity; this indicates the advantages these algorithms.
The ESS results of this study support the hypothesis that ESS was able to provide 
accurate oral dysplasia demarcation and can be used as an effective tool that may 
replace the invasive surgical biopsy. Although this early result was promising, more 
data from different tissues are needed for validation, since in this small dataset the 
patient,  site,  and  histological  grade  are  limited.  For  monitoring,  ESS  was  also 
applied and closely correlated,  although results were obtained were not significant; 
sparseness  of the  data,  the  tissue  heterogeneity  and  the  absence  of any  previous 
databases all may have contributed towards this insignificant outcome.
Current protocol demands that PDT doses are tailored to  suit the patient’s weight, 
which may result in either over/or under treatment with subsequent complications. 
Monitoring the relevant parameters during PDT and comparing them to the treatment 
response allows the  achievement of optimal  and reproducible treatment outcomes. 
The employment of a PpIX fluorescence spectroscopy as a tool for monitoring PDT 
treatment,  and the  expected response to  therapy  is  widely reported  (Pottier,  1990; 
Boere  et  al.,  2003;  Calin  et  al.,  2004).  Monitoring  the  bleaching  of  PpIX 
fluorescence  during  photodynamic  therapy  in  human  BCC  skin  tumours  was 
investigated in the present study. The response of lesions to PDT was lower in those 
slow bleaching.
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9.3  Conclusions
The research presented in this thesis demonstrates that PDT and its related optical 
spectroscopy tools may prove beneficial in terms of cancer diagnosis and treatment.
At the cellular level, PDT using m-THPC as a photosensitive agent, either alone or 
in combination with other anti-cancer agents  (cisplatin and small  molecules),  was 
found to be an effective antitumour regime.  This involved the control, not only of 
tumour  growth,  but  also  some  metastatic  activities.  Despite  the  difficulty  of 
determining the precise mechanisms behind this suppression of metastasis, this study 
provides evidence that PDT can, at least partly, regulate many of the processes that 
are known to be associated with malignancy. This effect may prove of clinical value 
in the treatment of head and neck cancers, since PDT is applied as a treatment for 
early cancer without metastasis.
Clinically, PDT has shown be an efficient treatment for BCC cancer treatment that 
can be applied with acceptable cosmetic outcome. For diagnosis of early lesions, FS 
and ESS are shown to be able to identify malignant changes in oral tissues and act as 
a screening tool for the detection of subsequent primary lesions with the advantages 
over other non-optical techniques of providing real-time, cost effective and pain-free 
biopsy methods,  unlike  surgical  biopsies.  In this  study,  FS  also  demonstrated the 
great  feasibility  of simultaneously  monitoring  5-ALA  induced  PpIX  fluorescence 
bleaching during PDT  which predicted the  outcome of BCC  tumours.  In order to 
validate all the observations presented in this thesis, larger patient populations plus 
increasing the number in each category are needed.
These  experiments  and  results  presented  here  offer  a  feasible  and  promising 
technology  which,  it  is  hoped,  will  lead  to  an  important  contribution  in  the 
advancements of the diagnosis and treatment of head and neck cancers.
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9.4  Future work
The use of light techniques in head and neck oncology is increasing, not only to treat 
dysplasia and malignancy but also for the purposes of the identification, monitoring 
and detection  of potential  complications.  Further research  is  required both at the 
clinical and in vitro levels.  At the cell level, further studies are needed to elucidate 
the molecular events behind the different effects of PDT on the invasive behaviour 
of oral cancer and to  clarify these relationships by carefully designed  in vitro  and 
subsequent, in vivo animal studies. In clinical terms, large multi-centre trials are vital 
in order to determine the sensitivity and specificity of the individual and combined 
techniques,  as  well  as  to  assess  and  improve  their  ability  in  terms  of the  early 
detection and management of head and neck oncology. This will help to determine 
the  optimal  approach for tumour growth,  recurrence  and metastasis.  Once  a more 
sound knowledge of cancer biology has been established, it may be possible to attach 
specific markers with specific optical characteristics directly to cancer cells, which 
will facilitate the tracing of suspicious areas with high sensitivity.
To expand the current knowledge about the biological basis of PDT and according to 
the findings presented here, using ELISA and zymograms which showed that some 
MMP protein levels were reduced following exposure to PDT, further studies would 
elucidate whether Foscan-PDT might have suppressed specific mRNA translation of 
distinct MMPs  as this was  subsequently reflected  in MMP  expression by reduced 
secretion into the culture supernatants. Thus, future work at the gene level is needed 
to  ascertain  whether  the  suppressive  effect  of PDT  on  MMPs  and  other  tumour 
promoting factors including VEGF and plasminogen activator are true and not just a 
failure  of the  cells  to  secrete  the  manufactured  protein.  Also,  the  mechanisms  of 
MMPs and other tumour promoting factors’ down regulation following PDT remain 
to be elucidated.
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Overall,  it would be  more  relevant  if all  biological molecules  investigated in this 
thesis could be evaluated in animal models before translating the acquired data to the 
clinical setting.
The  FS  method  applied  in  this  study  was  adequate,  but  lacked  the  capability  of 
providing optical images of large areas of oral lesions and the need for point by point 
scanning of tissues to be interrogated with the tip of an endoscope to assess the oral 
tissue  mucosa  and  find  the  points  of high  fluorescence.  This  procedure  was,  on 
reflection, perhaps time consuming and PpIX photobleaching might have occurred. 
Therefore,  a tool  or system with the ability to  switch from endoscope to complete 
image with wide  angle  lens  in a short time may enhance the  detection technique. 
Furthermore,  it  has  been  demonstrated  that  certain  cancers  at  an  early  stage  of 
development overexpress  certain molecules  e.g.  EGFR,  however,  by linking those 
ligands  to  long-wavelength-absorbing  molecules  that  can  both  fluoresce  and 
photosensitise may increase the sensitivity and specificity. This may be investigated 
for early detection and the simultaneous destruction of target cancers.
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Media and Solutions
Keratinocyte growth medium (KGM)  500ml
64% DMEM  320ml
22% Ham’s F12  112ml
10%FCS  50ml
1.8 xlO iM  Adenine  5ml
0.5 pg/ml Insulin  250pl
0.4 pg/ml Hydrocortisone  2ml
10 ng/ml Epidermal growth factor  0.5ml
1% Penicillin/streptomycin  5ml
10'10M Cholera toxin  500pl
2.5 pg/ml Fungizone  5ml
Serum free medium (SFM)  500ml
99% DMEM  495ml
1% Penicillin/Streptomycin  5ml
Additive free medium (AFM)  500ml
67% DMEM  325ml
22% F-12  120ml
10% FCS  50ml
1% Penicillin/Streptomycin  5ml
Freezing medium  Per ml
90% FCS 
10% DMSO
900 pi 
100 piAppendix: 1
12% Acrylamide resolving gel  ~10ml
Distilled H20  3.3ml
30% Acrylamide mix  4.0ml
1.5M Tris (pH 8.8)  2.5ml
1.5M Tris (pH 6.8)  0.1ml
10% Gelatin  0.1ml
10% Ammonium persulphate  0.1ml
TEMED  4pl
Stacking gel  5ml
Distilled H20  3.0 ml
30% Acrylamide mix  0.7 ml
1.5M Tris (pH 8.8)  1.25 ml
1.5M Tris (pH 8.8)  0.05 ml
10% Ammonium persulphate  0.02 ml
TEMED  0.01 ml
1.5M Tris-HCl  50ml
1.5M Tris-Cl pH 8.8  9.75g
dH20  to 50ml
10% SDS  50ml
SDS  5g
dH2G to 50ml
0.5M Tris-HCl  50ml
0.5M Tris-Cl pH 6.8  3g
dH20  to 50ml
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Sample loading buffer (5X)  10 ml
1M Tris (pH 6.8)  3.125 ml
50% Glycerol  5.0 ml
SDS  1  g
1% Bromophenol blue  1 ml
dH20   0.875 ml
Running buffer (lOx)  1000ml
Tris base  29 g
Glycine  144 g
SDS  10 g
dH20  to 1 litre
Renaturing buffer  500ml
Triton X-100  12.5 ml
Distilled H20  487.5 ml
Developing buffer  200 ml
1M Tris (pH 7.5)  10 ml
5M NaCl  8 ml
1M CaC12  1.0 ml
2.5% Triton X-100  1.6 ml
Coomassie blue stain  500  ml
Methanol  150  ml
Acetic acid  50 ml
Coomassie Brilliant Blue R  2.5  g
Distilled H20  300  ml
Coomassie destain  500 ml
Methanol  150 ml
Acetic acid  50 ml
Distilled H20  300 ml
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Appendix 2
Data from Results Chapters
Figure 4.14
Geometric mean fluorescence of flow cytometry (a5pl)
Control Foscan Light PDT
UP 2.19 2.75 203 14.33
VB6 5.03 5.35 4.37 9.01
H376 6.06 9.12 7.64 34.21
Figure 4.16
Geometric mean fluorescence of flow cytometry (avp6)
Control Foscan Light PDT
UP 34.64 32.43 33.65 27.61
VB6 74.64 77.16 75.02 59.47
H376 2.27 3.1 2.89 19.48
Figure 5.18
Geometric mean fluorescence of flow cytometry (EGFR)
Control Foscan Light PDT
UP 6.06 6.05 6.25 18.96
VB6 3.25 ND ND 3.48
H376 33.29 29.16 30.67 5.66
Figure 5.20
Geometric mean fluorescence of flow cytometry (HGFR)
Control Foscan Light PDT
UP 2 1.65 2.5 2.9
VB7 1 0.026 0.45 1.4
H376 0.7 0.9 0.6 1.3
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Figure 8.4
The results of an ANOVA where the area under the peak is explained by the time at 
which the spectrum was taken
Degrees of 
freedom (df)
Sum  Sq Mean Sq F  value /7-value
Times 2 2571.49 1285.75 3.04 0.0522
Residuals 108 45740.91 423.53
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